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Summary 
Skeletal muscle composed of myofibers and a small amount of muscle stem cells (MuSCs). 
It plays important roles in energy metabolism. Some of the key metabolites, such as NAD+ 
and acetyl-CoA, were recently found to regulate muscle and MuSCs function by modulating 
mitochondria function. In my PhD thesis projects, we aimed at exploring the link between 
NAD+ levels, mitochondrial function, muscle structural homeostasis and MuSCs senescence. 
We also investigated the impact of acetyl-CoA on MuSCs activation and proliferation, 
through the control of protein acetylation. These projects mainly focus on three aspects:  
Rejuvenation of adult stem cells by NAD+ repletion. Aging is accompanied by SCs 
senescence. However, the initial signaling events mediating SCs senescence are not well 
defined. We demonstrate the importance of mitochondrial activity as a pivotal modulator of 
MuSCs senescence. MuSCs from aged mice have reduced NAD+ levels, mitochondrial 
content and capacity for oxidative respiration. Importantly, the induction of the mitochondrial 
unfolded protein response (UPRmt), subsequent to increasing cellular NAD+ with the 
precursor nicotinamide riboside (NR), prevents MuSCs senescence and improves muscle 
function and regeneration in aged mice. NR also prevents MuSCs dysfunction in the mdx 
mouse, a known mouse model of accelerated MuSCs senescence. Extending these 
observations to other SC pools and on the organism as a whole, we demonstrate that NR 
delays neural and melanocyte SCs senescence, while also increasing mouse lifespan.  
Control of MuSCs function by acetyltransferase KAT2A. MuSCs are essential for skeletal 
muscle homeostasis and repair. The mechanism controlling MuSCs maintenance and 
differentiation, however, remains elusive. We found that the acetyltransferase KAT2A 
expression is essential for myogenic differentiation of MuSCs. KAT2A loss-of-function in cells 
blocks MuSCs differentiation, and in mice impairs muscle regeneration after damage. The 
regulation of KAT2A in MuSCs function might rely on its ability to enzymatically acetylate 
other proteins, and in particular the MuSCs transcription factor PAX7. 
NAD+ repletion improves muscle function in muscular dystrophy. Duchenne muscular 
dystrophy (DMD) is caused by dystrophin gene mutations that lead to progressive muscle 
degeneration. Our bioinformatics analysis in mice and DMD patients suggests a role for 
NAD+ in protecting the muscle from metabolic and structural degeneration. Validating these 
findings, we reveal that the mdx mouse is characterized by reductions in muscle NAD+ levels, 
concurrent to increased PARP activity and reduced expression of nicotinamide 
phosphoribosyltransferase (NAMPT), the key enzymes for NAD+ consumption and 
biosynthesis. Replenishing the NAD+ pool by dietary NR supplementation benefits muscle 
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function in mdx and mdx/Utr-/- mice, an effect replicated in C. elegans models of DMD. The 
beneficial effects of NAD+ repletion in muscular dystrophy rely on the improvement in 
mitochondrial function, structural protein expression and on reductions in general 
PARylation, inflammation and fibrosis.  
In summary, our work demonstrates the critical role of NAD+ and Acetyl-coA in maintaining 
muscle and MuSCs function. Repletion of NAD+ levels, by NR administration, and/or boosting 
the function of acetyltransferase KAT2A might be attractive strategies to maintain muscle 
homeostasis and MuSCs function in aging and muscular dystrophy. 
Key words: NAD+, Muscle stem cell, KAT2A, Acetylation, Aging, Metabolism, Muscular 
dystrophy
? ?
Résumé 
Le muscle squelettique est composé de myofibres ainsi que d’une petite quantité de cellules 
souches musculaires (CSM). Il joue un rôle important dans le métabolisme énérgétique. Il a 
été récemment mis en évidence que plusieurs métabolites majeurs tel que le nicotinamide 
adenine dinucleotide (NAD+) et l’acétyl-CoA possèdent une activité régulatrice sur la fonction 
du muscle et des CSM en modulant la fonction mitochondriale. Les projets de ma thèse PhD 
ont eu pour but d’explorer le lien entre les niveaux de NAD+, la fonction mitochondriale, 
l’homéostasie de la structure musculaire et la sénescence des CSM. Nous avons aussi 
investigué l’impact de l’acétyl-CoA sur l’activation et la prolifération des CSM au niveau du 
contrôle de l’acétylation des protéines. Ces projets se concentrent principalement sur trois 
aspects: 
Rajeunissement des cellules souches adultes par réplétion de NAD+. Le vieillissement 
est accompagné par une sénescence des CS. Cependant les événements initiaux de 
signalisation menant à la dégénérescence des CS ne sont pas clairement définis. Nous 
démontrons l’importance de l’activité mitochondriale comme pivots modulateurs de la 
sénescence des CSM. Les CSM de souris âgées présentaient une diminution du niveau de 
NAD+, du contenu en mitochondrie et de la capacité de respiration oxydative. Notablement, 
l’induction de la réponse mitochondriale au stress protéotoxique en conséquence à 
l’augmentation du niveau cellulaire de NAD+ à l’aide du précurseur de NAD+ nommé 
nicotinamide riboside (NR) prévient la sénescence des CSM, améliore la fonction et la 
régénération musculaire chez les souris âgées.  
Le NR prévient également la dysfonction des CSM chez les souris mdx, un modèle connu 
pour une sénescence accélérée des CSM. En élargissant ces observations à d’autres pools 
de CS et sur l’organisme entier, nous avons démontré que le NR retarde la sénescence des 
CS neurales et mélanocytaires tout en augmentant la durée de vie des souris.  
Contrôle de la fonction des cellules souches musculaires par l’acétyltransferase 
KAT2A. Les CSM sont essentielles pour l’homéostasie et la réparation du muscle 
squelettique. Les mécanismes contrôlant la maintenance et la différentiation des CSM 
restent cependant non élucidés. Nous avons découvert que l’expression de 
l’acétyltransferase KAT2A est essentielle pour la différentiation myogénique des CSM. La 
perte de fonction de KAT2A bloque la différentiation des CSM et altère la régénération 
musculaire après un dommage chez la souris. La régulation de KAT2A sur la fonction des 
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CSM pourrait dépendre de sa capacité  enzymatique à acétyler d’autres protéines et en 
particulier le facteur de transcription au niveau des CSM PAX7. 
La réplétion de NAD+ améliore la fonction musculaire dans la dystrophie musculaire. 
La dystrophie musculaire de Duchenne est causée par une mutation héritée au niveau du 
gène dystrophin qui mène à une dégénération progressive du muscle. Nos analyses 
bioinformatiques chez la souris et chez des patients atteints de maladie de Duchenne 
suggèrent un rôle protecteur du NAD+ contre la dégénérescence musculaire métabolique et 
structurelle. Validant ces découvertes, nous avons observé que les souris mdx sont 
caractérisées par une diminution significative du niveau de NAD+ musculaire et ce de 
manière concomitante à une augmentation de l’activité de PARP et à une réduction de 
expression de nicotinamidphosphoribosyltransferase (NAMPT) qui sont respectivement les 
enzymes clés pour la consommation et la synthèse de NAD+. En reconstituant le pool de 
NAD+ par une supplémentation alimentaire de NR, nous avons observé un bénéfice au 
niveau de la fonction musculaire chez les souris mdx et mdx/Utr-/-. Cet effet bénéfique a 
également été reproduit sur un modèle de maladie de Duchenne chez le C. elegans. L’effet 
bénéfique de la réplétion en NAD+ dans la dystrophie musculaire est pléiotropique et dépend 
de l’amélioration de la fonction mitochondriale, de l’expression de protéines structurelles et 
d’une réduction générale de la PARylation, de l’inflammation et de la fibrose.  
En résumé, notre travail démontre le rôle critique du NAD+ et de l’acétyl-coA dans le maintien 
de la fonction du muscle et des CSM. La réplétion des niveau de NAD+ par l’administration 
de NR et/ou le stimulation de la fonction de l’acétyltransferase KAT2A pourrait représenté 
une stratégique attractive pour le maintien de l’homéostasies musculaire et la fonction des 
SCM dans le vieillissement et la dystrophie musculaire. 
Mots clés: NAD+, Cellules souches musculaires, KAT2A, Acétylation, Vieillissement, 
Métabolisme, Dystrophie musculaire 
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Skeletal muscle, along with cardiac muscle and smooth muscle, constitutes our muscular 
system. It permits movement, maintains posture, supports breath and circulates blood 
throughout our body. Beside the locomotor function, skeletal muscle also plays essential 
roles in the energy metabolism(1-3). However, the functions of skeletal muscle can be 
compromised in diseases, such as muscular dystrophy, and in the process of aging(4-8). 
Moreover, muscle can be damaged even in the routine exercises, such as eccentric 
running(1). Replacing the damaged tissue by healthy muscle fibers, largely by muscle 
regeneration, therefore is very important in maintaining locomotor function, as well as 
metabolic homeostasis(9). In this section we discuss the basics of skeletal muscle structure, 
and introduce the maintenance of muscle homeostasis by muscle stem cell (MuSC)-reliant 
muscle regeneration. We highlight the pivotal role of energy metabolism, NAD+ levels and 
mitochondrial function in supporting both muscle structural homeostasis and MuSCs function. 
Importantly, the metabolic control of muscle and muscle stem cell function largely depend on 
the post-translational modification (PTM): acetylation, through the lysine acetyltransferases 
(KATs) and lysine deacetylases (KDACs)(2).  
1.1 Skeletal muscle and muscle structural homeostasis 
1.1.1 Introduction to skeletal muscle 
Skeletal muscle is a type of striated muscle and named after the fact that most of them are 
attached to the skeleton. Skeletal muscle is one of the three major muscle types and 
accounts for about 40% of adult human body weight. Through contraction and relaxation, 
skeletal muscles help to support movement, posture, blood circulation, breathing, 
swallowing, defecation, and urination. Additionally, skeletal muscles help with metabolic and 
temperature regulation. 
Individual skeletal muscles are made up of large numbers of giant cells, known as muscle 
fibers (Figure 1.1). Each fiber is formed from the fusion of many precursor cells and is 
therefore multinucleated. In humans, muscle fibers are approximately 50 μm in diameter and 
10 to 350 mm in length(10). They are arranged in bundles (called fascicle) and separated by 
sheets of connective tissue containing collagen called basal lamina. Each muscle fiber is 
surrounded by a cell membrane, which allows the contents of the fibers to be quite different 
from that of the body fluids outside them. Inside the fiber are the myofibrils, which constitute 
the contractile apparatus, and the sarcoplasmic reticulum, a system for controlling the 
myofibrils through changes in calcium concentration. Each myofibril runs the whole length of 
the muscle fiber with a variable number of segments, which called sarcomeres, the basic 
functional units of the muscle fiber and forms the basic machinery necessary for muscle 
contraction. The myofibril consists of myosin and actin proteins. The actual contraction takes 
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place by an interaction between the actin and myosin molecules (Figure 1.1). The net effect 
of many of these small movements and small forces is to shorten the myofibrils, and thus the 
whole muscle. Hence some part of the skeleton is moved, by means of the attachment of the 
muscle at each end to bone, directly or via tendons.  
 
Figure 1. 1 Anatomy of skeletal muscle and muscle fibers 
Skeletal muscles are normally attached to the bone by tendon and are covered in a layer of connective muscle 
tissue known as the epimysium. Muscle fibers are organized as bundles, known as fascicle, which are surrounded 
by blood vessels and another connective tissue, called perimysium. Muscle fibers are covered in a fibrous 
connective tissue, known as endomysium. Each muscle fiber itself contains cylindrical organelles known as 
myofibrils. Each muscle fiber contains hundreds to thousands of Myofibrils. These are bundles of actin and 
myosin proteins. Surrounding the myofibril there is a network of tubules and channels called the sarcoplasmic 
reticulum. Adapted from National Cancer Institute SEER training modules, NIH (training.seer.cancer.org).  
1.1.2 The dystrophin associated protein complex (DAPC) 
The peripheral myofibrils are connected to the sarcolemma along via interactions with 
subsarcolemmal protein complexes called costameres. Costameres consist mainly of 
proteins contained within protein complexes, named DAPC and the integrin-vinculin-talin 
complex (Figure 1.2)(11). These protein complexes transmit contraction forces from muscle 
fibers to the ECM and, eventually to neighboring myofibers(1). Beside the structural and 
mechanical function, there is evidence that the DAPC is involved in cell signaling via its 
interactions with calmodulin, Grb2 and nNOS(12). 
The DAPC protein complex, in addition to dystrophin, encompasses intracellular (syntrophin, 
α-dystrobrevin, and nNOS), transmembrane (β-dystroglycan, sarcoglycans, and sarcospan), 
and extracellular proteins (α-dystroglycan and muscle-specific laminin) (Figure 1.2)(13, 14). 
Disruption of the DAPC, as a result of structural or posttranslational defects in one of the 
components building this protein complex, weakens the sarcolemma and causes different 
types of muscular dystrophy depending on the altered protein(11). Such as, mutations in 
genes encoding the subunits of the sarcoglycans cause sarcoglycanopathies, a subtype of 
recessively inherited limb-girdle muscular dystrophies; the four recessive limb girdle 
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muscular dystrophies 2D, 2E, 2C and 2F are caused by absence of the α, β, γ or δ 
sarcoglycans, respectively(15); and the deficiency or truncation of dystrophin causes 
Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD), respectively, 
both of them are common types of muscular dystrophy in humans (1). 
 
Figure 1. 2 The dystrophin associated protein complex (DAPC) 
DAPC is a protein complex that connects the intracellular cytoskeleton to the extracellular matrix (ECM), which is 
composed of laminin, collagen, etc. The muscle-specific laminin directly interacts with α-dystroglycan, which in 
turn interacts with other DAPC components, which includes: β-dystroglycan. Dystrophin/utrophin α-dystrobrevin, 
syntrophin, plectin sarcoglycan and sarcospan complex, biglycan and caveolin-3. The α7β1 integrin dimer binds 
laminin extracellularly and actin intracellularly via the vinculin (V) and talin (T) proteins. Image from Rahimov et al, 
J Cell Biol, 2013 (11)  
1.2.3 Muscular dystrophy 
The muscular dystrophies are a group of heterogeneous muscular diseases characterized by 
progressive degeneration and weakness of skeletal muscle. The most common and severely 
debilitating neuromuscular disorder, DMD, affects 1 in 3,500 males(16). It is manifested by 
rapidly progressive proximal muscle wasting starting around 3 years of age, culminating with 
respiratory insufficiency and cardiac failure that leads to premature death by the mid-20s. 
The allelic disorder Becker muscular dystrophy (BMD) is less common and milder, with late 
disease onset and relatively advanced survival age. Both diseases are caused by mutations; 
in the DMD gene, the largest gene in the human genome, located on the X chromosome, 
which encodes the 427-kD protein dystrophin(17-20). As dystrophin is the important 
structural protein of DAPC complex and the integrity of DAPC is crucial for the contracting 
myofiber to withstand the mechanical stress generated by sarcomeres and to prevent its 
fragile sarcolemma from contraction-induced injuries(21). Deficiency of dystrophin therefore 
disrupts the DAPC, weakens the sarcolemma and causes muscular dystrophy.  
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Healthy muscle myofibers are roughly equal in diameter with multiple nuclei located to the 
periphery of the myofiber. However, dystrophic muscle displays variable size and centrally 
nuclei myofibers, which are caused by active muscle degeneration and regeneration. The 
muscle degeneration/damage activates MuSC to promote muscle regeneration. Although 
these cells are replenished by self-renewal, recurrent degeneration and regeneration of 
skeletal muscle in a diseased state depletes the MuSC pool and fails to further regenerate 
the muscle. Ultimately, this contributes to muscle wasting (discussed further in the next 
section)(1, 22), also known as muscle atrophy, a term that describes the loss of lean muscle 
mass. Furthermore, at the late stage of disease, atrophied muscle is gradually substituted by 
fibrous and fatty tissues, which is one of the hallmarks of muscular dystrophy. Disruption of 
sarcolemma causes leakage of muscle proteins such as creatine kinase (CK) into the serum. 
Thus, high level of CK concentration in circulating blood is used as another biomarker for 
DMD disease(1, 22). 
Even though the understanding of various muscular dystrophies has advanced considerably 
during past decades, no treatment is currently available to stop or reverse any form of 
muscular dystrophy(23). Animal models are valuable tools for studying the pathogenesis of 
diseases and provide a test-bed for pre-clinical trials. To study DMD, two of the most widely 
used animal models are mdx and mdx/Utr-/-(Dko) mice. The mdx mice do not express 
dystrophin but have a mild phenotype compared to humans. In contrast, the Dko mice, which 
are deficient for both dystrophin and another compensating muscle protein, utrophin, more 
closely resemble the human phenotype. Among the potential DMD treatments, boosting 
MuSCs function has been receiving more and more attention considering the appearance of 
MuSC depletion at the end of the disease(6, 24). 
1.2 Muscle stem cells 
1.2.1 Introduction to MuSCs 
MuSCs (also known as satellite cells), residing between the basal lamina and the 
sarcolemma of the muscle fiber, are adult stem cells that can self-renew and are capable of 
generating skeletal muscle cells (differentiation). Since Alexander Mauro identified MuSCs at 
the periphery of adult skeletal muscle myofibers half a century ago(25), accumulating 
evidence confirmed the role of MuSCs as primary contributors to the postnatal growth, 
maintenance and repair of skeletal muscles(9). [3H]thymidine tracing experiments indicated 
that MuSCs are mitotically quiescent in adult skeletal muscle, while upon muscle damage 
and/or exercise they rapidly enter the cell cycle(26). Activated MuSCs can then give rise to 
proliferating myoblasts, which fuse into multinucleated myotubes at the final stage of muscle 
regeneration(27). In addition to myogenic differentiation, activated MuSCs have to self-renew 
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to preserve the stem cell reservoir. The key mechanisms controlling and preserving the 
balance between self-renewal and differentiation of MuSCs throughout the lifespan of an 
individual have only been partially understood. In fact, complex genetic regulatory networks 
are involved in the control of MuSC maintenance and differentiation during myogenesis(28). 
Amongst all transcription factors, paired-box 7 (PAX7) and paired-box 3 (PAX3) are essential 
regulators of these transcriptional networks(28). 
1.2.2 Roles of PAX3 and PAX7 in the formation of skeletal muscle 
Pax genes, which encode transcription factors characterized by a Paired Domain (PD), play 
key roles in the formation of tissues and organs during embryonic development. Some of the 
PAX proteins also have an Octapeptide motif (OP) and a Homeobox DNA-binding domain 
(HD)(29). Based on the presence of these structural features and on the sequence homology 
between Paired Domains, the Pax gene family can be divided into four subgroups (Table 
1.1). PAX factors belonging to the same class show partial overlap in terms of tissue 
specificity and spatiotemporal expression(30). 
Table 1.1 The PAX family of regulatory factors in mammals 
 
Modified from: Buckingham et al, Annu. Rev. Cell Dev. Biol. (2007)(31) 
PAX7 and PAX3 belong to the same PAX class of transcription factors and are paralogs with 
conserved amino acid sequences(32). PAX7 is usually highly expressed in quiescent MuSCs 
and in proliferating myoblasts(33). Knock-out of the Pax7 gene in mice resulted in complete 
absence of MuSCs, which further caused muscle atrophy and ultimately led to death within 
the first 3 weeks of life (34). Though PAX7 together with its paralog PAX3 are key regulators 
of myogenesis, they have overlapping functions only in myogenic differentiation.  
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PAX3 is initially transcribed in the pre-somitic mesoderm adjacent to the first somite prior to 
confined expression in dermomyotome and myogenic progenitor cells that delaminate and 
migrate from the somites to more distant sites of myogenesis. Activated myogenic cells 
delaminate from the edge of the dermomyotome, a process which is associated with 
downregulation of PAX3, and rapidly differentiate(35). PAX3 is expressed throughout the 
dermomyotome, whereas PAX7 expression is originally induced in the central domain of 
dermomyotome in the mouse embryo, where PAX3/PAX7 positive cells reside. These double 
positive cells provide myogenic progenitors for muscle growth. In this situation, both PAX3 
and PAX7 are essential for the survival of these myogenic progenitors and contribute to the 
growing skeletal muscle mass(36).
Distinct phenotypes of Pax3- or Pax7-knockout mice (Table 1.2) indicated that PAX3 is 
uniquely involved in embryonic development(37), while PAX7 plays an essential role in the 
specification of MuSCs(31). Despite the fact that PAX3 is expressed at an earlier embryonic 
stage than PAX7, PAX7 is upregulated in PAX3-deficient mice, potentially to compensate for 
the loss of PAX3(38). Of note, in Pax7-null mice, PAX3 cannot compensate for the deficiency 
of PAX7 in the establishment of satellite cell lineage(39). Although PAX7 can rescue almost 
all phenotypes caused by PAX3-deficiency, it is unable to fully recover the lack of 
delamination and long-range migration of muscle progenitors to the limb bud, which suggests 
that PAX3 is solely responsible for this developmental activity(40). Taken together, these 
results indicate that PAX3 and PAX7 have partially overlapping but not redundant roles in 
myogenesis.  
Table 1.2 Pax3 and Pax7 mutant phenotypes and functions of these factors during prenatal myogenesis 
 
Modified from Buckingham et al, Seminars in Cell & Developmental Biology 44 (2015)(35)  
PAX3 and PAX7 not only control critical aspects of the behavior of muscle progenitor cells, 
including cell survival, cell proliferation and migration but also regulate the entry of these 
cells into the myogenic program(31). 
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As PAX3 has a robust expression exclusively in the embryo that is downregulated after birth, 
it was concluded that PAX3 plays an important role in orchestrating myogenesis in the 
embryo, yet is not required in most postnatal MuSCs. In contrast, PAX7 expression is 
maintained in all satellite cells and proliferating myoblasts but is sharply downregulated 
immediately before differentiation(41), implying a function of PAX7 in maintaining the 
undifferentiated state of MuSCs. Therefore, in response to muscle damage, activated MuSCs 
have to downregulate PAX7 and progressively initiate the synthesis of early myogenic 
regulatory factors (MRFs), such as Myogenic Factor 5 (MYF5) and Myoblast Determination 
Protein (MYOD), when withdrawing from the cell cycle and preparing for the myogenic 
differentiation(42) (Figure 1.1).  
1.2.3 MRFs in myogenesis 
Quiescent MuSCs are characterized by the expression of PAX7 but not MYOD or 
MYOG(43). Consequent to muscle damage, activation of MuSCs into myoblasts is typified by 
the upregulation of basic helix-loop-helix MRF transcription factors (MYF5, MYOD, MYOG, 
MRF4)(44). PAX3 and PAX7 lie upstream of the MRFs and the nature of the hierarchy 
depends on the spatiotemporal context(45). In embryonic myogenesis, PAX3 and PAX7 act 
upstream of both MYF5 and MYOD(46). In satellite cells of the postnatal skeletal muscle, 
MYOD expression depends on PAX3/7 while MYF5 is possibly independent of PAX 
regulation13.  
Gene targeting and expression analysis have displayed a functional classification of MRFs: 
MYF5 and MYOD belong to the group of determination factors, while MYOG and MRF4 
constitute the differentiation factors(47). Entry into the myogenic program depends on the 
determination factors conferring the skeletal muscle identity, followed by activation of 
myogenic differentiation factors and consequent formation of skeletal muscles.  
MYF5 and MYOD are expressed in proliferating myoblasts and subject to different cycle 
regulation(48). Previous work has demonstrated that MYF5 is expressed before MYOD at 
the onset of myogenesis(49). MYOD is shortly upregulated after the beginning of 
differentiation. The expression of MYOD as well as high levels of MYF5 led to the activation 
of MYOG that was reported to negatively regulate PAX7 at the protein level(50), and new 
muscle fiber formation (Figure 1.1). After this point, MYF5 and MYOD expression levels 
gradually decrease. The level of MYOG increases through differentiation, and then 
decreases prior to upregulation of MRF4(51). In addition to MRFs, the Myocyte Enhancer 
Factor 2 (MEF2) class of transcription factors also has an important regulatory role in the 
control of myogenesis(52).  
? ?
 
Figure 1. 3 MuSCs and regulation of muscle regeneration 
MuSCs are located beneath the basal lamina of muscle fibers. In quiescence, these MuSCs are marked by PAX7 
expression. After muscle injury, activated satellite cells start to express MYF5 and MYOD, downregulating PAX7 
and differentiate into muscle fibers. Self-renewal of MuSCs is assured by the high level of PAX7. Modified from: 
Buckingham et al., Annu. Rev. Cell Dev. Biol. 2007(31). 
1.2.4 MuSCs self-renewal 
A hallmark of MuSCs is their ability to self-renew. This property is clearly demonstrated by 
their remarkable ability to sustain the capacity of muscles to regenerate. The most classic 
experiment proving the MuSCs self-renewal is transplantation of myofibers into the hind limb 
of the immunodeficient mdx (scid-mdx) mouse model(53). It was found that grafted MuSCs 
could undergo a 10-fold expansion via self-renewal. Additionally, one grafted fiber could give 
rise to more than 100 myofibers, which contain around 25000-30000 differentiated 
myonuclei(54). However, it remains intriguing to understand how MuSCs renew themselves. 
It is known that PAX7 plays important roles in controlling the cell decision of self-renewal or 
differentiation upon the activation of MuSCs.  
After the accomplishment of muscle regeneration, activated MuSCs return to quiescence. 
The muscle regeneration process revealed that most MYOD+ / PAX7+ proliferating MuSCs 
differentiate into MYOG+ cells, and only a small proportion of MYOD+ / PAX7+ cells have been 
detected to repress MYOD expression and maintain PAX7 expression, eventually returning 
to quiescence(9) (Figure 1.3). The capacity of activated MuSCs to generate reserve cells 
may be an important mechanism to maintain the size of MuSCs reservoir. Recently, energy 
metabolism, especially the mitochondrial function has been linked the MuSCs 
activation/proliferation (55). 
1.3 Skeletal muscle and energy metabolism 
1.3.1 Energy metabolism in muscle 
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Skeletal muscles are not only indispensible for the locomotor function of the muscle but also 
serve as important metabolic organs in humans(56-58). Skeletal muscle is one of the main 
energy-consuming organs, burning glucose, triglycerides and ketone bodies for muscle 
contraction. It accounts for almost 80% of glucose utilization after insulin stimulation. 
Meanwhile, skeletal muscle can be used to generate heat (when shivering) and also function 
as storage of protein if we should face malnutrition. By modulating key metabolic signaling 
pathways, such as mTOR and sirtuins, energy metabolites directly affect both muscle and 
MuSCs function(59).  
To deal with these divergent activities, skeletal muscles are composed of myofibers with 
large differences in metabolic profile and contractile speed(60, 61). The presently dominating 
classification system for mammalian skeletal muscle is based on myosin heavy chain (MHC) 
isoforms. The major fiber types are type I, IIa, IIx and IIb (Table 1.3)(62). Rodent muscles 
express all four types of MHC, whereas IIb MHC is not expressed in human muscle. Among 
different skeletal muscle fiber types, type I fibers can be categorized as red, slow-twitch, or 
oxidative muscle. High in mitochondria, these fibers primarily undergo oxidative metabolism 
using triglycerides as energy resource, and are resistant to fatigue. By contrast, type II 
skeletal muscle fibers can be categorized as white, fast-twitch, or glycolytic muscle. These 
fibers are relatively low in mitochondria, primarily undergo glycolytic metabolism using fast 
energy resources, such as glucose and creatine phosphate. Fast-twitch muscles are 
susceptible to fatigue (Table 1.3)(63). The muscle fiber type transformation for slow-twitch 
muscle to fast-twitch muscle was found in metabolic diseases as well as aging, which 
accomplice with worse metabolic status. Inversely, exercise helps the opposite muscle fiber 
transformation and better energy metabolism(64). It is interesting that different muscle types 
differ in the density of MuSCs. Within the same muscle, the number of MuSCs found on slow 
muscle fibers is generally higher than those on fast myofibers(65). Whether the higher 
content of MuSCs in slow-twitch muscle fibers has biological significance in metabolism or 
muscle regeneration is unknown. 
Alterations of skeletal muscle energy metabolism are always accompanied with systemic 
metabolic disorder. For instance, in obesity and type II diabetic patients, lipid accumulation is 
found in the skeletal muscle(66).  
? ???
Table 1.3 Skeletal muscle fiber types 
 
CrP, creatine phosphate. Table modified from Pette et al., Microsc Res Tech, 2010(63)
1.3.2 Energy metabolism regulation by the skeletal muscle 
Not only skeletal muscle energy metabolism, through controlling cellular key metabolites, 
such as NAD+ and Acetyl-CoA levels, regulates muscle and muscle stem cell function, on the 
other hands, skeletal muscle also modulates energy metabolism. Skeletal muscle regulates 
systemic energy metabolism mainly at two levels: 1, Skeletal muscle itself is one of the main 
tissue that syntheses and consumes energetic metabolites. And 2, Skeletal muscle 
synthesizes and secretes multiple factors, known as myokines, to regulate systemic energy 
metabolism. Some of these myokines are primarily expressed in muscle while others are 
expressed also in other tissues. Among all myokines, myostatin and interleukin -6 (IL-6) are 
examples of well studied in their roles of metabolic regulation (Figure 1.5)(67). 
Myostatin acts as Transforming growth factor ? (TGFβ) ligand. It is expressed almost 
exclusively in skeletal and cardiac muscle. Myostatin-deficient animals have a doubling of 
muscle mass, and myostatin inhibition has been proposed to delay age-related sarcopenia 
by preserving muscle mass and possible strength (67). In addition to the regulation of muscle 
mass, myostatin knock-out animals have improved insulin sensitivity and reduced fat 
mass(68). Exercise increases systemic insulin sensitivity, which might be mediated by the 
production of the myokines insulin-like growth factor-1 (IGF-1), IL-6 etc. Although muscle-
derived IGF-1 is not detected in the circulation, it induces muscle hypertrophy in an 
autocrine/paracrine fashion following exercise. Furthermore, several IGF-binding proteins 
(IGFBP-3, -4, -5, and -6) are expressed in muscles. They differ in their capacity to enhance 
or block the anabolic effects of IGF-1 by sequestering it, extending its half-life, or inhibiting its 
interaction with IGF-1 receptors located on the muscle and MuSCs(67). IL-6 has been 
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proposed to act on the insulin-producing pancreatic β islets, therefore regulates systemic 
energy metabolism(69). 
Moreover, the metabolism in skeletal muscle also changes the level of several metabolites, 
such as NAD+ and acetyl-coA. These metabolites affect multiple aspects of systemic energy 
metabolism and MuSC function, often by participating in post-translational modification 
events (PTMs) (2).  
 
Figure 1. 4 Systemic regulation of metabolism by myokines 
Myokines modulate several metabolic processes in the pancreas, liver, adipose tissue, endothelium, the muscle 
itself, and other tissues, and may influence mammalian lifespan. Adapted from Demontis et al., Aging Cell, 
2013(67) 
1.4 Modulation of energy metabolism by protein acetylation 
1.4.1 KATs and KDACs 
Reversible acetylation, as a type of PTMs of proteins, was initially described as an epigenetic 
regulatory mechanism governing DNA accessibility. Since then, this process emerged to 
control not only histone but also non-histone acetylation for integrating key physiological 
processes such as, metabolism, circadian rhythm and cell cycle along with gene regulation in 
various organisms. The reversibility of acetylation makes it especially favorable for protein 
regulation in adaptation to metabolic changes. These acetylation reactions are catalyzed by 
KATs (previously known as histone acetyltransferases, HATs), which transfer an acetyl 
group from acetyl-CoA to a lysine residue on histone or non-histone proteins. In opposition, 
KDACs can remove these acetyl groups from lysines using either zinc as a cofactor or NAD+ 
as a co-substrate.  
Both KATs (Table 1.4) and KDACs (Table 1.5) are protein superfamilies comprised of 
several subfamilies. In higher eukaryotes, KATs can be classified as the nuclear localized A-
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type group or the cytoplasmic localized B-type group (70). Briefly, the three main subfamilies 
of A-type KATs include: the Gcn5-related N-acetyltransferases (GNATs), p300/CREB-
binding protein (p300/CBP, including p300 and CBP proteins) and the MOZ, YBF2, SAS2 
and TIP60  (MYST) families (Table 1.4)(70). Aside from these general canonical KAT 
families, there are several other nuclear enzymes that posses acetyltransferase activity, 
including nuclear receptor coactivators (NCOAs)(70), TATA box binding protein (TBP)-
associated factor 1 (TAF1)(70) and circadian locomotor output cycles kaput (CLOCK)(71). A-
type KATs catalyze most of the transcription-related acetylation events(70). Conversely, B-
type KATs likely catalyze the acetylation of newly synthesized histones in the cytoplasm and 
regulate their cytosolic-nuclear transport(72). Reversing the effects of KATs, KDACs are 
grouped into four classes, depending on sequence homology and domain organization. 
Specifically, classes I, II and IV identify different groups of zinc-dependent KDACs, whereas 
class III KDACs consists of NAD+-reliant sirtuins, ranging from SIRT1 to SIRT7 (Table 
1.5)(73).  
Table 1.4 The cellular location, activity, targets and null phenotype of lysine acetyltransferases 
 
A, acetylation; C, cytosol; M, mitochondria; N, nuclear; P, phosphorylation; U-A, ubiquitin-activating/conjugating. 
H, histone. 
Both KATs and KDACs are highly conserved. For instance, both the mammalian GNAT and 
sirtuin family homologue genes also exist in yeast and plants(74-76). Here we will 
predominantly focus on the GNAT enzymes, KAT2A/B, and pertinent classes of KDACs, 
such as the sirtuins, as the main regulators of energy metabolism in organisms ranging from 
yeast to mammals. 
1.4.2 SIRT1, a typical KDAC in energy metabolism 
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The importance of KDACs in energy metabolism was exemplified by the identification of the 
yeast ortholog of the mammalian sirtuin, Sir2p, as a regulator of lifespan extension during 
caloric restriction (CR)(77, 78). Now described to be involved in a large spectrum of key 
signaling pathways, researchers have chronicled the many ways in which sirtuins and other 
KDACs influence energy metabolism(75, 79). 
Table 1.5 The cellular location, activity, targets and null phenotype of lysine deactelyases
 
ADPR, ADP-ribosylation; B, biotinylation; C, cytosol;  D, deacylation; DA, deacetylation;DC, decrotonylation; DM, 
demalonylation; DS, desuccinylation; DG, deglutaryation; GA, Golgi apparatus; L, lipoylation; M, mitochondria; N, 
nuclear; PM, plasma membrane. 
The seven mammalian sirtuins have distinct subcellular localizations, enzymatic activities 
and targets (Table 1.5)(75). SIRT1, SIRT6 and SIRT7 are predominantly localized to the 
nucleus and deacetylate histones, transcription factors/cofactors, and metabolic enzymes. 
For example, SIRT1 deacetylates a wide range of metabolic regulators, including the 
peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α)(80, 81), Forkhead box 
protein O 1 (FOXO1)(82, 83), liver X receptors (LXR)(84, 85), cAMP response element-
binding protein (CREB) regulated transcription coactivator 2 (CRTC2)(86), peroxisome 
proliferator-activated receptor-γ (PPARγ)(87), and acetyl-CoA synthetase 1 (ACSS2)(88), 
amongst many other targets. The general effect of SIRT1 activation is to boost mitochondrial 
function and promote catabolism(81, 89-91).  
1.4.3 KATs in energy metabolism 
Consistent with the crucial role of KDACs on energy metabolism, KATs are also pivotal 
regulators of metabolism. Among them, KAT2A, also known as the general control of amino 
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acid synthesis 5 (GCN5), KAT2B, alternatively named p300/CBP associated factor (P/CAF), 
were demonstrated to play important roles in metabolism. 
KAT2A is the only nuclear acetyltransferase reported to acetylate PGC-1α in vivo and in vitro, 
leading to the attenuation of the activity of PGC-1α, one of the main mitochondrial biogenesis 
and function regulators(92). The ability of KAT2A to inhibit PGC-1α, can be enhanced by 
either SIRT6 (93) or insulin-induced cyclin D1 (CCND1)/ cyclin-dependent kinase 4 (CDK4) 
activity(94), by deacetylating or phosphorylating KAT2A in the liver, respectively. This 
KAT2A-mediated inhibition of PGC-1α in the liver reduces gluconeogenesis. In contrast, 
KAT2A-mediated repression of PGC-1α is reversed either with the repression of SIRT6, 
following glucagon-cAMP-protein kinase A (PKA) signaling(93), or with the induction of 
CBP/p300-interacting transactivator 2 (CITED2), found to bind KAT2A and block its 
interaction with PGC-1α(95). On a whole body level, KAT2A can inhibit PGC-1α-mediated 
energy expenditure, which is further fine-tuned by NCOA3(96). Specifically, NCOA3 binds to 
and activates the Kat2a promoter thereby increasing KAT2A expression, leading to PGC-1α 
acetylation and reduced mitochondrial energy expenditure in muscle and brown adipose 
tissue(96). Aside from KAT2A, KAT2B was also reported to regulate gluconeogenesis in the 
liver, however, the observed effects are controversial as both inhibitory(97) and 
stimulatory(98) outcomes have been demonstrated. One study suggested that KAT2B is 
recruited, along with WD repeat-containing protein 5 (WDR5), to gluconeogenic genes to 
induce histone H3 acetylation, resulting in gluconeogenesis(98). In contrast, another study 
found that KAT2B could acetylate and induce PGC-1α proteasomal degradation, prohibiting 
the gluconeogenic effect of PGC-1α(97). The discrepancy between these findings will require 
further investigation.  
Considering the embryonic lethality of a germline Kat2a-deficiency(99), creating Kat2a and 
Kat2b tissue-specific deficient mouse lines would help to tease out the different and 
redundant roles of these KATs on a tissue-by-tissue basis. A more extensive examination of 
the tissue-specific expression levels of these GNATs under various physiological conditions, 
and if they potentially regulate each other, would also help to further elucidate the differences 
between KAT2A and KAT2B.  
1.4.4 Importance of NAD+ for acetylation/deacetylation processes 
It was first hypothesized that NAD+ may act as the principal metabolite regulating protein 
deacetylation following the discovery that it is essential for the activity of sirtuins(77). This 
dynamic role of NAD+ in the regulation of sirtuin activity has now been well-established(100-
103), implying that the availability of NAD+ for sirtuin-directed deacetylation has a robust 
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effect on the acetylation status of the proteome and consequently cellular metabolic 
homeostasis.  
NAD+ exists in different pools in cells. Experimental evidence concerning the exchange of 
NAD+ between the nucleus and cytosol is lacking, nonetheless these two pools have been 
classically considered to be relatively homogenous(104, 105). However, since neither NAD+ 
nor NADH can diffuse through membranes(106, 107), the subcellular translocation and 
localized synthesis of NAD+ using precursors, such as NAM or NAM mononucleotide (NMN), 
likely govern subcellular NAD+ pool dynamics (Figure 1.5)(108, 109). This is supported by the 
finding that mice deficient in the nuclear NMNAT1 enzyme, important for nuclear NAD+ 
synthesis from NAM or NMN, are embryonic lethal, indicating that cytosolic or mitochondrial 
NAD+ synthesis by NMNAT2 or NMNAT3 cannot compensate for the loss of nuclear NAD+ 
synthesis during embryogenesis(110). Interestingly, the mitochondrial NAD+ pool is also 
separated from the rest of the cell(109, 111) and can be maintained even if cytosolic NAD+ 
levels are perturbed(109, 112, 113). In fact, evidence is accumulating that mitochondria 
possess their own machinery for NAD+ production(107, 109, 111) and can therefore be, at 
least acutely, self-sufficient. Furthermore, the NAD+ ratio between the nucleo-cytosolic and 
mitochondrial pools appears to be tissue-specific. For instance, mitochondrial NAD+ 
constitutes 70% of the total cellular NAD+ in cardiac myocytes(112), 50% in neurons(114) 
and 30-40% in hepatocytes and astrocytes(114, 115). Interestingly, changes in exogenous 
NAD+ were shown to influence mitochondrial NAD+ levels more than the cytoplasmic NAD+ 
pool(116). Yet despite this surprising observation, the mitochondrial and cytoplasmic pools 
are still inherently interconnected through the exchange of NADH and NAD+ between the 
cytosol and the mitochondria via the malate-aspartate and glycerol-3-phosphate shuttles.  
? ???
 
Figure 1. 5 NAD+ and acetyl-CoA subcellular distributions in mammals and yeast 
A, In mammals, de novo NAD+ synthesis occurs in the cytosol, whereas NAD+ salvage from NAM or NMN can 
take place in cytosol, nucleus and mitochondria. PARPs and CD38/157 compete with surtuins for NAD+, the 
availability of which also depends on the cytosolic or mitochondrial conversion of NAD+ to NADH. Acetyl-CoA 
generated from glycolysis and lipids in the cytosol can contribute to the mitochondrial acetyl-CoA pool. In the 
cytosol, acetyl-CoA can be produced from acetate by AceCS1 or from citrate by ACL. Cytosolic acetyl-CoA can 
be transformed into malonyl-CoA by ACC1, during lipid synthesis. Malonyl-CoA can be reconverted to acetyl-CoA 
by MCD. Citrate and acetate from cytosol can diffuse into the nucleus, where they are converted to acetyl-CoA by 
ACL and AceCS1, respectively. Nuclear PDC also contributes to the nuclear acetyl-CoA pool. B, In yeast, 
pyruvate can be converted to acetyl-CoA via the PDC or it can be converted to acetaldehyde, then acetate and 
finally to acetyl-CoA in mitochondria or the cytosol. Acetate to acetyl-CoA conversion is catalysed by Acs1p in the 
mitochondrion or Acs2p in the cytosol. In mitochondria, acetyl-CoA enters the TCA cycle whereas in the cytosol 
acetyl-CoA is used by Acc1p in the first step of lipid synthesis. Unlike mammals, in yeast, lipid oxidation is 
restricted to the peroxisome. Yeast lacks ACL and MCD orthologues so they cannot produce acetyl-CoA from 
citrate or malonyl-CoA. Pathways that need further validation are indicated by dashed lines. Sirtuins are shown in 
green, KATs in blue, enzymes affecting acetyl-CoA levels in grey and non-sirtuin NAD+-consuming enzymes in 
black. ACL, ATP-citrate lyase; ACSS1 and ACSS2 or Acs1p and 2p, acetyl-CoA synthetases 1 and 2; ACC1 or 
Acc1p, acetyl-CoA carboxylase; ETC, electron transport chain; KAT, lysine acetyltransferase; MCD, malonyl-CoA 
decarboxylase; NA, nicotinic acid; NAD+, nicotinamide adenine dinucleotide; NAM, nicotinamide; NMN, NAM 
mononucleotide; NR, nicotinamide riboside; PARP, poly ADP-ribose (PAR) polymerase; PDC, pyruvate 
dehydrogenase complex; SIRT, sirtuin; Sir2p, sirtuin 2; TCA cycle, tricarboxylic acid cycle. 
Overall, the dynamic cellular ratio of oxidized to reduced forms of NAD+ molecules is 
governed by multiple reactions involving the interconversion of NAD+ and NADH (Figure 1.5). 
Within the cytosol, glycolysis of glucose into two pyruvate molecules generates two NADH 
molecules, which can be reoxidized by lactate dehydrogenase in the cytosol or by the 
electron transport chain (ETC) in the mitochondria. Within the mitochondria, the pyruvate 
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dehydrogenase complex (PDC) converts a single pyruvate molecule into acetyl-CoA, 
producing one molecule of NADH. This acetyl-CoA molecule then enters the tricarboxylic 
acid (TCA) cycle to generate three more molecules of NADH and one molecule of FADH2, 
which pass on their electrons to the ETC to produce ATP. 
Both the de novo biosynthesis and salvage pathways contribute to intracellular NAD+ 
formation (Figure 1.6)(104, 117-119). The de novo synthesis pathway, starting from the 
essential amino acid tryptophan, produces NAD+ in the cytosol, the location for all enzymes 
catalyzing this process(104, 120). NAD+ can also be synthesized from precursor molecules, 
such as, NAM or nicotinamide riboside (NR), through common components of the NAM 
salvage pathway(118) or from nicotinic acid (NA), which is converted to NAD+ through the 
Preiss-Handler pathway (Figure 1.6). 
 
Figure 1. 6 Pathways leading to the NAD+ production 
De novo synthesis of NAD+ begins with tryptophan (purple) and includes five enzymes (not represented on the 
figure): tryptophan 2,3-dioxygenase (hepatic) or indoleamine 2,3-dioxygenase 1 (nonhepatic), arylformamidase, 
kynurenine 3-mono oxygenase, kynureninase and 3-hydroxyanthranilic acid dioxygenase. NA leads to NAD+ 
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synthesis through the Preiss–Handler pathway (green), and shares the same intermediate, NaMN, as de novo 
synthesis. In yeast, NAM is converted into NA by the nicotinamidase Pnc1p (yellow), while in mammals NAM 
leads to the production of NMN, catalysed by the enzyme NAMPT (pink). NR is converted to NMN in both 
mammals and yeast; however, yeast can also convert NR to NAM via the enzymes Urh1p and Pnp1p (blue). 
Reactions not catalysed/present in mammals indicated by dashed lines. Abbreviations: NA, nicotinic acid; NAD+, 
nicotinamide adenine dinucleotide; NADS, NAD+ synthase; NAM, nicotinamide; NAMPT, nicontinamide 
phosphoribosyltransferase; NAPT, nicotinic acid phosphoribosyltransferase; NMN, NAM mononucleotide; 
NMNAT, nicotinamide mononucleotide adenylyl transferase; NR, nicotinamide riboside; NRK, nicotinamide 
riboside kinase; Pnc1p, pyrazinamidase/nicotinamidase 1; Pnp1p, purine nucleoside phosphorylase; QPRT, 
quinolinate phosphoribosyltransferase; Urh1p, uridine hydrolase. 
Irrespective of the precursor used for NAD+ biosynthesis, NAD+ salvage is the most important 
process for maintaining NAD+ levels, making the rate-limiting enzyme for this pathway, 
nicotinamide phosphoribosyltransferase (NAMPT)(103), crucial for cellular metabolism. 
Specifically, NAMPT metabolizes NAM into NMN(121). NMN can then be converted into 
NAD+ by NMN adenylyltransferase 1 (NMNAT1) in the nucleus,(122, 123) NMNAT2 in the 
cytosol and Golgi(108, 123) or NMNAT3 in the cytosol and mitochondria (Figure 1.7)(108, 
109, 124). The expression levels and the requirement for NAMPT varies considerably 
between different tissues in mice, with the highest levels detected in brown adipose tissue 
(BAT), liver and kidney(125). Accordingly, NAMPT overexpression increases NAD+ levels 
followed by SIRT1 activation(109, 126-128). In contrast, Nampt-deficiency reduces NAD+ 
levels in mice(125). 
 
Figure 1. 7 Cross-compartmental junctions in cellular NAD+ metabolism 
In the nucleus, NAM and NMN are likely to be transported into the mitochondrial and nuclear compartments from 
the cytosol. Specific NMNAT isoforms and NAMPT are required in each compartment for the salvage of NAD+; 
however, the presence of NAMPT in the mitochondria is unconfirmed. In addition to the import of reducing 
equivalents of NADH by the malate–aspartate and glyceraldehyde 3-phosphate shuttles, the TCA cycle also 
contributes to the overall level of mitochondrial NADH. The reducing power of NADH is then used to make ATP by 
the electron transport chain, producing NAD+ and ATP. Pathways that need further validation indicated by dashed 
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lines. Abbreviations: ETC, electron transport chain; G3P, glucose-3-phosphatase; M/A, malate–aspartate; NAD+, 
nicotinamide adenine dinucleotide; NAM, nicotinamide; NAMPT, nicontinamide phosphoribosyltransferase; NMN, 
NAM mononucleotide; NMNAT, nicotinamide mononucleotide adenylyl transferase; NR, nicotinamide riboside; 
NRK, nicotinamide riboside kinase; PARP, poly ADP-ribose (PAR) polymerase; TCA, tricarboxylic acid. 
Interestingly, of all the NAD+ precursors, NR appears to be the only metabolite transported 
directly into the cell, in both yeast and mammalian cells. This was hypothesized following 
observations that NMN must first be converted to NR, in the periplasmic space by Pho5p in 
yeast(129) and through an unknown mechanism in mammals(130), before it is transported to 
the cytosol. NR can then be converted back to NMN, through several pathways for NAD+ 
biosynthesis in yeast(131), while in mammalian cells it is converted to NMN through 
phosphorylation by the NR kinases 1 and 2 (NRK1 & 2)(132). Since the mitochondrial 
compartment lacks NRK activity(130), it is likely that NR is converted into NMN in the cytosol, 
which is then supplied to other compartments, such as the mitochondria (Figure 1.7)(108, 
109). 
The beneficial effects of promoting NAD+ biosynthesis, either by enhancing the activity of 
enzymes involved in NAD+ production or via administration of NAD+ precursors, on sirtuin 
activity and metabolic homeostasis have been established in numerous studies(101, 103, 
131, 133-136). 
1.5 Control of MuSCs function through protein acetylation 
1.5.1 Linking histone acetylation and MuSCs function 
Despite the fact that transcriptional regulation is important in MuSCs function, epigenetic 
control also plays a crucial role during myogenesis. Chip-seq approaches provided direct 
evidence that with ageing, epigenetic changes accumulate and may lead to functional 
decline in quiescent MuSCs(137). Recently, the role of the deacetylase SIRT1 in skeletal 
MuSCs has been brought to light(55). It was reported that transition of MuSCs from 
quiescence to proliferation requires metabolic reprogramming, decreasing the activity of the 
histone deacetylase SIRT1. This led to the elevated H4K16 acetylation levels and activation 
of muscle genes transcription. As the acetylation event is reversible, there are possibly KATs 
that could reverse the deacetylation catalyzed by SIRT1 and enhance MuSCs differentiation. 
In fact, it was shown that upon muscle differentiation, p300 is enriched at distinct Myod 
regulatory elements, resulting in an increase of histone acetylation correlating with Myod 
expression(138). In spite of many reports on the impacts of histone acetylation during 
MuSCs differentiation or self-renewal, only a limited number of studies investigated the role 
of the acetylation of transcription factors in MuSCs function. 
1.5.2 KAT2B and p300/CBP in muscle differentiation 
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Histone acetyltransferases (HATs) are considered to play a crucial role in the transcriptional 
activation of DNA that is tightly packed in the chromatin. Biochemical experiments provided 
evidence that hyperacetylated histones accumulate within transcriptionally active chromatin, 
whereas hypoacetylated histones accumulate within transcriptionally silenced chromatin. 
P300/CBP and KAT2B coactivators have acetyltransferase activities and regulate 
transcription, cell cycle progression and differentiation. KAT2B can associate with P300/CBP 
and MYOD to form a multimeric protein complex, which has been proven to be critical for 
MYOD-directed transcription and myogenic differentiation(139). In muscle specific 
differentiation, KAT2B and P300/CBP both function as coactivators, but contribute 
differentially to the MYOD-directed transcriptional stimulation, with KAT2B providing the 
acetyltransferase function and P300/CBP bringing all components of the complex 
together(139). Furthermore, KAT2B-mediated acetylation of MYOD is proven to be 
functionally relevant as a non-acetylatable MYOD mutant loses transcriptional and myogenic 
potency(140).  
1.5.3 Role of KAT2A in stem cells  
Similar to KAT2B, KAT2A also physically interacts with p300/CBP(141), but mice lacking 
p300/CBP showed phenotypes different from those lacking KAT2A, which suggest that 
function of KAT2A is unique and not supplementary to p300/CBP(142). The conclusion from 
these phenomena is that different histone acetyltransferases are required as cofactors for 
specific development processes. In recent years, the role of KAT2A in other tissues has been 
gradually deciphered. Mice with a conditional Kat2a allele were created as well as mice with 
a knock-in of a mutant Kat2a lacking catalytic activity, both exhibiting a neuronal phenotype 
with absence of apoptosis(143). KAT2A was also identified as being essential for normal 
embryonic stem cell pluripotency(144). More recently, the loss of KAT2A has been reported 
to accelerate cerebellar degeneration in a mouse neurodegeneration model(145). Apart from 
the interaction between KAT2A and p300/CBP, the importance of the interaction of KAT2A 
with other cofactors in development processes is still not very clear. KAT2A was shown to be 
an important transcriptional cofactor for Myc in vivo with an impact on neural stem cell 
differentiation(146), reflected by an upregulation of neuronal differentiation genes and a 
downregulation of a cluster of genes that inhibit differentiation in both N-myc- and Kat2a-KO 
mice. Despite this evidence of KAT2A regulating stem cell function, the role of KAT2A as an 
acetyltransferase in MuSCs is still unknown.  
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2.1 Abstract 
Adult stem cells (SCs) are essential for tissue maintenance and regeneration yet are 
susceptible to senescence during aging. We demonstrate the importance of the amount of 
the oxidized form of cellular nicotinamide adenine dinucleotide (NAD+) and its impact on 
mitochondrial activity as a pivotal switch to modulate muscle SC (MuSC) senescence. 
Treatment with the NAD+ precursor nicotinamide riboside (NR) induced the mitochondrial 
unfolded protein response (UPRmt) and synthesis of prohibitin proteins, and this rejuvenated 
MuSCs in aged mice. NR also prevented MuSC senescence in the mdx mouse model of 
muscular dystrophy. We furthermore demonstrate that NR delays senescence of neural SCs 
(NSCs) and melanocyte SCs (McSCs), and increased mouse lifespan. Strategies that 
conserve cellular NAD+ may reprogram dysfunctional SCs and improve lifespan in mammals. 
2.2 One sentence summary 
NR rejuvenates stem cells and improves mouse lifespan 
2.3 Introduction 
In adults, tissue homeostasis is highly dependent on stem cell (SC) function. These adult 
SCs are not only essential in continuously-proliferating tissues, like the hematopoietic, 
intestinal and skin systems, but also in normally quiescent tissues, such as skeletal muscle 
and brain that require regeneration after damage or exposure to disease (147). Aging is 
accompanied by a decline in adult SC function, termed SC senescence, which leads to loss 
of tissue homeostasis and regenerative capacity (148, 149).  
Homeostasis and regeneration of skeletal muscle depends on normally quiescent muscle 
stem cells (MuSCs), which are activated upon muscle damage to expand and give rise to 
differentiated myogenic cells that regenerate damaged muscle fibers (1, 65). These 
responses are blunted in aged muscle, probably because of reduced number and function of 
MuSCs (150-152). In aging, MuSC dysfunction may be caused by extrinsic signals (4, 153) 
or intrinsic cellular senescence signaling pathways (154) or both. One general regulator of 
cellular senescence, cyclin-dependent kinase inhibitor 2A (CDKN2A, p16INK4A), shows 
increased expression in geriatric MuSCs, which causes permanent cell cycle withdrawal and 
senescence of MuSCs in very old mice (28-32 months of age) (154). However, reductions in 
MuSC number and function can already be observed before this stage (150, 154), indicating 
that MuSC senescence may be initiated at an earlier time point. Pre-geriatric mice, 
approximately two years old, can exhibit features of MuSC senescence (5, 7, 152, 155, 156). 
However, the early mechanisms that instigate MuSC senescence are still largely unknown.  
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One of the hallmarks of organismal aging is the appearance of mitochondrial dysfunction 
(148, 149). Mitochondrial dysfunction, induced by calorie-dense diets or aging, can result 
from depletion of NAD+ (the oxidized form of nicotinamide adenine dinucleotide), whereas 
NAD+ repletion, with precursors such as nicotinamide riboside (NR), can reverse this process 
(101, 157-160). Stem cells are thought to rely predominantly on glycolysis for energy, a 
process that would reduce cellular concentrations of NAD+ (161). Mitochondrial function is 
linked to SC maintenance and activation (55, 162-164), yet its role in senescence is 
unknown. 
2.4 Results 
2.4.1 Mitochondrial dysfunction is a biomarker of MuSC senescence 
To identify the role of mitochondrial function in SCs we compared MuSCs from young and 
aged mice to investigate SC senescence. To identify the principal mechanisms initiating 
MuSC senescence, we examined publically available MuSC gene expression datasets from 
young (~3 months) and aged (~24 months) mice using gene set enrichment analysis (GSEA; 
GEO dataset IDs: GSE47177(7), GSE47104(155) and GSE47401(152)). Enrichment scores 
of young versus aged datasets revealed upregulation of senescence pathways and 
downregulation of cell cycle pathways with age (Figure 2.  1A, and figure 2.  S1, A and B). 
This is consistent with the idea that irreversible cell cycle arrest is a primary marker of 
cellular senescence (148, 149). In all three datasets, tricarboxylic acid (TCA) cycle and 
oxidative phosphorylation (OXPHOS) pathways were among the most downregulated 
pathways in aged MuSCs (Figure 2.  1A, and figure 2.  S1, A and B). Analysis of gene 
ontology (GO) terms that were significantly (Gene Set Enrichment Analysis; FWER p<0.05) 
downregulated in aged MuSCs, further demonstrated links to mitochondrial function (figure 2.  
S1C). Common downregulated genes during aging showed a substantial overlap (113 genes; 
11.59%) with mitochondrial genes (165) (Figure 2. 1B), in contrast to the minimal (11 genes; 
1.92%) overlap amongst common upregulated genes (figure 2. S1D). Among the 113 
downregulated mitochondrial genes in aged MuSCs, 41.6% were related to the TCA cycle 
and OXPHOS (figure 2.  S1E), which is higher than their percent composition of the whole 
mitochondrial proteome (~14%)(166, 167). This indicates a dominant decline in expression of 
mitochondrial respiratory genes in aged MuSCs. The reduction in mitochondrial OXPHOS 
and TCA cycle genes was consistent for all independent datasets (figure 2.  S1, F and G). 
We isolated primary aged and young MuSCs and confirmed reduced abundance of 
OXPHOS and TCA cycle transcripts (Figure 2.  1C), and reduced oxidative respiration rates 
in both freshly isolated (Figure 2.  1D) and cultured MuSCs (figure 2.  S1H). MuSC 
mitochondrial dysfunction in aged mice was further confirmed by the loss of mitochondrial 
membrane potential (Figure 2.  1E) and a reduction in cellular ATP concentrations (Figure 2.  
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1F). Several important markers and regulators of the UPRmt, a stress response pathway that 
mediates adaptations in mitochondrial content and function, were downregulated in aged 
MuSCs (figure 2.  S1F and Figure 2.  1G). Despite the absence of consistent changes in 
cyclin-dependent kinase inhibitor 2A (CDKN2A) (figure 2.  S1I) or mitogen-activated protein 
kinase 14 (MAPK14; p38) pathways, previously reported to regulate MuSC senescence, 
expression of cell cycle genes was decreased and expression of genes encoding the 
senescent proinflammatory secretome was increased (figure 2.  S1, I-K). The reduction in 
cell cycle signaling was accompanied by increased expression of genes in the cyclin-
dependent kinase inhibitor 1 (CDKN1A; p21CIP1)-mediated pathway (figure 2.  S1K), 
suggesting that early senescence in MuSCs may involve CDKN1A.
 
Figure 2. 1 Mitochondrial dysfunction in muscle stem cells (MuSCs) during aging 
A, Gene-set enrichment analysis (GSEA) demonstrates up- and downregulated signaling pathways in MuSCs 
from two-year-old mice, compared to four-month-old mice. Analysis of microarray data from the publicly available 
GEO data set (accession number GSE47177) using Kyoto encyclopedia of genes and genomes (KEGG) 
enrichment. Signaling pathways were ranked on the basis of normalized enrichment scores (NESs); positive and 
negative NESs indicate down- or upregulation in aged MuSCs, respectively. Specific pathways related to MuSC 
function are highlighted in red and blue. B, Area-proportional Venn diagram representing 113 common genes 
between the significantly downregulated genes (P < 0.05) in MuSC transcriptomes originating from aged mice 
(GSE47177 and GSE47401 (155)), and genes from the human mitochondrial transcriptome (165). C-G, Young (1 
month old) and aged (22-24 months old) C57BL/6J mice received a dietary supplement with NR for 6 weeks. C, 
qRT-PCR validation of transcriptional changes in mitochondrial genes of freshly sorted MuSCs. D, Oxygen 
consumption rate (OCR) in freshly isolated MuSCs, following 16h of recovery at 37°C. E-F, Mitochondrial 
membrane potential, measured by tetramethylrhodamine, methyl ester (TMRM) assay (H) and cellular ATP levels 
(I) in freshly isolated MuSCs.  G, Relative gene expression for UPRmt genes and cell senescence markers in 
freshly sorted MuSCs. Data are normalized to 36b4 mRNA transcript levels. All statistical significance was 
calculated by Student’s t test. All data are shown as mean ± s.e.m. *P < 0.05, **P < 0.01, ***P < 0.001. C-D and 
F-G, n=6; E, n=3 mice per group. 
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2.4.2 NAD+ repletion improves MuSC function in aged mice 
Given the importance of NAD+ concentrations in the control of mitochondrial function (101, 
104), we examined the potential of NAD+ repletion to improve MuSC numbers and muscle 
function in aged mice. Amounts of NAD+ in freshly isolated MuSCs were lower in those 
isolated from aged mice and 6 weeks of NR treatment increased NAD+ concentration in 
MuSCs from young and old mice (Figure 2.  2A). Amounts of NADH were relatively stable 
(figure 2.  S2A). Muscle from aged mice contained fewer MuSCs (Figure 2.  2, B and C and 
figure 2.  S2, B and C). However, NR treatment increased MuSC numbers in young and old 
mice (Figure 2.  2, B and C and figure 2.  S2, B and C). The increase in MuSC numbers was 
confirmed with paired box protein Pax-7 (PAX7) staining, a known MuSC marker (65)  
(Figure 2.  2D and figure 2.  S2, D and E). The effect of NR in young or aged mice appeared 
not to result from changes in muscle or body mass, as these measures remained 
comparable among all groups over the short treatment period (figure 2.  S2, F to I). NR 
treatment also enhances muscle function in aged animals through an independent 
mechanism acting directly on the muscle fibers (101), as was apparent from improvements in 
maximal running times and distances, along with limb grip strength in aged mice (Figure 2.  2, 
E to G). Young animals showed no such changes (figure 2.  S2, J to L).  
 
Figure 2. 2 Improved muscle stem cell numbers and muscle function in NR-treated aged mice 
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Young (3 months old) and aged (22-24 months old) C57BL/6J mice received chow diet (CD) or CD supplement 
with NR for 6 weeks. All results are compared to age-matched mice given a control diet. A, NAD+ concentrations 
in freshly isolated MuSCs. B-C, Percentage of FACS quantified CD34+/integrin α7+/Lin-/Sca-1- MuSCs relative to 
the total Lin-/Sca-1- cell population (B) or to muscle weight (C). D, Representative images of PAX7 and laminin 
immunostained tibialis anterior (TA) muscle. Arrows point to PAX7-positive SCs. 20 x 20μm insets show a single 
MuSC. Scale bar = 50µm. E-G, Comparison of maximal running duration (E), running distance (F) and grip 
strength (G) in NR-treated aged mice. H, H&E stained TA tissue-sections from NR-treated aged mice 7 and 14 
days after cardiotoxin (CTX)-induced muscle damage. Scale bar = 100µm. I, Images of PAX7 and laminin 
immunostained TA muscle cross-sections taken from NR-treated aged mice 7 days after CTX-induced muscle 
damage. Arrows point to PAX7-positive MuSCs. 20 x 20μm insets show a single MuSC. Scale bar = 50µm. J, 
Quantification of the signal intensity ratio between MYOD1 and PAX7 in PAX7-positive MuSCs, performed on 
sections isolated 7 days after muscle damage in aged mice. Images not shown. K, Newly regenerated muscle 
fibers, stained by embryonic myosin heavy chain (eMyHC) 7 days after muscle damage in aged mice. Scale bar = 
50µm. L, Dystrophin immunostaining of TA muscle sections in aged  (16 months old) mdx mice 4-weeks after 
receiving transplantations of MuSCs isolated from control or NR-treated aged C56BL/6J donors. Scale bar = 
100µm. All statistical significance was calculated by Student’s t test or two-way ANOVA. All data are shown as 
mean ± s.e.m. *P < 0.05, **P < 0.01, ***P < 0.001. Main effects for treatment or age are denoted as † or ‡, 
respectively, with interactions denoted as ε. A, n = 6 mice; B-D and H-K, n = 3-6 mice per group; E-G, n = 10 
control diet; n = 7 NR-treated mice; L, n = 12 donor mice, n = 3 recipient mice for each treatment. Corresponding 
young control data for Fig 2, E to I are found in S2, J to O, respectively. 
Impairments in muscle regeneration efficiency have been linked to the decline in MuSC 
function in aged mice (150). We therefore examined the benefits of NR on muscle 
regeneration with cardiotoxin (CTX)-induced muscle damage (65). NR treatment accelerated 
muscle regeneration in aged and young mice (Figure 2.  2H and figure 2.  S2M). NR-induced 
improvements in regeneration were paralleled by increases in PAX7-stained MuSCs in aged 
mice (Figure 2.  2I and figure 2.  S2N), but not in young mice (figure 2.  S2, O and P). NAD+ 
repletion also improved the stemness of the aged MuSCs, as demonstrated by a reduction in 
myoblast determination protein 1 (MYOD1)-stained PAX7 immunostained cells (Figure 2.  2J 
and figure 2.  S2Q), as MYOD1 is a transcriptional factor that activates MuSC differentiation. 
7 days after CTX-induced damage, NR-treated aged mice exhibited improvements in 
embryonic myosin heavy chain staining, a protein expressed in fetal and newly regenerating 
adult muscle fibers (168) (Figure 2.  2K). When MuSCs were transplanted from NR-treated or 
control aged mice into mdx mice (figure 2.  S2R) (a mouse model of Duchenne muscular 
dystrophy that gradually loses MuSC function in aging due to the strain of continual muscle 
regeneration). MuSCs isolated from NR-treated donors more effectively replenished the 
MuSC compartment and stimulated myogenesis of dystrophin-positive myofibers when 
transplanted into either young or aged mdx recipients (figure 2.  S2S and Figure 2.  2L, 
respectively). Thus, NR treatment can both improve muscle regeneration and MuSC 
transplantation efficiency.  
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The inappropriate accumulation of non-myogenic fibro-adipogenic progenitors (FAPs) and 
inflammatory cells have been reported to impair MuSC function and muscle regeneration, 
especially in aged muscle or with chronic damage, as found in mdx mice (169). NR treatment 
largely attenuated increases in FAP numbers 7 days after CTX induced damage in aged 
mice, but had no effect on FAPs under basal conditions (figure 2.  S2, T to V). This effect is 
consistent with benefits to FAP clearance in later periods of muscle regeneration (169). NR 
also alleviated macrophage infiltration 7 days after CTX induced regeneration in aged mice 
(figure 2.  S2, W and X).  
2.4.3 NR prevents MuSCs senescence by improving mitochondrial function 
To explain the improvements in MuSCs from aged animals after NAD+ repletion, we 
examined effects on MuSC senescence. Freshly isolated MuSCs from NR-treated young and 
aged mice were immunostained for phosphorylation of histone 2A.X at Ser139 (γH2AX), a 
marker of DNA damage (148). γH2AX-stained nuclei were more abundant in MuSCs from 
aged animals, and staining was reduced with NR treatment (Figure 2.  3, A and B, young 
controls found in figure 2.  S3, A and B). The reduction of the nuclear damage response in 
MuSCs was confirmed by a single-cell gel electrophoresis (comet) assay, a sensitive 
measure of DNA strand breaks as an indicator of senescence (Figure 2.  3C), as well as by 
staining for β-galactosidase, another classical senescence marker (148) (figure 2.  S3C). A 
6-hour NR treatment of late passage C2C12 myoblasts also reduced the expression of cell 
senescence and apoptosis markers (170) (Figure 2.  3D). MuSCs isolated from NR-treated 
aged mice showed enhanced potential to form myogenic colonies (Figure 2.  3E and figure 2.  
S3D). Thus, NR exerts a protective effect against intrinsic MuSC senescence.  
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Figure 2. 3 NR treatment prevents MuSC senescence and improves mitochondrial function 
Aged (22-24 months old) C57BL/6J mice or 8 months old SIRT1MuSC-/- mice received a dietary supplement with 
NR for 6 weeks. All isolated MuSCs were freshly FACS sorted for assay. Most comparative data from young mice 
(1 month old) are presented in Figure 2.  S3. A-B, Immunostaining (A) and quantification (B) of γH2AX staining in 
freshly sorted MuSCs from aged mice. 20 x 20μm insets show single MuSCs. C, Single-cell gel electrophoresis 
(comet) assay of MuSCs from aged mice. C, chow diet; N, NR treated. NDD, non-damaged DNA; MDD, 
moderately-damaged DNA; HDD, heavily-damaged DNA. D, Proteins levels in C2C12 myoblasts with NR 
treatment for 1, 3 or 6 hrs. E, Colony formation ability assay in isolated MuSCs. F-G, Quantification of transcript 
expression for cell cycle and inflammatory secretome genes (F) or OXPHOS and TCA cycle genes (G) in MuSCs. 
H, Abundance of proteins from MuSCs of young (Y) and aged (A) mice fed with a chow (C) or NR diet (N). Protein 
abundance was calculated using peptide intensity detected in the SWATH-MS map. Roman numerals indicate 
corresponding OXPHOS complexes. T, TCA cycle. I, Protein levels in MuSCs. J-K, OCR (J) and ECAR (K), in 
MuSCs following 16h of recovery at 37°C. L, Mitochondrial membrane potential, measured by a TMRM assay in 
MuSCs. M, Cellular ATP concentration in MuSCs. N, H&E stained TA muscle from wild type or SIRT1MuSC-/- mice 
7 days after cardiotoxin (CTX)-induced muscle damage. Scale bar = 100µm. O-Q, Representative images (O) and 
quantification of PAX7-positive MuSCs in random fields of view (160x160µm) (P) and the percentage of SIRT1-
positive MuSCs (Q) in immunostained TA 7 days after CTX-induced muscle damage. Arrows point to PAX7-
positive MuSCs. 20 x 20μm insets show a single MuSC. Scale bar = 50µm. R, Quantification of γH2AX-positive 
MuSCs in immunostained TA 7 days after CTX-induced muscle damage. All statistical significance was calculated 
by Student’s t test or two-way ANOVA. All data are represented as mean ± s.e.m. *P < 0.05, **P < 0.01, ***P < 
0.001. Main effects for treatment or age are denoted as † or ‡, respectively, with interactions denoted as ε. A-C, 
and N-R n = 3-6 mice per group; E, n = 24 in each group; F-G and J-M, n = 6 mice per group; H, protein extracted 
and pooled from 6 mice in each group. Corresponding young control data found in Figs. 3, A, B, E, F, G and L are 
found in Figs. S3 A, B, D, E, F and G, respectively. 
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NR treatment of MuSCs from aged mice reduced abundance of mRNAs encoding CDKN1A 
and related proinflammatory proteins and increased the expression of cell cycle genes 
(Figure 2.  3F). These effects were not seen in non-senescent MuSCs from young animals 
(figure 2.  S3E). NR treatment of MuSCs from aged animals increased expression of genes 
whose products function in the TCA cycle and OXPHOS (Figure 2.  3G), an effect that was 
not evident in young animals (figure 2.  S3F). To quantify protein expression level at different 
conditions, we applied a new mass spectrometry-based proteomics technique, the sequential 
windowed acquisition of all theoretical fragment ion mass spectra (SWATH-MS)(171), which 
allows accurate and reproducible protein quantification across sample cohorts. Using this 
technique, we have quantified the expression changes of more than 1100 proteins in MuSCs 
across the various conditions. The SWATH-MS results show that a significant amount of 
proteins that function in OXPHOS and in the UPRmt were decreased in MuSCs from aged 
animals (Figure 2.  3H). The overall amount of these same proteins was increased after NR 
supplementation (two-way AVOVA test, P < 0.05, Figure 2.  3H). Protein immuno-blotting of 
freshly isolated MuSCs from aged animals confirmed increased expression of proteins 
related to cell cycle and senescence that could not be detected by SWATH-MS (Figure 2.  3I).  
MuSCs from NR treated aged mice exhibited increases in oxidative respiration (Figure 2.  3, 
J and K). NR-treated MuSCs from aged animals also showed increased mitochondrial 
membrane potential (Figure 2.  3L and figure 2.  S3G) and increased abundance of ATP 
(Figure 2.  3M). To test whether this protective effect of NR on MuSC senescence relies on 
mitochondrial function we created a tamoxifen-inducible sirtuin-1 (SIRT1) MuSC-specific 
knockout mouse (SIRT1MuSC-/-), by crossing SIRT1flox/flox mice with the Pax7creER strain. SIRT1 
is an NAD+-dependent deacetylase that increases mitochondrial biogenesis (101). The 
beneficial effect of NR on muscle regeneration after CTX injection appeared attenuated in 
SIRT1MuSC-/- mice (Figure 2.  3N). Supporting this qualitative observation, SIRT1-knockout in 
MuSCs blocked the beneficial effects of NR on MuSC activation (Figure 2.  3, O to Q) and 
senescence (Figure 2.  3R and figure 2.  S3H) 7 days after regeneration. These data indicate 
that NR inhibits MuSCs senescence by improving mitochondrial function in a SIRT1-
dependent manner. This finding is consistent with a report linking FOXO3 activation, a SIRT1 
target, to improved mitochondrial metabolism in hematopoietic stem cells (172). 
2.4.4 Rejuvenating MuSCs by activating the UPRmt and prohibitin pathways 
We further explored how UPRmt might regulate senescence by examining the role of 
prohibitins, a family of stress response proteins. Prohibitins sense mitochondrial stress and 
modulate senescence in fibroblasts in mammals (173), maintain replicative lifespan in yeast 
(174), and promote longevity in worms (175), animals that lack adult SCs. Expression of 
prohibitins, Phb and Phb2, was reduced in the bioinformatics analysis (figure 2.  S1F), and in 
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freshly isolated aged MuSCs (figure 2.  S4A). NR increased the expression of prohibitin 
proteins in C2C12 myoblasts (Figure 2.  4A) and transcripts in MuSCs of young and aged 
mice (Figure 2.  4B and figure 2.  S4B). NR treatment was also shown to increase the 
expression of prohibitins concurrent to markers of UPRmt and cell cycle (figure 2.  S4C). 
Moreover, the overexpression of prohibitins, in the absence of NR, likewise increased UPRmt 
and cell cycle protein expression (Figure 2.  4C). Demonstrating the dependency of the NR 
effect on prohibitins, improvements in UPRmt and cell cycle protein expression were not 
observed with NR treatment following the knockdown of prohibitins (Fig 4D and figure 2.  
S4D). To confirm the regulation of prohibitins on cell cycle proteins and to explore the effect 
of prohibitins on MuSC function, Phb was depleted in vivo through an intramuscular injection 
of shPhb lentivirus (PHB and PHB2 are functional only as a heterozygous protein complex) 
(176).  Impairment of muscle regeneration and a reduction in MuSC numbers was observed 
in shPhb lentivirus injected mice, 7 days after CTX-induced muscle regeneration (Figure 2.  4, 
E and F). Quantifying these results, Phb knockdown is shown to block the NR induced 
increase of MuSCs number upon regeneration (Figure 2.  4, G and H). Importantly, Phb 
knockdown does not induce more MuSCs senescence in aged mice, yet prevents the 
beneficial effect of NR on MuSCs senescence (Figure 2.  4I and figure 2.  S4E). Initiation of 
the UPRmt by thiamphenicol also induced expression of prohibitins and cell cycle genes in 
C2C12 cells (figure 2.  S4F). These results indicate that NR activates the UPRmt and the 
prohibitin signaling pathway, as it inhibits MuSC senescence. 
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Figure 2. 4 Effects of NR on prohibitins, UPRmt and MuSC senescence 
A, Expression of HSP60, CLPP and prohibitins in C2C12 myoblasts upon NR treatment at the indicated time 
points. B, Quantification of transcript expression for UPRmt and prohibitin genes in MuSCs from aged (22-24 
months old) C57BL/6J mice following 6 weeks of chow or NR diets. C, Expression of prohibitins and cell cycle 
proteins in C2C12 myoblasts with the combined overexpression of Phb and Phb2. D, Expression of prohibitins 
and cell cycle genes with a 6-hour NR treatment in C2C12 myoblasts after a combined Phb and Phb2 shRNA 
knockdown. E, H&E staining of TA muscle in NR-treated or intramuscular shPhb lentivirus-injected C57BL/6J 
mice 7 days of after cardiotoxin (CTX)-induced muscle damage. Scale bar = 100µm. F-H, Representative images 
(F) and quantification of PAX7-positive MuSCs in randomly chosen field of views (160x160µm) (G) and the 
percentage of PHB-positive MuSCs (H) in immunostained TA muscle 7 days after CTX-induced muscle damage. 
Arrows point to PAX7-positive MuSCs. 20 x 20μm insets show single MuSC. Scale bar = 50µm. I, Quantification 
of γH2AX-positive MuSCs in immunostained TA muscle cross-sections taken from control and NR-treated mice 7 
days after CTX-induced muscle damage. All statistical significance was calculated by Student’s t test or two-way 
ANOVA. All data are represented as mean ± s.e.m. *P < 0.05, **P < 0.01, ***P < 0.001. Main effects for treatment 
or age are denoted as † or ‡, respectively, with interactions denoted as ε. B, n = 6 mice; E-I, n=3 mice per group. 
Corresponding young control data found in Figure 2. 4B are found in figure 2. S4B.
2.4.5 NR reprograms senescence prone MuSCs in mdx mice 
With continuous muscle regeneration, MuSCs in mdx mice are abnormally active at a young 
age, leading to MuSC depletion and dysfunction later in life. As a result, primary MuSCs 
isolated from 14-week-old mdx mice were more intensively and frequently stained with β-
galactosidase and had a larger cell size than those of control mice (Figure 2.  5A and figure 2.  
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S5, A and B). Similar to the effect in aged animals, NR treatment of mdx mice increased 
MuSC numbers by ~1.8 fold in vivo (Figure 2.  5, B to D and figure 2.  S5, C and D), as also 
confirmed by PAX7 immunostaining (figure 2.  S5E). Along with the increase in MuSCs, there 
was an increase in regenerated muscle fibers following NR treatment (Figure 2.  5E and 
figure 2.  S5F). We extended this analysis by examining the self-renewal capacity of mdx 
mouse MuSCs. The cellular redox ratio decreases as MuSCs differentiate (177), which can 
be detected by an increase in 450nm autofluorescence (178). In line with NR increasing the 
number of MuSCs in mdx mice, we found reduced autofluorescence from MuSCs isolated 
from these animals (Figure 2.  5, F to H). We performed β-galactosidase staining on primary 
MuSCs that had been isolated from mdx mice treated or without NR treatment in vivo, and 
were then further cultured with or without NR in vitro. MuSCs isolated from NR-treated mice 
were less prone to senescence (Figure 2.  5I and figure 2.  S5G). When MuSCs isolated from 
control mdx mice were treated with NR in vitro there was also a reduction in senescence 
(Figure 2.  5I and figure 2.  S5G). The inhibition of MuSCs senescence in NR-treated mdx 
mice was confirmed by the attenuation of. γH2AX and cleaved caspase-3 immunostaining 
(Figure 2.  5J). To evaluate MuSC function, CTX-induced muscle regeneration was 
examined in NR-treated mdx mice. Consistent with the prevention of MuSC senescence, 
muscle regeneration was improved with NR in both aged (Figure 2.  5K and figure 2.  S5H) 
and young mdx mice (figure 2.  S5I). We also examined the effect of NR on the FAP 
population and muscle regeneration in mdx mice. NR treatment increased MuSCs and 
reduced FAP numbers in basal conditions and 7 days after CTX-induced damage (figure 2.  
S5, J to L). Abnormal activation of FAPs in mdx mice contributes to fibrosis (169). mdx mice 
treated with CTX and then exposed to NR showed lower levels of macrophage infiltration 7 
days after damage (figure 2.  S5, M and N). Our results hence indicate a beneficial effect of 
NR on MuSC function and regeneration in mdx mice. 
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Figure 2. 5 Increased stem cell number and function in NR-treated mdx mice 
mdx mice  received a dietary supplement with NR for 10 weeks. All results were compared to mdx mice given a 
control diet. A, β-galactosidase staining of MuSCs isolated from C57BL/10SnJ or mdx mice and cultured in vitro 
for three generations. Scale bar = 10µm. B-D, FACS contour plots of Sca-1-/Lin- cells isolated from muscle. 
Percentage of the CD34+/integrin α7+/Lin-/Sca-1- MuSC populations are noted in red in contour plots (B), and 
quantified relative to the total Lin-/Sca-1- cell population (C) or to muscle weight (D). E, Immunostaining of and 
eMyHC+ fibers in tissue-sections of NR-treated mdx mice 7 days after CTX-induced muscle damage. F-H, FACS 
contour plots (F), quantification (G) and distribution (H) of MuSC autofluorescence as a measure of the relative 
NAD(P)H concentration upon UV light excitation. Autofluorescence emission was detected using 405/450 nm. 
Arrow in (H) points to the highly autofluorescent stem cell population. I, Quantification of β-galactosidase staining 
of FACS-sorted MuSCs from C57BL/6J (B6), untreated (mdx) or NR-treated mdx (mdx with NR) mice challenged 
with PBS or NR for 6 hours in vitro. J, Immunostaining showing γH2AX and cleaved caspase-3 in MuSCs cultured 
in vitro for three generations. Arrow points to a γH2AX-positive nucleus. Scale bar = 10µm. K, H&E staining of 
tissue-sections from NR-treated aged mdx mice (16 months old) with 7 days of recovery following CTX induced 
muscle damage. Scale bar = 100µm. All statistical significance was calculated by Student’s t test or one-way 
ANOVA. All data are represented as mean ± s.e.m. *P < 0.05, **P < 0.01, ***P < 0.001. A-H and J-K, n = 3-5 per 
treated group; I, n = 3 mice and n = 6 in vitro treatments. More than 500 cells were quantified in each condition. 
2.4.6 NR attenuates senescence of neural stem cells and melanocyte stem cells and 
increases mouse lifespan 
Aging is accompanied by a decline in the number and function of neural stem cells (NSCs) 
(163) and melanocyte stem cells (McSCs) (179). Therefore, to examine the generalized 
importance of NAD+ homeostasis in somatic SCs, we assessed the effect of NR in NSCs 
from aged mice. NR increased proliferation as shown by 5-ethynyl-2-deoxyuridine (EdU) and 
antigen Ki-67 (Ki67) staining, and induced neurogenesis indicated by doublecortin (DCX) 
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staining, in both the subventricular zone (SVZ) (Figure 2.  6, A to D) and the dentate gyrus 
(DG) of the hippocampus (figure 2.  S6, A to D) in aged mice. Nicotinamide mononucleotide 
(NMN), another NAD+ precursor, also has beneficial effects in aged neural stem cells (163). 
Similarly, NR rescued the decline of McSCs in hair follicles of aged mice, as reflected by 
increases in mast/stem cell growth factor receptor Kit (c-KIT) and short transient receptor 
potential channel 2 (TRP2), known McSCs markers, in NR-treated aged mice (Figure 2.  6, E 
and F). NR treatment of C57BL/6J mice slightly increased lifespan (chow diet, mean 
829±12.0; NR, mean 868±12.4 days, p = 0.034) (Figure 2.  6G). The beneficial effect of NR 
on survival was further confirmed by Cox proportional hazards analysis (Figure 2.  6H). 
Although the lifespan benefit is small, it was obtained with the NR treatment commencing 
late in life at 24 months. This argues that aging, in part, may stem from the dysregulation of 
general SC NAD+ homeostasis. 
 
Figure 2. 6 NR improves neural and melanocyte stem cell (NSC and McSC) function and increases the 
lifespan of aged C57BL/6J mice 
Aged (22-24 months old) C57BL/6J mice received a dietary supplement with NR for 6 weeks. A-B, 
Representative images (A) and quantification (B) of EdU-positive NSCs in the subventricular zone (SVZ) from 
young and aged mice following NR treatment. Scale bar = 50µm. C-D, Representative images (C) and 
quantification of Ki67- and doublecortin (DCX)-positive NSCs in the subventricular zone (SVZ) harvested from 
young and aged mice treated with or without NR (D). Arrows point to Ki67-positive NSCs. Scale bar = 50µm. E-F, 
Representative images (E) and quantification (F) of c-KIT and TRP2 double positive McSCs in the bulge of hair 
follicles from dorsal skin harvested from young and aged mice treated with or without NR. Arrows point to double 
positive McSCs. Scale bar = 50µm. G, Kaplan-Meier survival curves of control- and NR-treated aged mice, with 
the NR treatment beginning at 2 years (700 days) of age. H, Hazard rate decreased under NR treatment. 
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Individual lifespans were collected and used to estimate the hazard function of each population using numerical 
differentiation of the Kaplan–Meier survival estimator (solid lines). The shaded areas represent the 95% 
confidence bands of the true hazard. The p value was calculated with the use of a Cox proportional hazards 
model. All statistical significance was calculated by Student’s t test or two-way ANOVA, except in (G and H). All 
data are represented as mean ± s.e.m. *P < 0.05, **P < 0.01, ***P < 0.001. Main effects for treatment or age are 
denoted as † or ‡, respectively, with interactions denoted as ε.  A-F, n = 6, H, n=30 per treated group. 
2.5 Conclusions 
Oxidative stress, potentially introduced by mitochondrial respiration, is thought to be 
circumvented in stem cells by their reliance on glycolysis as a primary energy resource (180). 
However, our study demonstrates that mitochondrial oxidative respiration is important for the 
functional maintenance of multiple types of adult SCs during aging. In fact, the reduction in 
cellular NAD+ pools blunts the adaptive UPRmt pathway (158), ultimately leading to a loss of 
mitochondrial homeostasis with a concurrent reduction in the number and the self-renewal 
capacity of MuSCs. Accordingly, by boosting MuSC concentration of NAD+, proteotoxic 
stress resistance may be restored due to the activation of the UPRmt pathway, stimulating the 
prohibitin family of mitochondrial stress sensors and effectors. This will in turn improve 
mitochondrial homeostasis, protecting MuSCs from senescence and safeguarding muscle 
function in aged mice (figure 2.  S6E). Most importantly, using a MuSC-specific loss-of-
function model for Sirt1, an essential regulator governing mitochondrial homeostasis (181), 
the importance and essential nature of the relationship between the NAD+-SIRT1 pathway, 
mitochondrial activity and MuSCs function was unequivocally established in vivo. Maintaining 
healthy mitochondria, by replenishing NAD+ stores, seems furthermore to have beneficial 
effects beyond MuSCs, and also protect NSC and McSC populations from aging  
In combination, our results demonstrate that the depression of prohibitin signaling, leading to 
mitochondrial dysfunction, can be reversed in aging using a nutritional intervention to boost 
NAD+ concentrations in SCs, and suggest that NAD+ repletion may be revealed as an 
attractive strategy for improving mammalian lifespan. 
2.6 Supplementary materials 
2.6.1 Experimental methods 
Animals. Young (1 month old) and aged (20-24 months old) C57BL/6JRj mice were 
purchased from Janvier Labs. Five weeks old male C57BL/10SnJ and C57BL/10ScSn-
Dmdmdx/J mice, were purchased from The Jackson Laboratory. SIRT1MuSC-/- mice were 
created at the EPFL SPF animal core facility by crossing SIRT1flox/flox mice (157) with the 
Pax7creER strain (B6.Cg-Pax7tm1(cre/ERT2)Gaka/J, purchased from Jackson laboratory). Mice were 
fed with pellets containing vehicle or NR (400 mg/kg/day) for 6-8 weeks. The pellets were 
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prepared by mixing powdered chow diet (2016S, Harlan Laboratories) with water or with NR 
dissolved in water. Pellets were dried under a laminar flow hood for 48 hours. Animal 
phenotyping experiments were carried out according to standard operational procedures 
(SOPs) established and validated within the Eumorphia program (182). To induce SIRT1 
knockout in MuSCs, a 20mg/ml of Tamoxifen/corn oil solution was given to 
SIRT1flox/flox:Pax7creER mice via intraperitoneal injection for 5 consecutive days at 1mg/10g of 
mouse body weight. SIRT1flox/flox mice were injected at the same dosage of tamoxifen and 
served as controls. All mice were housed in micro-isolator cages in a room illuminated from 
7:00am-7:00pm with ad libitum access to diet and water. Animal experiments were 
authorized by the local animal experimentation committee of the Canton de Vaud under 
licenses 2665 and 2890. 
Endurance running test. Mice were fasted 2 hours before running on a treadmill. The 
exercise regimen commenced at a speed of 9cm/s with an inclination of 5 degrees. The 
speed was gradually increased 3cm/s every 12 minutes. Mice were considered to be 
exhausted, and removed from the treadmill, following the accumulation of 5 or more shocks 
(0.1 mA) per minute for two consecutive minutes. The distance traveled and time before 
exhaustion were registered as maximal running distance and period(101, 157). 
Grip strength test. Muscle strength was assessed by a grip strength behavior task. The 
grasp strength of each mouse for all four limbs was measured on a pull-grid assembly 
connected to a grip strength meter (Columbus Instruments). The mouse was drawn along a 
straight line parallel to the grid until the grip was broken, providing the peak force in grams. 
This was repeated 4 times with 5 min intervals between measurements.  
Survival test. Sixty 24-months-old C57BL/6JRj mice were randomly divided into two groups. 
Mice were housed with no more than 4 mice per cage. Cohorts of 30 mice were fed with a 
control chow diet with or without NR (400 mg/kg/day) supplementation. Mice were observed 
daily to record their survival – i.e. when they were found dead or were determined to be 
moribund by an experienced veterinary physician. Survival analyses were performed using 
the Kaplan-Meier method and the significance of differences between survival curves 
calculated using the log rank test (133).  The time-dependent hazard rate was estimated 
through numerical differentiation of the Kaplan–Meier cumulative hazard estimate. To 
generate confidence bands for the true hazard rate under the assumption that it is locally 
smooth, death times were fitted with a piecewise-polynomial B-spline hazard model using the 
R package bshazard (183). The p value was calculated with the use of a Cox proportional 
hazards model (184). 
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FACS based muscle stem cell isolation. Gastrocnemius, soleus, quadriceps, and tibialis 
anterior muscles from both limbs were excised and transferred into PBS on ice. All muscles 
were trimmed, minced and digested with 0.1mg/ml of type II collagenase (Sigma) in PBS for 
15 min at 37°C. Samples were then centrifuged at 750g for 5min and further digested in 1 
mg/ml of collagenase/dispase (Roche) for 30 min at 37°C. Muscle slurries were sequentially 
filtered through 100, 70 and 40 μm cell strainers. The isolated cells were then washed in 
washing buffer (PBS + 2.5% FBS) then resuspended in 200μl of washing buffer and 
immediately stained with antibodies, including the MuSC markers CD31 (1:800, eBioscience, 
eFluor450 conjugated); CD34 (1:200, eBioscience, eFluor660 conjugated); CD45 (1:200, 
eBioscience, eFluor450 conjugated); CD11b (1:400, eBioscience, eFluor450 conjugated); 
Sca-1 (1:1000, eBioscience, PE-Cy7 conjugated); and α7 integrin (1:300, MBL) for 30 min at 
4°C. Secondary staining was performed with a mixture of goat anti-mouse antibody (1:800, 
Life technologies, Alexa Fluor 488 conjugated) and propidium Iodide (PI, Sigma) for 15 min 
at 4°C in the dark. Stained cells were analyzed and sorted using the FACSAria II instrument 
(BD Biosciences). Debris and dead cells were excluded by forward scatter, side scatter and 
PI gating. Cells were sorted either directly on slides for immunostaining or into lysis buffer for 
NAD+ measurements and into TriPure (Roche) reagent for RNA extraction. 
Cell culture and treatments. FACS sorted MuSCs were grown on a 10% Matrigel 
(Corning)-coated dish and flasks with Fams F-10 media (Gibco), supplemented with 20% 
fetal bovine serum (FBS, Gibco), 2.5ng/ml basic fibroblast growth factor (bFGF, Sigma) and 
penicillin/streptomycin (1x, Gibco). Dishes were coated with 10% growth factor-free Matrigel 
solution on ice for 7 min then transferred to a 37°C cell culture incubator overnight before use. 
Cells were grown for three generations in vitro before experiments with cells plated and 
passaged at 10^3 cells/ml and 50% confluence, respectively. C2C12 mouse myoblasts were 
grown in DMEM (4.5g/L glucose, Gibco) supplemented with 10% FBS and 
penicillin/streptomycin (1x, Gibco). Cell transformations with Phb (Santa Cruz) and Phb2 
shRNA (Santa Cruz) were performed using jetPEI DNA transfection kit (Polyplus), according 
to manufacturer’s instructions. Cells were treated with 1mM NR or PBS for 6 hours before 
cell harvesting or fixation.  
Single-cell gel electrophoresis (comet) assay. The alkaline comet assay was performed 
according to the manufacturer’s instructions (Trevigen, 4250-050-K).  Briefly, FACS sorted 
MuSCs were resuspended in PBS and combined with molten LMAgarose (37°C) at the final 
concentration of 1x104 cells/ml. 50 μl of this LMAgarose dilution was immediately pipetted 
onto sample areas of CometSlides and allowed to stay 10min at 4°C in dark. After 60 
minutes cell lysis, CometSlides were immersed in Alkaline unwinding solution for 60min at 
4°C. Alkaline electrophoresis was then performed at 21 volts for 30min at room temperature. 
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Slides were then washed in distilled water, followed by 70% ethanol and dried for 15min at 
37°C. After staining with Propidium Iodide (PI), all CometSlides were then completely dried 
and observed under a fluorescent microscope (Leica). 
Mitochondrial membrane potential assay.  Mitochondrial membrane potential was 
measured using Tetramethylrhodamine, methyl ester (TMRM, Life Technology) following the 
manufacturer’s instructions. Briefly, MuSCs were sorted and resuspended in PBS at 1x105 
cells/ml. Cells were then stained with TMRM at the final concentration of 20nM for 30min at 
room temperature. Cells were then washed three times with PBS and mitochondrial 
membrane potentials were analyzed using a LSRII (BD) FACS machine with the excitation 
and emission wavelengths of 535nm and 610/620nm respectively. MuSCs from the same lot 
but treated with 10mM FCCP were used as negative control. 
β-galactosidase assay. MuSCs were sorted directly on 8 chamber slides (Thermo 
Scientific). Senescence-associated β-galactosidase activity was detected using the 
senescence β-galactosidase staining kit (Cell signaling), according to manufacturer’s 
instructions. 
Myogenesis assay. Five MuSCs were sorted directly into wells of a Matrigel-coated 96-well 
cell culture plate, containing MuSC growth medium (F10, 20% FBS, 2.5ng/ml bFGF, 1x 
pen/strep), using the automated cell deposition unit (ACDU) of the FACSAria II instrument 
(BD Biosciences). Cells were cultured at 37°C for 5 days. Cell colony formations were 
counted using the DM IL LED Inverted Microscope (Leica) after fixation in freshly made or 
defrosted 4% paraformaldehyde (PFA) for 10 min.  
 
Cardiotoxin-induced muscle regeneration. Animals were anesthetized using Isoflurane in 
oxygen from a precision vaporizer. 50μl of 20μM Naje mossambica mossambica cardiotoxin 
(Sigma) was injected intramuscularly cross the skin and directly into the tibialis anterior (TA) 
muscle. For SIRT1MuSC-/- mice, cardiotoxin was injected on the third day of the 5 consecutive 
days of tamoxifen injections, as described above. Mice were sacrificed at 7 and 14 days after 
injury. TA muscles were immediately embedded in Thermo Scientific™ Shandon™ 
Cryomatrix™ and frozen in isopentane, cooled in liquid nitrogen, for 2min before being 
transferred to dry ice and stored at -80°C. Representative wide field images for HE stained 
cardiotoxin treated muscles are shown in the Supplementary Information Figure 2.  1 
(magnified images are seen in Figure 2.  2I). 
? ???
MuSCs transplantation. Double-sorted MuSCs isolated from 24 months old NR or normal 
chow diet fed C57B/6J mice were resuspended in 10ul of F10 media with 20% FBS and 
injected directly into the cardiotoxin pre-injured TA muscle of mdx mice 24hrs after the injury. 
The recipient mice were either 5 weeks (young, 8000 MuSCs transplanted) or 16 months 
(aged, 15000 MuSCs transplanted) old. The cardiotoxin pre-injury was performed as 
described above. Recipient mice were sacrificed 4 weeks after transplantation, TA muscle 
were harvested and prepared for cryosectioning. 
Phb shRNA lentivirus production and intramuscular Phb knockdown. To make Phb 
shRNA lentivirus, Phb shRNA sequences ( Forward: 5’-
AATTTCTCCCGCTCTCGGAACATCACTCGAGTGATGTTCCGAGAGCGGGAGATTTTTTT
AT-3’ and reverse: 5’-
AAAAAAATCTCCCGCTCTCGGAACATCACTCGAGTGATGTTCCGAGAGCGGGAGA-3’, 
modified from Sigma, TRCN0000313177) or Scramble shRNA sequences (Forward: 5’- 
AATTCCTAAGGTTAAGTCGCCCTCGCTCGAGCGAGGGCGACTTAACCTTAGGTTTTTTT
AT -3’ and reverse: 5’- 
AAAAAAACCTAAGGTTAAGTCGCCCTCGCTCGAGCGAGGGCGACTTAACCTTAGG-3’, 
modified from Addgene, #1864) were sub-cloned into the GFP-containing pLKO 3G vector 
(Addgene #14748). Subconfluent HEK293T cells were then cotransfected, by calcium 
phosphate precipitation, with 20 µg of the above described pLKO 3G vectors together with 15 
µg of pCMV-R 8.74, and 10 µg of pMD.G, to produce lentiviruses. After 24 hours, the 
medium was changed. Supernatant containing recombinant lentiviruses was collected at 48h 
and 72h after transfection and virus was purified by ultracentrifugation. shRNA efficiency was 
tested in C2C12 cells infected with the above lentiviruses at a MOI of 10. For intramuscular 
Phb knockdown, 24 month old mice were injected with 108 TU/ml of either Phb or scramble 
shRNA lentivirus into the tibialis anterior muscle of each leg 24hrs after CTX-induced injury, 
as previously described (185). The CTX injury was performed as described above. Mice 
were sacrificed 7 days after CTX injury and the TA muscles were harvested and prepared for 
cryosectioning and histological analysis. 
Histology.  TA muscles were harvested from anaesthetized mice and immediately frozen in 
Tissue-TEK® OCT compound (PST). 8-μm cryosections were collected and fixed with 4% 
paraformaldehyde, which are either stained with haematoxylin/eosin (HE) or antibodies. For 
immunostainings, heat activated antigen retrieval was performed in pH 6.0 citrate buffer for 
10min at 65°C. After washing with PBS-0.1% tween 20 (PBST), the sections were blocked 
with 10% affinipure Fab goat anti mouse IgG (Jackson Immunoresearch) in PBST for 60min 
and PBST containing 2% BSA and 5% goat serum for 30min at room temperature. Primary 
antibodies were then applied over night at 4°C. The following antibodies were used: anti-
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eMHC (Developmental Studies Hybridoma Bank, DSHB, University of Iowa), anti-Pax7 
(DSHB, University of Iowa), anti-γH2AX Ser 139 (Millipore), anti-Laminin (Sigma), anti-
PDGFR (Cell signaling), anti-F4/80 (Sigma), anti-c-KIT (BD Pharmingen), anti-TRP2 (Santa 
Cruz), anti-activated-caspase3 (Cell signaling). Subsequently, the slides were washed in 
PBST and incubated with appropriate secondary antibodies and labeling dyes. For 
immunofluorescence, secondary antibodies were coupled to Alexa-488 or Alexa-568 
fluorochromes (Life technology), and nuclei were stained with DAPI (Invitrogen). After 
washing in PBST, tissue sections were mounted with Dako mounting medium (Dako). 
Collected brain samples were taken from mice perfused with PBS and 4% PFA. Harvested 
whole brains were further fixed in 4% PFA overnight, and thereafter cryoprotected in 30% 
sucrose for 48 hours prior to embedding in OCT compound (PST) in preparation for 
cryosectioning. All immunostainings were performed using the same protocol as described 
for muscle samples. Antibodies used were anti-Ki67 (AbCam) and anti-doublecortin (Santa 
Cruz). 
For cellular immunostaining, freshly isolated MuSCs were sorted directly into 8-chamber 
slides (Thermo Scientific) and examined immediately after 30min of sedimentation or 
cultured for 3 generations. Cells were then fixed with either 4%PFA or 3% H2O2 in methanol 
for 10-15min. After 15min permeabilization with 0.5% Triton X-100, cells were blocked and 
immunostained using a similar protocol to that used for muscle tissue sections. All samples 
were imaged with a DMI4000 B Inverted Microscope (Leica) or the VS120-S6-W slides 
scanner (Olympus). Images were analyzed using ImageJ software. For immunofluorescence 
quantification, positively stained cells were defined as those with an intensity that was higher 
than a given threshold, which was then applied to all images. The thresholds were set up 
using sample slides before analyzing experimental data. More than 3 whole muscle cross-
section areas, or more than 6 randomly chosen microscope scopes from each animal in all 
experimental conditions were used for quantification. All in vitro cultured or FACS sorted cells 
(> 500 per condition) were applied for analysis if cell number quantifications were performed.    
NAD+ and NADH quantification. MuSCs were isolated from the gastrocnemius, soleus, 
quadriceps, TA and EDL muscles from both hindlimbs of the control or NR-treated young and 
aged mice (4 groups). Approximately 5,000-8,000 MuSCs were collected from each animal, 
with 6 animals in each group, and sorted directly into 200μl of lysis buffer provided by the 
NAD+/NADH assay kit (Biovision, k337-100)(55). NAD+ and NADH concentrations were then 
measured following the manufacturer’s instructions, which were modified by scaling down 
assay volumes by 50% in all steps. Results were calculated according to the standard curve, 
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which was created using NADH standards from the kit. Final NAD+ and NADH concentrations 
for each sample were normalized to the total cell number 
Gene expression analyses. Total RNA was extracted from MuSCs by sorting cells directly 
into TriPure RNA isolation reagent (Roche) or from cultured C2C12 myoblasts using TriPure 
reagent according to the product manual. Total RNA was transcribed to cDNA using 
QuantiTect Reverse Transcription Kit (Qiagen). Expression of selected genes was analyzed 
using the LightCycler480 system (Roche) and LightCycler® 480 SYBR Green I Master 
reagent (Roche). The acidic ribosomal protein 36b4 gene (ribosomal protein, large, P0, 
Rplp0) was used as house keeping reference. 
Proteomics. Protein sample preparation and SWATH mass spectrometry (SWATH-MS) 
measurements were performed as follows: protein extraction and trypsin (Promega) 
digestion were done as previously described (186). ~20 μg of protein extracts from young, 
young-NR, aged and aged-NR mouse muscle stem cells were processed respectively. After 
digestion, the peptide samples were cleaned by Sep-Pak tC18 cartridges (Waters, Milford, 
MA, USA) and evaporated on a vacuum centrifuge until dry, and re-solubilized in 2% 
acetonitrile/0.1% formic acid prior to MS measurement. The SWATH and shotgun mass 
spectrometry were performed on the 5600 TripleTOF mass spectrometer as previously 
described (171). Alternatively, a set of 64 variable isolation windows was consecutively 
constructed covering the 400 to 1200 m/z precursor range. The spectral library was 
constructed using the results from shotgun-MS with SpectraST (187), as previously 
described (188). The SWATH-MS targeted data extraction was performed using 
OpenSWATH (189), which applies a target-decoy model to estimate the false-discovery rate 
(FDR) using the mProphet algorithm (190). Peptide features were retained to reach the 1% 
FDR threshold. Protein abundances were estimated using the three most intensive 
transitions from the three most intensive peptides, and normalized with the total protein 
abundance in each sample.  
Western blotting. C2C12 cells were lysed in a buffer composed of 50 mM Tris, 150 mM 
KCl, EDTA 1 mM, NP40 1%, nicotinamide 5mM, sodium butyrate 1mM and protease 
inhibitors cocktail (Roche) at pH 7,4. Proteins were separated by SDS-PAGE and transferred 
onto nitrocellulose membranes. Blocking and antibody incubations were performed in 3% 
BSA. The following primary antibodies were used: anti-cleavage caspase 3 (Cell Signaling); 
Anti-γH2AX (Millipore); anti-HSP60 (Enzo Life Science); anti-β-actin (Sigma); anti-PHB 
(Biolegend); anti-PHB2 (Santa Cruz); anti-CKD4 (Novus biologicals); anti-CCND1 (Santa 
Cruz); anti-CCND3 (Santa Cruz); anti-HSP90 (BD Biosciences); HSP70 (Abcam); anti-MT-
CO1 (Biolegend); anti-ATP5A (Biolegend); anti-Grp78 (Abcam); anti-α-Tubulin (Sigma); and 
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anti-CLPP (Sigma). All secondary antibodies were from Jackson Immunoresearch. Antibody 
detection reactions were developed by enhanced chemiluminescence (Advansta, CA, USA) 
and imaged using the c300 imaging system (Azure Biosystems). Full images of Western 
blots are shown in the Supplementary Information Figure 2.  2. 
Respirometry on primary MuSCs. Basal and uncoupled oxygen consumption rates (OCRs) 
and the extracellular acidification rate (ECAR) were measured using the Seahorse 
extracellular flux bioanalyzer (XF96, Seahorse Bioscience Inc.)(191). To uncouple 
mitochondria, 5μM of FCCP was injected after a basal respiration measurement. All 
measurements were performed in triplicates and results were normalized to total cell number 
seeded after FACS sorting. 
Bioinformatic analysis. Quadriceps microarray data from young and aged mice MuSCs (7, 
152, 155) were analyzed for transcript expression using the Kyoto encyclopedia of genes 
and genomes (KEGG), gene ontology (GO) or gene set enrichment analysis (GSEA) 
analysis. Raw microarray data are also publicly available on GEO under the accession 
numbers GSE47177, GSE47401 and GSE47104. All gene expression heat maps were 
drawn using GENE-E software. 
Statistical analysis. The sample size (n) for each experimental group is described in each 
figure legend. GraphPad Prism software was used for all statistical analyses. Quantitative 
data displayed as histograms are expressed as means ± standard error of the mean 
(represented as error bars). Results from each group were averaged and used to calculate 
descriptive statistics. Student’s t test was used for comparisons between two groups with 
statistical significance was set at a P value of  *P < 0.05, **P < 0.01 and ***P < 0.001. For 
multiple comparisons, a two-way analysis of variance (ANOVA) was performed followed by a 
Newman–Keuls post-hoc test. Significance for a main effect of treatment was set at a P 
value of †P < 0.05, ††P < 0.01 and †††P < 0.001, a main effect of age was set at a P value 
of ‡P < 0.05, ‡‡P < 0.01 and ‡‡‡P < 0.001 and an interaction was set at a P value of  εP < 
0.05, εεP < 0.01 and εεεP < 0.001. Survival analyses were performed using the Kaplan-Meier 
method and the significance of differences between survival curves calculated using the log-
rank test. The time-dependent hazard rate was estimated through numerical differentiation of 
the Kaplan–Meier cumulative hazard estimate. The p-value was calculated with the use of a 
Cox proportional hazards model. 
2.6.2 Supplementary figures 
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figure 2.S 1 Mitochondrial dysfunction in muscle stem cells (MuSCs) during aging 
A-B, Gene-set enrichment analysis (GSEA) demonstrates up- or downregulated signaling pathways in MuSCs 
from two-year-old mice, compared to 4-month-old mice. Analysis was performed on microarray data from the 
publicly available GEO data sets GSE47104 (155) (A) and GSE47401 (152) (B) using Kyoto encyclopedia of 
genes and genomes (KEGG) enrichment. Signaling pathways are ranked on the basis of their normalized 
enrichment scores (NESs); positive and negative NESs indicate down- or upregulation in aged MuSCs, 
respectively. Specific pathways related to MuSC function are highlighted in red and blue. C, Top 10 ranked 
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downregulated pathways in MuSCs from aged animals (GSE47177), based on gene ontology (GO) enrichment. 
Pathways are ranked by family wise error rate (FWER) p values. D, Area-proportional Venn diagram representing 
common genes (P < 0.05) between the significantly upregulated genes in MuSC transcriptomes originating from 
aged mice (GSE47177 (7) and GSE47401), and genes from the human mitochondrial transcriptome (165). E, Pie 
chart illustrating the percent composition of the common 113 mitochondrial genes found in C. TXN, transcription, 
TLN, translation. F, Custom gene-set analysis showing enrichment of mitochondrial respiratory chain (OXPHOS), 
TCA cycle and mitochondrial unfolded protein response (UPRmt) related transcripts from MuSCs of young (Y) and 
aged (A) mice obtained from three independent data sets (GSE47177, GSE47401 and GSE47104 (152)). Roman 
numerals indicate corresponding OXPHOS complexes. G, Gene-set analysis showing enrichment of the 
mitochondrial transcriptome from MuSCs of young and aged mice obtained from three independent data sets 
(GSEl7177, GSE47401 and GSE47104). H, Oxygen consumption rate (OCR) in isolated primary MuSCs, cultured 
in vitro for three generations. I, Gene-set analysis showing enrichment of cell senescence related genes from 
MuSCs of young and aged mice obtained from three independent data sets (GSE47177, GSE47401 and 
GSE47104). J, Relative expression for cell cycle genes in freshly isolated primary MuSCs, cultured in vitro for 
three generations. K, Relative gene expression for cell senescence markers in freshly sorted MuSCs. Data are 
normalized to 36b4 mRNA transcript levels. All data are shown as mean ± s.e.m. *P < 0.05, **P < 0.01, ***P < 
0.001. Statistical significance was calculated by Student’s t test. H, J-K, n = 6 mice per group. 
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figure 2.S 2 Improved muscle stem cell numbers and muscle function in NR-treated mice 
A-X, Young (1 months old) and aged (22-24 months old) C57BL/6J mice received a dietary supplement with NR 
(400 mg/kg/day) for 6 weeks. A, NADH levels in MuSCs freshly isolated from control and NR diet-fed mice. B, 
FACS contour plots of Sca-1-, Lin- (CD11b- CD23-, CD45-) cells isolated from muscle tissue. Percentage of the 
CD34+/integrin α7+/Lin-/Sca-1- MuSCs were noted in red in contour plots. C, Quantification of FACS-sorted 
CD34+/integrin α7+/Lin-/Sca-1- MuSCs isolated from control and NR diet-fed mice. Cell numbers were normalized 
to the entire live cell population. D-E, Representive image of PAX7 immunostained muscle cross-sections taken 
from control and NR-treated young mice (D) and the quantification of PAX7+ MuSCs of young mice (E). Myofibers 
were counterstained with Laminin. Arrows point to PAX7-positive SCs. 20 x 20μm insets show single MuSC. 
Scale bar = 50µm. F-I, Body weight (F) and TA (G), gastrocnemius (H), and quadriceps (I) muscle weights for 
each cohort. J-L, Comparison of maximal running duration (J), running distance (K) and grip strength (L) between 
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control and NR-treated young mice. M, TA muscle structure in tissue-sections from control and NR-treated young 
mice with 7 and 14 days of recovery following CTX induced muscle damage. Images show representative H&E 
staining of muscle cross sections. Scale bar = 100µm. N, quantification of immunostained PAX7-positive MuSCs 
in TA muscle cross-sections taken from control and NR-treated mice 7 days after CTX-induced muscle damage. 
O-P, Representative images (O) and quantification (P) of PAX7 immunostained muscle cross-sections taken from 
control and NR-treated young mice 7 days after CTX-induced muscle damage. Myofibers were counterstained 
with Laminin. Arrows point to PAX7-positive SCs. 20 x 20μm insets show single MuSC. Scale bar = 50µm. Q, 
Quantification of the signal intensity ratio between MYOD1 and PAX7 in PAX7-positive MuSCs, performed on 
sections isolated 7 days after muscle damage in young mice. Images not shown. R, The schema of MuSCs 
transplantation experiments. MuSCs were double sorted from control and NR diet treated C57BL/6J mice and 
transplanted into the different hind limbs of the same mdx mouse. S, Dystrophin immunostaining of TA muscle 
sections in young  (5 weeks old) mdx mice 4-weeks after receiving transplantations of MuSCs isolated from 
control or NR-treated aged C56BL/6J donors. Scale bar = 100µm. T-V, Representative images (T) and 
quantification of PAX7+ MuSCs (U) and PDGFR+ FAPs (V) in immunostained muscle cross-sections taken from 
control and NR-treated aged mice under basal conditions or 7 days after CTX-induced muscle damage. Scale bar 
= 50µm. W-X, Representative images (W) and quantification of F4/80+ macrophages (MPs) (X) in immunostained 
muscle cross-sections taken from control and NR-treated aged mice under basal conditions or 7 days after CTX-
induced muscle damage. Myofibers were counterstained with Laminin. Scale bar = 50µm. Statistical significance 
was calculated by Student’s t test or two-way ANOVA. All data are represented as mean ± s.e.m. *P < 0.05, **P < 
0.01, ***P < 0.001. Main effects for treatment or age are denoted as † or ‡, respectively. A-C, n = 6 mice per 
group; D-I, M-Q and T-X, n = 3-6 mice per group; J-L, n = 10-12 mice in each group; S, n = 12 donor mice, n = 3 
recipient mice for each treatment. 
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figure 2.S 3 NR treatment prevents muscle stem cell senescence by improving mitochondrial function 
Young (1 months old) C57BL/6J mice or 8 months old SIRT1MuSC-/- mice received a dietary supplement with NR 
(400 mg/kg/day) for 6 weeks. All results are compared to mice given a control diet. Data of the aged mice (22-24 
months old) from the same experiments were mainly presented in Figure 2.  3. A-B, Immunostaining (A) and 
quantification (B) of γH2AX in freshly sorted MuSCs from young mice treated with NR. 20 x 20μm insets show 
single MuSC.  C, β-galactosidase staining of freshly sorted MuSCs from young and aged mice given chow or NR 
supplemented diets. Scale bar = 10µm. D, Colony formation ability assay in freshly FACS sorted MuSCs from 
young mice treated with NR. E-F, Quantification of transcript expression for cell cycle and inflammatory 
secretome genes (E) or mitochondrial OXPHOS and TCA genes (F) in young MuSCs isolated from mice treated 
with NR. G, Mitochondrial membrane potential, measured by TMRM assay, in freshly isolated MuSCs from young 
NR-treated mice. H, Representative images of γH2AX and PAX7-positive cells in immunostained TA muscle 
cross-sections taken from control and NR-treated mice 7 days after CTX-induced muscle damage.  All data are 
represented as mean ± s.e.m. Statistical significance was calculated by Student’s t test. *P < 0.05. A-D, and G-H 
n = 3-6 mice per group; E-F, n = 6 mice per group. 
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figure 2.S 4 Effects of NR on MuSC senescence are mediated by prohibitin activation of UPRmt 
A, Quantification of transcript expression for prohibitins in MuSCs from young (one-month old) and aged (22-24 
months old) mice fed a chow diet (CD). B, Quantification of transcript expression for UPRmt related genes and 
prohibitins in MuSCs from young (one-month old) C57BL/6J mice fed CD or receiving a dietary supplement with 
NR (400 mg/kg/day) for 6 weeks.  C, Western blots showing the expression of prohibitins, UPRmt markers and cell 
cycle related proteins in C2C12 myoblasts upon a 6-h NR treatment. D, Expression of prohibitins and cell cycle 
related genes in C2C12 myoblasts after the combined Phb and Phb2 shRNA knockdown in normal DMEM cell 
growth media. E, Representative images of γH2AX and PAX7-positive cells in immunostained TA muscle cross-
sections taken from control and NR-treated Phb knockdown mice 7 days after CTX-induced muscle damage. F, 
Expression of prohibitins and cell cycle related genes in C2C12 myoblasts treated for the indicated periods with 
50 μg/ml thiamphenicol (TAP), which induces a mitonuclear imbalance and UPRmt.  All data are represented as 
mean ± s.e.m. Statistical significance was calculated by Student’s t test. *P < 0.05, **P < 0.01, ***P < 0.001. A-B, 
n = 6 per treatment group. E, n=3 mice per group. 
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figure 2.S 5 Increased stem cell number and stemness in NR-treated mdx mice 
mdx mice received a dietary supplement with NR (400 mg/kg/day) for 10 weeks. A-B, Quantification of β-
galactosidase-positive cells (A) and cell size (B) for primary MuSCs isolated from C57BL/10SnJ or mdx mice and 
cultured in vitro for three generations. C-D, Quantification of FACS sorted CD34+/integrin α7+/Lin-/Sca-1- MuSCs 
isolated from control and NR diet-fed mdx mice, cell numbers were normalized to the entire cell population (C) or 
to the entire live cell population (D). E, Immunostaining of MuSCs (PAX7+) in tissue-sections of NR-treated mdx 
mice 7 days after CTX-induced muscle damage. Myofibers were counterstained with Laminin. Arrows point to 
PAX7+ MuSCs. 20 x 20μm insets show single MuSC. Scale bar = 50µm.  F, Immunostaining of neo-regenerated 
muscle fibers, indicated by eMyHC-positive fibers, in tissue-sections of NR-treated mdx mice under basal 
conditions. Images show the whole TA muscle cross-section. Myofibers were counterstained with Laminin. G, 
Representative images of β-galactosidase staining of FACS-sorted MuSCs from C57BL/6J, untreated (mdx) or 
NR-treated mdx (mdx with NR) mice challenged with PBS or NR for 6 hours. H, Immunostaining of neo-
regenerated muscle fibers, indicated by eMyHC-positive fibers, in tissue-sections of NR-treated aged mdx mice 
(16 months old) 7 days after CTX-induced damage. Myofibers were counterstained with Laminin. Scale bar = 
50µm. I, Muscle structure in tissue-sections from NR-treated young mdx mice (14 weeks old) with 7 days of 
recovery following CTX-induced muscle damage. Images show representative H&E staining of whole TA muscle 
cross-sections. Scale bar = 100µm. J-L, Representative images (J) and quantification of PAX7+ MuSCs (K) and 
PDGFR+ FAPs (L) in immunostained muscle cross-sections taken from control and NR-treated mdx mice under 
basal conditions or 7 days after CTX-induced muscle damage. Scale bar = 50µm. M-N, Representative images 
(M) and quantification of F4/80+ macrophages (MPs) (N) in immunostained muscle cross-sections taken from 
control and NR-treated mdx mice without under basal conditions or 7 days after muscle damage. Myofibers were 
counterstained with Laminin. Scale bar = 50µm. All data are represented as mean ± s.e.m. Statistical significance 
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was calculated by Student’s t test. *P < 0.05, **P < 0.01. ***P < 0.001. A-F and H-N n = 3-6 mice per treatment 
group. G, n = 3 mice and n = 6 in vitro treatments. More than 500 cells were quantified in each condition. 
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figure 2.S 6 NR improves neural stem cell (NSC) of aged C57BL/6J mice 
Aged (22-24 months old) C57BL/6J mice received a dietary supplement with NR (400 mg/kg/day) for 6 weeks, 
which were then compared to control-diet-fed young or aged mice. A-B, Representative images (A) and 
quantification (B) of proliferating EdU-positive NSCs in the dentate gyrus (DG) of the hippocampus from young 
and aged mice following NR treatment. Arrows point to EdU-positive NSCs. C-D, Representative images (C) and 
quantification of Ki67-positive NSCs and the neuron regeneration marker, doublecortin (DCX), in the dentate 
gyrus (DG) of the hippocampus (D) harvested from young and aged mice following NR. Arrows point to Ki67-
positive NSCs. E. Hypothethical mechanistic scheme showing how NR prevents adult stem cell senescence. 
Statistical significance was calculated by two-way ANOVA. All data are represented as mean ± s.e.m. *P < 0.05, 
**P < 0.01, ***P < 0.001. Main effects for treatment or age are denoted as † or ‡, respectively. A-D, n = 6 in each 
group. 
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Chapter 3. Control of muscle stem cell 
function by the acetyltransferase 
KAT2A 
Adapted from:  
Zhang, H., Luan, P., Ryu, D., Sorrentino, V., Menzies, K. J. Schoonjans, K., & Auwerx, J. 
Control of muscle stem cell function by the acetyltransferase KAT2A. Under preparation 
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3.1 Abstract 
Muscle stem cells (MuSCs) are essential for skeletal muscle homeostasis and repair. The 
complete mechanism controlling MuSC maintenance and differentiation, however, remains 
elusive. We found that KAT2A expression is essential for myogenic differentiation of MuSCs. 
KAT2A loss-of-function in cells blocks MuSC differentiation, and in mice impairs regeneration 
after muscle damage. The regulation of KAT2A in MuSCs function might rely on its ability to 
enzymatically acetylate proteins, a well-known protein modification, such as the MuSC 
transcription factor PAX7. 
3.2 One sentence summary 
KAT2A regulates MuSCs function through PAX7 acetylation 
3.3 Introduction 
Skeletal muscle homeostasis and regeneration relies on functional MuSCs or satellite cells. 
With muscle stress or damage, quiescent MuSCs are activated to differentiate into new 
fibers, join existing fibers, or replenish the existing pool of MuSCs through self-renewal. 
However, these responses are blunted in muscle with aging or with myopathies, such as 
Duchenne’s muscular dystrophy (DMD), and are often a result of the decline in MuSC 
number and function. Deciphering each of the factors that modulate satellite cell 
specification, maintenance, proliferation and differentiation will provide the foundation for 
developing new strategies for the treatment of muscular diseases as well as muscle 
sarcopenia, which is defined as the loss of muscle mass during aging. Recent reports have 
begun to indicate the role of posttranslational modifications, such as acetylation, in MuSC 
activation and function during aging(7, 192-194). However, the current knowledge of 
posttranslational modifications regulating MuSC homeostasis remains rudimentary. 
3.4 Results 
3.4.1 KAT2A is upregulated in activated MuSCs 
To investigate potential acetylation modulators in the control MuSC activation and 
differentiation, we examined publically available MuSC gene expression datasets of 
quiescent and activated MuSCs isolated from control and muscle-damaged mice(7). We first 
analyzed transcriptomes from MuSCs that had been identified and isolated using the yellow 
fluorescent protein (YFP)-conjugated to the MuSC marker PAX7, the well-known 
transcription factor involved in MuSC maintenance. Expression of most of the known lysine 
acetyltransferases (KATs) and lysine deacetylases (KDACs), which catalyze 
posttranslational protein modifications(2) are dynamically altered during MuSCs activation 
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and differentiation (Figure 3.1A). Intriguingly, among all the KATs, Kat2a is the only transcript 
that is upregulated in activated in MuSCs during muscle regeneration (60 hours after muscle 
damage), which subsequently begins to decline during the differentiation of MuSCs (84 hours 
after damage), pointing to a possible strict time-dependent necessity for KAT2A expression 
during MuSCs activation (Figure 3.1A). This was further confirmed in MuSCs isolated using a 
extensive profile of cell surface markers (VCAM+/CD31-/CD45-/Sca1-) (Figure 3.S1A). Aging 
on the other hand is accompanied by a decline in MuSC activation(8). In line with these 
observations, Kat2a expression is reduced in aged MuSCs (Figure 3.1B and figure 3.S1B). 
Recently, MuSCs were reported to be in a more activated quiescent state after contralateral 
leg muscle damage, a state termed GAlert MuSCs(195). Interestingly, Kat2a is the only KAT 
that is upregulated in the GAlert phase in MuSCs (Figure 3.1C). Based on these observations, 
we hypothesized that acetylation likely plays a role in muscle regeneration and that KAT2A 
upregulation may be considered a biomarker and regulator of MuSCs activation. 
 
Figure 3. 1 KDAC and KAT gene expression patterns in MuSCs during muscle regeneration 
A-C, Clustered heatmap of the gene expression profiles for (A) PAX7+ quiescent and activated MuSCs prior to 
and 36, 60 and 84hr after BaCl2-induced muscle injury(7); (B) MuSCs isolated from young (2-3 months old) and 
aged (2-years old) mice(7); (C) MuSCs isolated from the undamaged control (Quie), and muscles which was 
contralateral to the leg that received the injury (GAlert)(195). 
3.4.2 KAT2A is essential for the differentiation of MuSCs. 
To confirm the function of KAT2A in muscle stem cells, we performed knockdowns (KDs) of 
Kat2a and its ortholog Kat2b in isolated primary MuSCs using adenoviral-driven Kat2a or 
Kat2b shRNA constructs. Interestingly, MuSCs lacking KAT2A completely lost their ability to 
differentiate into contracting myotubes. While control myoblasts differentiated into myotubes 
in a 2% concentration of horse serum medium after 4 days, the Kat2a loss-of-function (LOF) 
primary MuSCs have an altered morphology and exhibit reduced cell numbers (Figure 3.2A). 
Importantly, Kat2b LOF, which was reported to be required for the activity of MYOD1, an 
? ???
important transcription factor regulating MuSCs differentiation(194), shows much less 
efficiency in blocking MuSCs differentiation (Figure 3.2A). Kat2a and Kat2b double KD cells 
show a similar morphology as single Kat2a LOF (Figure 3.2A). The necessity of KAT2A in 
myogenic differentiation was further confirmed at the transcript level of myosin heavy chain I 
(encoded by gene Myh7), IIA (encoded by gene Myh2) and IIB (encoded by gene Myh4) by 
real-time qPCR (Figure 3.2B), and at the protein level by immuno-staining for MYH2 (Figure 
3.2C). All of these myosin heavy chain proteins can be used as markers for the development 
of the contractile apparatus. We then tested the function of KAT2A in C2C12 myoblasts, a 
murine cell line that is derived from satellite cells and whose behavior corresponds to that of 
progenitor lineage. Cycling C2C12 myoblasts are comparable to activated satellite cells in a 
muscle fiber(196). Upon inducing differentiation, C2C12 myoblast lose their myogenic 
potential for differentiation when Kat2a alone or both Kat2a and Kat2b are knocked down 
(figure 3.S2A). Compared to Kat2a LOF, Kat2b LOF C2C12 myoblasts differentiate more 
normally after exposure to differentiation medium for 4 days (figure 3.S2A). In normal C2C12 
myoblasts, we observe a decrease in PAX7 and MYOD1 expression levels, along with an 
increase of MYH7 and MYH2 levels under differentiation in vitro (Figure 3.2D). Interestingly, 
KAT2A expression is reduced during the process of C2C12 differentiation while KAT2B 
maintains a more stable level of expression (Figure 3.2D). This confirms our bioinformatics 
analyses (Figure 3.1A), which indicated that there is a decline of Kat2a expression during 
MuSCs differentiation. Kat2a, but not Kat2b, LOF in C2C12 cells caused the loss of 
expression of MYH7 and MYH2, as well as MYOD1, indicating that KAT2A controls MuSC 
activation and differentiation by controlling the expression of myogenic transcription factors 
(Figure 3.2E and figure 3.S2B).  
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Figure 3. 2 KAT2A controls the myogenic differentiation of MuSCs 
A, morphology of primary MuSCs differentiated for 4 days, with or without shRNA inducing Kat2a and/or Kat2b 
LOF; B, transcript expression of Kat2a, Kat2b and muscle myosin heavy chain genes after Kat2a and/or Kat2b 
LOF and 4 days induction of differentiation, N = 6 per condition. All comparisons are compared to the PBS treated 
control cells (Ctrl.). Statistical significance was calculated by a one-way ANOVA with a post-hoc dunnett's test. 
**P<0.01, ***P<0.001. C, protein expression of the myoblast differentiation marker MYH2 in primary MuSCs 4 
days after differentiation, with or without Kat2a and/or Kat2b LOF. D, protein expression at different differentiation 
time points for C2C12 cells, GAPDH served as a loading control; E, protein expression at 2.5 and 5 days after 
differentiation in C2C12 cells with or without Kat2a and/or Kat2b LOF. 
3.4.3 KAT2A is required for the muscle regeneration 
Stemming from our bioinformatics analysis (Figure 3.1) and functional assays of KAT2A in 
MuSCs in vitro (Figure 3.2), we decided to analyze the role of KAT2A in vivo with a focus on 
muscle stem cell function and muscle physiology. Conditional MuSC-specific Kat2a LOF 
mice were created by crossing the B6.129S-Pax7tm1(cre/ERT2)Gaka/J (Pax7-Cre) strain with 
B6.Kat2aflox/flox (Kat2aL2/L2) mice (figure 3.S3). The Pax7-Cre:Kat2aL2/L2 mouse has functional 
KAT2A and PAX7 under normal conditions, yet once given tamoxifen, Kat2a is deleted in 
PAX7-expressing cells, specifically in MuSCs (i.e. Kat2aMuSC-/-). We found, when compared to 
control adult mice, that Kat2aMuSC-/- mice have reduced MuSCs numbers 5-days after 
tamoxifen injection (Figure 3.3, A and B). Accompanying this observation, there was a 
decrease in the muscle fiber size 2-weeks after tamoxifen induced Kat2a LOF. This was 
indicated by both the average size and distribution of muscle fiber cross-sectional areas 
(Figure 3.3, C and D) and mini-Feret diameters (Figure 3.3, E and F). Muscle regeneration 
ability is one of the key indicators of MuSCs function(9, 197). We therefore examined the role 
of KAT2A on muscle regeneration with cardiotoxin (CTX)-induced muscle damage. Indeed, 
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Kat2a LOF mice showed delayed muscle regeneration, as indicated by hematoxylin and 
eosin (H&E) staining of tibialis anterior muscle cross-sections following 7 days of recovery 
after muscle damage (Figure 3.3G). Collectively, all the data indicate that KAT2A, as an 
important regulator of MuSCs function, is also essential for muscle regeneration. 
 
Figure 3. 3 KAT2A controls MuSCs differentiation and muscle regeneration 
A, FACS contour plot of Sca-1-/Lin-/PI- cells isolated from control and Kat2aMuSC-/- mouse limb muscles. 
Percentage of VCAM+/Sca-1-/Lin-/PI- MuSC populations are noted in red contour blots. B, quantified MuSCs 
relative to the total Sca-1-/Lin-/PI- cell population. C-D, quantification of average (C) and distribution (D) of muscle 
fiber cross-section area (CSA) for control and Kat2aMuSC-/- mice. E-F, quantification of average (E) and distribution 
(F) of muscle fiber mini-Feret diameter for control and Kat2aMuSC-/- mice. G, Hematoxylin and eosin (H&E) staining 
of tibialis anterior muscle cross sections in control and Kat2aMuSC-/- mice at the indicated days after CTX-induced 
muscle damage. N = 3 mice per condition. Statistical significance was calculated by Student t test. *P<0.05, 
**P<0.01, ***P<0.001 
3.4.4 KAT2A regulates MuSC function through PAX7 acetylation.  
PAX7 is a transcription factor that controls muscle stem cell maintenance in adults(198, 199). 
While the activity of many transcription factors is regulated by reversible acetylation, whether 
or not PAX7 can be acetylated is unknown. Given that PAX7 functions as a transcription 
factor in myogenesis and that KAT2A also plays essential roles in MuSCs 
activation/differentiation (demonstrated above), it may be possible that KAT2A regulates the 
function of PAX7 by changing its acetylation status. To test this hypothesis, C2C12 cells 
were first transfected with a plasmid to overexpress Pax7 (PAX7 gain of function; GOF) 
and/or transduced with an adenoviral vector for the LOF or GOF of Kat2a. Indeed we 
observed the co-immunoprecipitation of KAT2A when performing a pull-down assay with 
anti-PAX7 (Flag) antibody. This suggests an interaction between these two proteins (Figure 
3.4A). Moreover, endogenous PAX7 was induced in Kat2a LOF cells, whereas endogenous 
Kat2a levels were increased upon PAX7 overexpression (Figure 3.4B). These data indicate a 
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reciprocal regulation between KAT2A and PAX7 at the protein level. Importantly, KAT2A 
overexpression leads to increased PAX7 acetylation (Figure 3.4C), which might affect the 
activity and/or stability of PAX7. 
 
Figure 3. 4 Acetylation of PAX7 by KAT2A 
Proteins were extracted 2 days after C2C12 cells were transduced with adenovirus to induce a GOF (OE) or LOF 
(KD) of Kat2a and/or transfected with a plasmid overexpressing Pax7. A, Interaction between PAX7 and KAT2A 
was verified by immunoprecipitation of PAX7 conjugated with a Flag-tag followed by the immunoblotting of KAT2A. 
B, Protein expression after Pax7 GOF and/or with Kat2a GOF or LOF. C, Acetylation of PAX7 was examined by 
of Western blot analysis with anti-KAT2A antibody following immunoprecipitation of PAX7 with anti-Flag in C2C12 
cell lysates. 
3.5 Conclusions 
Despite the fact that histone acetylation has been linked to MuSCs activation(55) and several 
myogenic transcription factors, such as MYOD1 and MEF2 have been reported to be 
acetylated in myogenic differentiation(193, 194), the potential role of KAT2A, which catalyzes 
the acetylation of both histones and transcriptional factors/cofactors, has never been 
examined. Our work demonstrates the crucial role of KAT2A in MuSC activation and 
differentiation. Kat2a, but not its ortholog Kat2b, is upregulated temporarily during the early 
stages of MuSC activation and is downregulated in MuSC aging. Kat2a LOF inhibits 
myoblast differentiation of both C2C12 myoblasts and primary MuSCs. The essential role of 
KAT2A in MuSC activation was further demonstrated in vivo by observing MuSC-specific 
Kat2a LOF mice, which exhibited delayed muscle regeneration. The effect of KAT2A on 
MuSC activation and differentiation might be mediated by controlling myogenic transcription 
factor expression and PAX7 acetylation. Our work therefore identified a new posttranslational 
modification for PAX7, a major MuSCs regulator, and unveiled KAT2A as a main regulator of 
PAX7 activity. Therefore our study highlights the existence of a signaling cascade leading to 
the acetylation of PAX7 during MuSCs activation and differentiation.  
3.6 Supplementary materials 
3.6.1 Materials and Methods 
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Animals. Kat2aMuSC-/- mice were created at the EPFL SPF animal core facility by crossing 
Kat2aflox/flox mice (157) with the Pax7creER strain (B6.Cg-Pax7tm1(cre/ERT2)Gaka/J, purchased from 
Jackson laboratory). Animal phenotyping experiments were carried out according to standard 
operational procedures (SOPs) established and validated within the Eumorphia program 
(182). To induce KAT2A knockout in MuSCs, a 20mg/ml of Tamoxifen/corn oil solution was 
given to Kat2aflox/flox:Pax7creER mice via intraperitoneal injection for 5 consecutive days at 
1mg/10g of mouse body weight. Kat2aflox/flox mice were injected at the same dosage of 
tamoxifen and served as controls. All mice were housed in micro-isolator cages in a room 
illuminated from 7:00am-7:00pm with ad libitum access to normal chow diet (2016S, Harlan 
Laboratories) and water. Animal experiments were authorized by the local animal 
experimentation committee of the Canton de Vaud under licenses 2665 and 2890. 
Grip strength test. Muscle strength was assessed by a grip strength behavior task after 5 
weeks of NR treatment. The grasp strength of each mouse for all four limbs was measured 
on a pull-grid assembly connected to the grip strength meter (Columbus Instruments). The 
mouse was drawn along a straight line parallel to the grid until the grip is broken and the 
peak amount of force in grams was recorded. This was repeated 4 times with 5 minute 
intervals. 
FACS based muscle stem cell isolation. Gastrocnemius, soleus, quadriceps, and tibialis 
anterior muscles from both limbs were excised and transferred into PBS on ice. All muscles 
were trimmed, minced and digested with 0.1mg/ml of type II collagenase (Sigma) in PBS for 
15 min at 37°C. Samples were then centrifuged at 750g for 5min and further digested in 1 
mg/ml of collagenase/dispase (Roche) for 30 min at 37°C. Muscle slurries were sequentially 
filtered through 100, 70 and 40 μm cell strainers. The isolated cells were then washed in 
washing buffer (PBS + 2.5% FBS) then resuspended in 200μl of washing buffer and 
immediately stained with antibodies, including the MuSC markers CD31 (1:800, eBioscience, 
eFluor450 conjugated); CD34 (1:200, eBioscience, eFluor660 conjugated); CD45 (1:200, 
eBioscience, eFluor450 conjugated); CD11b (1:400, eBioscience, eFluor450 conjugated); 
Sca-1 (1:1000, eBioscience, PE-Cy7 conjugated); and α7 integrin (1:300, MBL) for 30 min at 
4°C. Secondary staining was performed with a mixture of goat anti-mouse antibody (1:800, 
Life technologies, Alexa Fluor 488 conjugated) and propidium Iodide (PI, Sigma) for 15 min 
at 4°C in the dark. Stained cells were analyzed and sorted using the FACSAria II instrument 
(BD Biosciences). Debris and dead cells were excluded by forward scatter, side scatter and 
PI gating. Cells were sorted either directly on slides for immunostaining or into lysis buffer for 
NAD+ measurements and into TriPure (Roche) reagent for RNA extraction. 
Cell culture and treatments. FACS sorted MuSCs were grown on a 10% Matrigel 
(Corning)-coated dish and flasks with Fams F-10 media (Gibco), supplemented with 20% 
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fetal bovine serum (FBS, Gibco), 2.5ng/ml basic fibroblast growth factor (bFGF, Sigma) and 
penicillin/streptomycin (1x, Gibco). Dishes were coated with 10% growth factor-free Matrigel 
solution on ice for 7 min then transferred to a 37°C cell culture incubator overnight before use. 
Cells were grown for three generations in vitro before experiments with cells plated and 
passaged at 10^3 cells/ml and 50% confluence, respectively. C2C12 mouse myoblasts were 
grown in DMEM (4.5g/L glucose, Gibco) supplemented with 10% FBS and 
penicillin/streptomycin (1x, Gibco). Gene expression or knockdown was performed using 
either adenovirus infection or cell transformations with Kat2a shRNA (Santa Cruz) using 
jetPEI DNA transfection kit (Polyplus), according to manufacturer’s instructions. Cells were 
treated with 1mM NR or PBS for 6 hours before cell harvesting or fixation.  
Cardiotoxin-induced muscle regeneration. Animals were anesthetized using Isoflurane in 
oxygen from a precision vaporizer. 50μl of 20μM Naje mossambica mossambica cardiotoxin 
(Sigma) was injected intramuscularly cross the skin and directly into the tibialis anterior (TA) 
muscle. For SIRT1MuSC-/- mice, cardiotoxin was injected on the third day of the 5 consecutive 
days of tamoxifen injections, as described above. Mice were sacrificed at 7 and 14 days after 
injury. TA muscles were immediately embedded in Thermo Scientific™ Shandon™ 
Cryomatrix™ and frozen in isopentane, cooled in liquid nitrogen, for 2min before being 
transferred to dry ice and stored at -80°C.  
Histology.  TA muscles were harvested from anaesthetized mice and immediately frozen in 
Tissue-TEK® OCT compound (PST). 8-μm cryosections were collected and fixed with 4% 
paraformaldehyde, which are either stained with haematoxylin/eosin (HE) or antibodies. For 
immunostainings, heat activated antigen retrieval was performed in pH 6.0 citrate buffer for 
10min at 65°C. After washing with PBS-0.1% tween 20 (PBST), the sections were blocked 
with 10% affinipure Fab goat anti mouse IgG (Jackson Immunoresearch) in PBST for 60min 
and PBST containing 2% BSA and 5% goat serum for 30min at room temperature. Primary 
antibodies were then applied over night at 4°C. The following antibodies were used: anti-
eMHC (Developmental Studies Hybridoma Bank, DSHB, University of Iowa), anti-Pax7 
(DSHB, University of Iowa), anti-Laminin (Sigma). Subsequently, the slides were washed in 
PBST and incubated with appropriate secondary antibodies and labeling dyes. For 
immunofluorescence, secondary antibodies were coupled to Alexa-488 or Alexa-568 
fluorochromes (Life technology), and nuclei were stained with DAPI (Invitrogen). After 
washing in PBST, tissue sections were mounted with Dako mounting medium (Dako). 
For cellular immunostaining, freshly isolated MuSCs were sorted directly into 8-chamber 
slides (Thermo Scientific) and examined immediately after 30min of sedimentation or 
cultured for 3 generations. Cells were then fixed with either 4%PFA or 3% H2O2 in methanol 
for 10-15min. After 15min permeabilization with 0.5% Triton X-100, cells were blocked and 
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immunostained using a similar protocol to that used for muscle tissue sections. All samples 
were imaged with a DMI4000 B Inverted Microscope (Leica) or the VS120-S6-W slides 
scanner (Olympus). Images were analyzed using ImageJ software. For immunofluorescence 
quantification, positively stained cells were defined as those with an intensity that was higher 
than a given threshold, which was then applied to all images. The thresholds were set up 
using sample slides before analyzing experimental data. More than 3 whole muscle cross-
section areas, or more than 6 randomly chosen microscope scopes from each animal in all 
experimental conditions were used for quantification. All in vitro cultured or FACS sorted cells 
(> 500 per condition) were applied for analysis if cell number quantifications were performed. 
Gene expression analyses. Total RNA was extracted from MuSCs by sorting cells directly 
into TriPure RNA isolation reagent (Roche) or from cultured C2C12 myoblasts using TriPure 
reagent according to the product manual. Total RNA was transcribed to cDNA using 
QuantiTect Reverse Transcription Kit (Qiagen). Expression of selected genes was analyzed 
using the LightCycler480 system (Roche) and LightCycler® 480 SYBR Green I Master 
reagent (Roche). The acidic ribosomal protein 36b4 gene (ribosomal protein, large, P0, 
Rplp0) was used as house keeping reference. 
Western blotting. C2C12 cells were lysed in a buffer composed of 50 mM Tris, 150 mM 
KCl, EDTA 1 mM, NP40 1%, nicotinamide 5mM, sodium butyrate 1mM and protease 
inhibitors cocktail (Roche) at pH 7,4. Proteins were separated by SDS-PAGE and transferred 
onto nitrocellulose membranes. Blocking and antibody incubations were performed in 3% 
BSA. The following primary antibodies were used: anti-β-actin (Sigma); anti-KAT2A (cell 
signaling); anti-KAT2B (cell signaling); anti-HSP90 (BD Biosciences). All secondary 
antibodies were from Jackson Immunoresearch. Antibody detection reactions were 
developed by enhanced chemiluminescence (Advansta, CA, USA) and imaged using the 
c300 imaging system (Azure Biosystems).  
Bioinformatic analysis. Quadriceps microarray data from young and aged mice MuSCs (7, 
152, 155) were analyzed for transcript expression using the Kyoto encyclopedia of genes 
and genomes (KEGG), gene ontology (GO) or gene set enrichment analysis (GSEA) 
analysis. Raw microarray data are also publicly available on GEO under the accession 
numbers GSE47177, GSE47401 and GSE47104. All gene expression heat maps were 
drawn using GENE-E software. 
Statistical analysis. The sample size (n) for each experimental group is described in each 
figure legend. GraphPad Prism software was used for all statistical analyses. Quantitative 
data displayed as histograms are expressed as means ± standard error of the mean 
(represented as error bars). Results from each group were averaged and used to calculate 
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descriptive statistics. Student’s t test was used for comparisons between two groups with 
statistical significance was set at a P value of  *P < 0.05, **P < 0.01 and ***P < 0.001. For 
multiple comparisons, a two-way analysis of variance (ANOVA) was performed followed by a 
Newman–Keuls post-hoc test.  
3.6.2 Supplementary figures 
 
figure 3.S 1 KDAC and KAT gene expression patterns in MuSCs during muscle regeneration 
A-B, clustered heatmap of the gene expression profiles for (A) CD34+ quiescent and activated MuSCs prior to 
and 36, 60 and 84hr after BaCl2-induced muscle injury(7); (B) MuSCs isolated from young (2-3 months old) and 
aged (2-years old) mice(7) in quiescent or activated MuSCs prior to 60 hours after BaCl2-induced muscle injury. 
 
figure 3.S 2 KAT2A controls the myogenic differentiation of MuSCs 
A, morphology of C2C12 myoblast differentiated at the indicated days, with or without shRNA induced Kat2a 
and/or Kat2b LOF; B, protein levels of the myoblast differentiation marker MYH7 and myogenic differentiation 
regulators MEF2C and MEF2D, in C2C12 myoblast at the indicated differentiation time points, with or without 
Kat2a and/or Kat2b LOF. Actin served as a loading control. 
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figure 3.S 3 Schema of making Kat2aMuSC-/- mice 
Kat2aMuSC-/- mice were created by crossing Kat2aflox/flox mice with the Pax7creER strain (B6.Cg-Pax7tm1(cre/ERT2)Gaka/J), 
purchased from Jackson laboratory. 
 
? ???
Chapter 4. NAD+ repletion improves 
muscle function in muscular dystrophy 
Adapted from : 
Ryu, D.*, Zhang, H.*, Ropelle, E. R.*, Mazala, D. G., Sorrentino, V., Mázala D. G., 
Mouchiroud, L., Marshall, P. L., Campbell, M. D., Ali, A. S., Knowels, G. M., Bellemin, S., 
Lyer, S., Wang, X., Gariani, K., Sauve, A. A., Canto, C., Conley, K. E., Walter, L., Lovering, 
R. M., Chin, E. R., Jasmin, B. J., Marcinek, D. J. Menzies, K. J.#, & Auwerx, J.# NAD+ 
repletion improves muscular dystrophy by countering increased levels of PARylation. 
Science Translational Medicine, 8 (361): 361ra139. (2016) (*, equal contribution). 
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4.1 Abstract 
Duchenne muscular dystrophy (DMD) is caused by inherited mutations in the dystrophin 
gene that lead to progressive skeletal muscle degeneration. In diverse populations of mice 
we observe strong correlations between transcripts related to mitochondrial biogenesis, the 
dystrophin-sarcoglycan complex, and nicotinamide adenine dinucleotide (NAD+)-synthesis, 
suggesting a role for the essential cofactor NAD+ in protecting muscle from metabolic and 
structural degeneration. Furthermore, human transcriptome data from patients with DMD, 
and other muscle diseases, exhibit a particular signature of enrichment for various poly ADP-
ribose (PAR) polymerases (PARPs) and the nicotinamide N-methyltransferase (NNMT) 
transcript, all major consumers of NAD+ involved in pleiotropic events, including 
inflammation. Validating these findings, we reveal that the mdx mouse, a model of DMD, is 
characterized by significant reductions in muscle NAD+ levels, concurrent to increased PARP 
activity and reduced expression of nicotinamide phosphoribosyltransferase (NAMPT), the 
rate-limiting enzyme for NAD+ biosynthesis. Replenishing NAD+ stores by dietary 
nicotinamide riboside supplementation benefits muscle function in mdx and mdx/Utr-/- mice, 
an effect replicated in C. elegans models of DMD. The beneficial effects of NAD+ repletion in 
muscular dystrophy are pleiotropic and rely on the improvement in mitochondrial function and 
structural protein expression and on reductions in general PARylation, inflammation and 
fibrosis. We furthermore validated non-invasive magnetic resonance spectroscopy (MRS) 
monitoring of NAD+ levels as a clinical biomarker of disease severity and efficacy of NAD+ 
boosting strategies. In combination, these studies suggest that the replenishment of NAD+ 
may be of benefit to patients with muscular dystrophies characterized by PARP/NNMT gene 
expression signatures.  
4.2 One sentence summary 
NAD+ repletion by NR diet improves muscle function in muscular dystrophy 
4.3 Introduction 
Muscular dystrophies result from the reduced support network that connects myofilament 
proteins within the cell to the basal lamina outside the cell, rendering the sarcolemma more 
susceptible to damage. As an X-linked mutation, DMD affects 1 in 3500 males and often 
leads to death due to heart or respiratory failure (200, 201). With no effective treatment, the 
deterioration of muscle function and strength results from increased muscle damage, fibrosis 
and necrosis. DMD symptoms are shared by other pathologies that involve muscle wasting, 
such as cancer, AIDS and aging, all characterized by declines in metabolic and physiological 
parameters, with progressive weakness in skeletal muscle. Despite considerable advances 
in exon skipping and other genetic and pharmacological approaches to treat DMD, there are 
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still many caveats in the delivery, effectiveness and safety of these therapies (reviewed in 
(202)), thus leaving a necessity for other therapeutic strategies.? 
Fatigue and muscle weakness, as seen in DMD, are also symptoms of mitochondrial 
myopathies and metabolic diseases (reviewed in (203)). Recent studies have linked SIRT1-
dependent mitochondrial biogenesis to reductions in mdx mice pathology and muscle 
atrophy (204-207). Interestingly, NAD+ repletion provides protection from metabolic diseases 
and mitochondrial dysfunction induced by diet or aging, often in a SIRT1-dependent manner 
(101, 157-160). Sirtuins in general consume NAD+ as a cofactor for the deacetylation of 
proteins while also generating nicotinamide (NAM). Similarly, PARP proteins are known to 
consume NAD+ during the poly ADP-ribosylation (PARylation) of proteins. As a result, PARP 
inhibition or genetic loss of function of PARP1 in mice, increases muscle NAD+ levels and 
sirtuin-directed mitochondrial biogenesis (208, 209). Initial evidence for an involvement of 
PARP activity in DMD was revealed with increased PARP1 expression, from 20 patient 
biopsies, that was correlated to reduced telomere length (210). We provide evidence that 
PARP expression in DMD biopsies spans across 10 members of the PARP family, creating a 
unique signature of expression common with that of other (neuro-)muscular diseases, thus 
warranting an analysis of NAD+ metabolism in various models of DMD ranging from C. 
elegans to mice. In addition, NAD+ can promote the polymerization of laminin and subcellular 
localization of paxillin, an integrin-associated adaptor protein, improving cell adhesion in a 
zebra fish models of muscular dystrophy (211). Taking these evidences into consideration, 
we hypothesized that NAD+ availability, balanced, in part, by the conversion of NAM to 
nicotinamide mononucleotide (NMN) by the rate limiting salvage enzyme NAMPT, the further 
conversion of NMN to NAD+ by NMN adenylyltransferases     (NMNATs), and finally NAD+ 
consumption by a panel of PARP proteins (Figure 4. 1A; reviewed in (212)), could have a 
multifaceted influence on the development of muscle weakness and fatigue in in DMD and 
potentially other (neuro-)muscular diseases.  
Our study reveals that in a mouse model of DMD, widespread PARylation of proteins leads 
to severe NAD+ depletion, which is linked to reduced mitochondrial and structural gene 
expression. Repleting NAD+ levels with nicotinamide riboside treatment, an NAD+ booster, 
not only restored mitochondrial function but also expression of proteins in the dystrophin-
associated glycoprotein complex and improved muscle function in multiple species. We 
furthermore validate NAD+ as a biomarker for the diagnosis and treatment of muscle 
dysfunction that could have broad clinical applications, not only in muscular dystrophy, but 
also in other muscle diseases characterized by mitochondrial dysfunction or PARP 
activation. 
4.4 Results 
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4.4.1 Correlations between transcripts related to NAD+ with muscular dystrophy 
To evaluate the relationship between muscle NAD+ metabolism and muscle health, we first 
examined correlations between transcripts of NAD+ salvaging or consuming enzymes and 
diverse muscle parameters. By assessing natural transcript variance in quadriceps muscles 
of 42 strains of genetically-diverse BXD mice (described in (157, 213-215)) (figure 4. S1, A to 
B), we observed that Nampt and Nmnat3 expression levels correlate positively to muscle 
mass (Figure 4. 1, B and C). Nampt also correlates robustly to increased expression of 
transcripts related to mitochondrial biogenesis (Figure 4. 1D). Using custom-generated gene 
sets from BXD strains expressing the highest and lowest levels of Nampt transcripts, genes 
related to mitochondrial biogenesis, autophagy and muscle regeneration, along with Nmnat1, 
were found to be enriched with Nampt (figure 4. S1C) (216). Based on this preliminary 
analysis, we performed a principal component analyses on these networks now using all 42 
BXD strains. In the resulting factor loading plot, we observed that transcripts encoding genes 
relating to mitochondrial biogenesis, the dystrophin-sarcoglycan complex and muscle 
regeneration are strongly correlated to expression of Nampt, Nmnat1 and Nrk1, an enzyme 
responsible for converting nicotinamide riboside (NR) into NMN, suggesting a beneficial 
effect of NAD+-synthesis on several levels of muscle function (Figure 4. 1E). A circular 
schematic was then plotted using the same set of genes in order to demonstrate the positive 
and negative correlations amongst each of them (Figure 4. 1F). Interestingly, we found that 
genes associated with the pathogenesis of muscle dystrophy in mdx mice were negatively 
correlated in this principal component analysis, while genes related to mitochondrial 
biogenesis and muscle structure and growth correlated positively. We then examined the 
expression of transcripts involved in NAD+ homeostasis in extant human skeletal muscle 
datasets from patients with DMD in comparison to controls (217, 218). In contrast to the 
previously described elevation in PARP1 expression in DMD muscle (210), we discovered a 
consistent enrichment signature of PARP transcripts, and of the nicotinamide N-
methyltransferase (NNMT) transcript, an enzyme known to shunt NAD+ away from 
biosynthesis through methylation (219, 220), with no change in PARP1 expression (Figure 4. 
1G). Surprisingly, this PARP/NNMT gene enrichment signature was very well replicated in 
biopsies from patients with a large variety of muscular dystrophies or (neuro-)muscular 
disease (figure 4. S2A). Alternatively, genes associated with biosynthesis were not 
significantly altered in any of these patient datasets (Figure 4. 1H and figure 4. S2B). These 
findings demonstrated the high likelihood for NAD+ depletion in DMD, but also in other 
(neuro-)muscular diseases. 
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Figure 4. 1 The relationship between transcripts involved in NAD+-biosynthesis and consumption with 
muscular dystrophy in mice and DMD patients 
(A) Schematic illustrating NAD+ consumption by Sirtuins and PARPs and the salvage of NAD+ from NAM via 
NAMPT and NMNAT enzymes. In 42 strains of genetically-diverse BXD mice (B) Nampt and (C) Nmnat3 
transcripts were each positively correlated to various measurements of muscle mass, as a percentage of body 
weight. (D) Nampt transcript expression in the BXD strains was also positively correlated with transcript 
expression for regulators of mitochondrial transcription and for genes encoding components of the mitochondria. 
(E) Further analysis of the BXD strains showed that mitochondrial-related transcripts (Tfam, Hspd1, Atp5h and 
Tomm70a) remain positively correlated to NAD+-synthesis transcripts (Nampt, Nmnat1 and Nrk1), as seen on a 
factor loading plot (biplot), where angles more than 90° between gene vectors represent negative correlation (and 
an angle of 180° indicates perfect negative correlation). Also, NAD+-synthesis transcripts positively correlate to 
transcripts of utrophin (Utr) and dystrophin-associated glycoproteins (Dag1, Sgcb, Sgcd) and muscle growth 
(Maged1 and Il6), while they are negatively correlated to genes previously reported to be involved in the 
pathology of mdx mice (Tgfb1, Tnf, Mstn, Il1b and Redd2). These transcripts were then plotted in a (F) circular 
schematic using a Pearson’s r ≥ |0.2| in BXD strains showing negative (red) and positive (green) correlations. The 
expression of transcripts related to NAD+ (G) consumption or (H) biosynthesis show an enrichment signature of 
PARP genes and of the NNMT gene in human DMD skeletal muscle datasets (n=5/group) (217, 218). 
4.4.2 NAD+ as a biomarker of elevated PARP activity in mdx mice 
Given the central role of NAD+ in mitochondrial homeostasis and organismal metabolism 
(104), we set out to determine if reduced NAD+ levels could explain the attenuation of 
mitochondrial function in the muscle of mdx mice and could be used as an in vivo biomarker 
of muscle damage. Indeed, in vivo non-invasive 31P MRS measurements of NAD+ levels 
were lower in mdx muscle compared to controls (Figure 4. 2A). Reduced NAD+ levels were 
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also confirmed by mass spectrometry measurements (157) in postmortem muscle specimens 
(Figure 4. 2B). From the high expression of PARP transcripts in DMD patients (Figure 4. 1H), 
we hypothesized that the over-activation of PARPs could underpin the depletion of NAD+ 
levels in mdx mice, an idea further bolstered by our recent data showing the contrasting 
situation of elevated NAD+ levels in Parp1KO mice (100) or in PARP inhibitor-treated mice 
(157). As hypothesized, PARP activity and global protein PARylation levels were increased 
in mdx muscle (Figure 4. 2C), which also reinforces the usefulness of the mdx model for 
comparisons to DMD. Furthermore, reduced NAMPT protein levels and NAD+ salvage may 
also contribute to the reductions in NAD+ levels in mdx muscle (Figure 4. 2D). Of note, 
NMNAT1 and NMNAT3 levels were not changed in mdx mice. These results indicate that 
mdx-induced damage leads to PARP activation, attenuated NAD+ salvage and reduced 
NAD+ levels, which serve as a potential biomarker for muscular dysfunction. 
 
Figure 4. 2 NAD+ as a biomarker and limiting factor for in vivo energetics and mitochondrial function in 
mdx mice 
Measurements on gastrocnemius from 16-week-old male mdx or control mice. As a potential new biomarker for 
muscular dystrophy, (A) NAD+ levels were reduced, as measured by 31P MRS (n=7, WT; n=12, mdx). (B) These 
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values paralleled total intracellular NAD+ levels measured by mass spectrometry in tissue extracts (n=5). 
Reductions in NAD+ levels may be due to augmented NAD+ consumption, evidenced by enhanced (C) PARP 
activity and total PARylation content (n=4), in addition to reduced NAD+ salvage demonstrated by lower (D) 
NAMPT protein, with NMNAT1 and NMNAT3 unchanged, using a Ponceau loading control. (E) Schematic of in 
vivo 31P MRS of mdx skeletal muscle mitochondrial energetics. Dynamic MR spectra were acquired during the 
following periods: rest (2 min), ischemia (9 min), and recovery (9 min). (F) HPLC and 31P MRS measurements of 
ATP and Phosphocreatine (PCr), respectively, showing unchanged ATP levels (n=7) and a reduction in the 
PCr/ATP ratio (n=7, WT; n=5, mdx). As the resting ATPase activity did not change (indicating unaltered ATP 
demand) (n=7 for WT; n=5, mdx), mdx animals must function at an increased fraction of their now reduced 
maximal capacity (ATPmax) (n=7, WT; n=5, mdx) to meet the unchanged ATP demand, when MRS data is 
compared to control animals. mdx muscle exhibited corresponding reductions in mitochondrial proteins and 
function in mdx muscle, as represented by (G) nuclear- and mitochondrial-encoded mitochondrial protein 
expression, compared to a Ponceau loading control, (H) Blue-native PAGE of isolated mitochondria and (i) citrate 
synthase (CS) activity (n=9).  
4.4.3 Limited NAD+ affects in vivo energetics and mitochondrial function in mdx mice 
To corroborate the known positive relationship between mitochondrial biogenesis and NAD+ 
metabolism (reviewed in (212)), we assessed mdx skeletal hindlimb muscles mitochondrial 
energetics using in vivo 31P MRS to measure ATP and phosphocreatine (PCr) fluxes (Figure 
4. 2E). PCr buffers cellular ATP levels through the creatine kinase reaction. Therefore the 
ratio of PCr/ATP reflects the cellular energy state. The lower PCr/ATP ratio in the mdx 
hindlimb is a reflection of energy stress and demonstrates a greater load on the mitochondria 
to maintain ATP levels (Figure 4. 2F). This greater load on the mitochondria in mdx hindlimb 
muscles is also apparent in the relationship between resting and maximal mitochondrial ATP 
production. As previously reported in mdx mice (221), the maximum mitochondrial oxidative 
phosphorylation rate (ATPmax) was reduced in vivo compared to WT mice, while the resting 
ATPase activity, which reflects resting mitochondria ATP synthesis, was unchanged (Figure 
4. 2F). Thus, mdx hindlimb mitochondria had to function at a greater fraction of their capacity 
to meet ATP demand (ATPase), than in the WT mice, and were therefore under a greater 
energy stress (lower PCr/ATP). Explaining these energetic impairments and reaffirming the 
role of NAD+ in mitochondria, protein levels for both nuclear- and mitochondrial-encoded 
OXPHOS subunits, including ATP5A, UQCRC2, MTCO1 and SDHB were lower in mdx mice 
(Figure 4. 2G).  A lower abundance of complexes I, II, IV and V in mdx skeletal muscles was 
also evidenced by Blue-native gel electrophoresis (Figure 4. 2H). Coordinately, citrate 
synthase (CS) activity in mdx muscle extracts were reduced compared to control samples 
(Figure 4. 2I). Together these data confirm that NAD+ levels are attenuated in mdx muscles, 
resulting in impaired tissue energetics and mitochondrial function. 
4.4.4 NR enhances muscle function in cells and dys-1;hlh-1 mutant C. elegans 
Boosting NAD+ levels using various NAD+ precursors, may hence recover mitochondrial 
function, potentially improving muscle health (101, 222). To test this hypothesis, we first 
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evaluated the effects of the NAD+-precursor NR on mitochondrial function in mouse skeletal 
muscle C2C12 cells. Notably, NR increased NAD+ levels (Figure 4. 3A), improving 
mitochondrial complex abundance in differentiated C2C12 myotubes (Figure 4. 3B). NR also 
increased the maximal electron transport system (ETS) capacity in C2C12 myotubes, 
following exposure to the uncoupler, FCCP (Figure 4. 3C). Consistent with the fact that the 
beneficial impact of NAD+ boosting is reliant on sirtuin-mediated protein deacetylation, global 
protein acetylation was reduced in NR-treated C2C12 myotubes (Figure 4. 3D). Furthermore, 
NR modulated myotube mitochondrial protein expression and FOXO1 acetylation in SIRT1-
dependent fashion, as evidenced by pharmacological (using the SIRT1 inhibitor EX527) and 
genetic (using a SIRT1 shRNA) SIRT1 loss of function (LOF) experiments (Figure 4. 3E). 
We further ascertained the involvement of SIRT1 in mediating the effect of NR, by studying 
the mobility of worms carrying mutations for both the dystrophin-like gene dys-1 and the 
MyoD homologue hlh-1 that display time-dependent impairments of locomotion and muscle 
degeneration during aging (223). NR improved the mobility of dys-1;hlh-1 mutant worms over 
the course of 6 days of aging, an effect that was completely attenuated upon feeding worms 
with sir-2.1 RNAi (RNAi for the worm otholog of SIRT1) (Figure 4. 3F). Following 8 days 
there was also a sir-2.1-dependent improvement in worm paralysis with NR treatment (Figure 
4. 3G).  Importantly, dys-1;hlh-1 worms exhibited less muscle degeneration when treated 
with NR (Figure 4. 3H). This beneficial effect was again lost with sir-2.1RNAi (Figure 4. 3H). 
Altogether, these results suggest that NR enhances mitochondrial function in C2C12 muscle 
cells and improves mobility and the dystrophy phenotype in C. elegans, in a SIRT1-
dependent manner. 
 
Figure 4. 3 NR enhances mitochondrial function in C2C12 myotubes and increases SIRT1-dependent 
muscle integrity and function in dys-1;hlh-1 double mutant C. elegans 
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C2C12 myotubes were treated with 0.5 to 1 mM NR. 12 hrs of NR increases (A) intracellular NAD+ levels (n=6), 
inducing (B) mitochondrial biogenesis, as demonstrated by Blue-native PAGE of mitochondrial complexes from 
isolated mitochondria, and (C) increased OCR in myotubes exposed to the uncoupler FCCP (n=6). (D) Total 
protein acetyl-lysine levels in myotubes were reduced after 3-6hrs of exposure to 0.5 and 1mM NR. (E) SIRT1 
inhibition with EX527 (10 μM) in myotubes or knockdown with an shSirt1 adenovirus attenuated increases in 
mitochondrial proteins and reductions in FOXO1 acetylation following NR treatment. (F) Improvements in dys-
1;hlh-1 mutant worm fitness on days 2-6 of adulthood following NR, and its sir-2.1-dependence shown in animals 
fed RNAi for sir-2.1 [R11A8.4], as measured by examining worm motility using the worm tracker (158) (n=3, 60 
worms per experiment). Reduced worm paralysis (n=3, 60 worms per experiment) (G) and muscle degeneration 
(n=6, 60 worms per experiment) (H) in dys-1;hlh-1 mutant worms following NR was not observed in dys-1;hlh-1 
worms fed RNAi for sir-2.1. Arrows indicate degenerated muscle fibers.  
4.4.5 NR reduces PARylation and improves in vivo muscle energetics in mdx mice  
These data incited us to determine the efficacy of NR to prevent or delay the onset of 
mitochondrial dysfunction in muscular dystrophy. Therefore, using a preventive approach we 
fed a chow diet supplemented with NR (400 mg/kg/day) to 4-week-old mdx mice for 12 
weeks and assessed NAD+ levels and mitochondrial energetics in vivo using the same 31P 
MRS approach. NR-treatment enhanced in vivo NAD+ bioavailability in the hindlimb muscles 
of mdx mice (Figure 4. 4A), as again confirmed with postmortem measurements of 
gastrocnemius biopsies (Figure 4. 4B). Of note, NAD+ levels were also lower in the livers of 
mdx mice and were restored by NR supplementation, whereas no change was observed in 
NAD+ levels in subcutaneous white adipose tissue (figure 4. S3, A and B). In the muscle, this 
increase in NAD+ levels occurred concurrent to a reduction in PARP activity and global 
PARylation (Figure 4. 4C), along with elevated NAMPT, NMNAT1 and NMNAT3 protein 
expression in mdx muscle (Figure 4. 4D). With unchanged ATP levels (Figure 4. 4E), NAD+ 
repletion improved the PCr/ATP ratio, indicating less energy stress in NR treated muscles. 
The reduced energy stress was supported by an elevation in the mitochondrial capacity 
(higher ATPmax) without a change in resting ATPase activity (Figure 4. 4F). Therefore, as 
NR-treated mdx mice exhibited a higher ATPmax, their hindlimb muscle mitochondria were 
able to work at a lower fraction of their capacity to meet ATP demand (ATPase) and were 
therefore under a lower energy stress (higher PCr/ATP). On a mechanistic level, this was 
accompanied by increased abundance of individual OXPHOS proteins and of mitochondrial 
complexes II, IV and V (Figure 4. 4, G and H). In addition, CS activity and cytochrome c 
oxidase histochemical staining of gastrocnemius was increased in NR treated mdx muscles 
(Figure 4. 4, I and J). As a result, NR increased the running capacity in mdx mice (Figure 4. 
4K), in the absence of body weight and lean mass differences (figure 4. S3 C and D). 
Interestingly, the respiratory exchange ratio (RER) was lower in mdx compared to control 
mice, an effect that was surprisingly attenuated with NR (figure 4. S3 E). NR therefore 
effectively corrected the mitochondrial profile of mdx animals leading to in vivo improvements 
? ???
in muscle energetics and function, all of which correlated well with the measurements of 
NAD+ as a biomarker for disease severity and treatment effectiveness. 
 
Figure 4. 4 In vivo monitoring of NAD+ provides an efficacy biomarker for improvements in the phenotype 
of NR-treated mdx mice 
16-week-old mdx mice received a dietary supplement with NR (400 mg/kg/day) for 12 weeks. (A) 31P MRS 
measurements of increasing NAD+ levels upon NR treatment in mdx mice (n=5, mdx; n=10, mdx NR). (B) The 
recovery of mdx muscle NAD+ levels was verified by the analysis of gastrocnemius extracts by MS (n=5). (C) 
PARP activity and total protein PARylation was reduced (n=4), while (D) NAMPT, NMNAT1 and NMNAT3 content 
increased, following NR treatment of mdx mice. (E) Unchanged ATP levels were measured by HPLC in 
gastrocnemius (n=7, mdx; n=10, mdx NR). (F) in vivo 31P MRS measurements of mitochondrial energetics 
revealed an improvement in the PCr/ATP ratio (n=5, mdx; n=10, mdx NR), unchanged resting ATPase activity 
(n=5, mdx; n=10, mdx NR), and a recovery of ATPmax (n=5, mdx; n=10, mdx NR) in NR treated mdx mice. NR 
treated mdx animals hence function at a reduced fraction of their capacity (ATPmax) to meet ATP demand. The 
enhancement of NAD+ metabolism with NR prevented improved (G) ATP5A, UQCRC2, MTCO1 and SDHB 
protein levels, using a Ponceau loading control, (H) mitochondrial complexes as evidenced by Blue-native PAGE 
of isolated gastrocnemius mitochondria, using a Coomassie loading control, (I) CS activity in frozen 
gastrocnemius extracts (n=9, mdx; n=6, mdx NR), and (J) cytochrome c oxidase staining of soleus (arrow) and 
gastrocnemius (asterisks) muscle fibers. (K) NR increased the running distance and time during an endurance 
treadmill test in mdx mice (n=9, mdx; n=12, mdx NR).  
4.4.6 NAD+ repletion protects mdx muscle from damage, inflammation and fibrosis  
As the transcripts of the dystrophin-sarcoglycan complex and muscle regeneration are 
strongly correlated to Nampt, Nmnat1 and Nrk1 expression in the BXD reference population 
(Figure 4. 1, E and F), we next determined if changes in NAD+ altered muscle integrity in mdx 
mice. Indeed, this positive correlation was consistent with the robust increase in α-
dystrobrevin and δ-sarcoglycan protein in the gastrocnemius of mdx mice treated in a 
preventive mode with NR (Figure 4. 5A). The NR treated mdx mice, furthermore, displayed 
less susceptibility to muscle damage, evidenced by reduced permeability to Evans Blue 
(Figure 4. 5, B-D), decreased plasma creatine kinase levels (Figure 4. 5E) and increased grip 
strength (figure 4. S4A). More importantly, the susceptibility to injury was reduced in mdx 
animals during repeated lengthening contractions, from a loss of 64% (SEM = ±15) loss to a 
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34% (SEM = ±12) in animals treated with NR (Figure 4. 5F). These mice also showed a 
reduced number of centralized nuclei in tibialis anterior muscles (Figure 4. 5, G). The 
average minimal Feret’s diameter, and corresponding distribution, showed an increase in 
fiber size with NR treatment in mdx mice (Figure 4. 5, G and H and figure 4. S4B). This was 
confirmed in these same mice by quantifying the average and distribution of cross-sectional 
area of muscle fibers (Figure 4. 5, G and H and figure 4. S4C). In conjunction with the 
improved muscle function and the reduced level of muscle damage with NR, muscle 
inflammation was decreased in NR treated mdx mice. This was reflected by the ability of NR 
treatment to reduce macrophage infiltration in the skeletal muscle of mdx animals (figure 4. 
S4D) and to attenuate Tnfα transcript levels in mdx mice (figure 4. S4E), with no effect on the 
expression of anti-inflammatory genes Il13 and Il4 (data not shown). The reduction of 
skeletal muscle inflammation following NR was also recapitulated in the diaphragm, as 
demonstrated by reductions in staining for CD45 in muscle transverse- and longitudinal-
sections (Figure 4. 5I and figure 4. S4F). Closely related to inflammation and damage, a 
population of muscle resident cells expressing mesenchymal PDGF receptor alpha 
(PDGFRα), capable of differentiating in vitro to fibrogenic or adipogenic lineages and named 
fibro/adipogenic precursors (FAPs) (224, 225), were examined following NR treatment in 
mdx mice. The number of FAP cells is known to be higher in both mdx and mdx/Utr-/- mice, 
causing the deposition of both skeletal muscle fat and connective tissues (226, 227). 
Importantly, FAP cell numbers were lower in both the TA (figure 4. S4, G and H) and in 
transverse- and longitudinal-sections of the diaphragm (Figure 4. 5J and figure 4. S4, I and J) 
of mdx mice given an NR supplement. In line with the reduction of FAP cell numbers, NR 
treatment reduced the appearance of fibrosis in both transverse- and longitudinal-sections of 
the diaphragm of mdx mice (Figure 4. 5J and figure 4. S4 K).  
Importantly, using a therapeutic approach, a 12-week NR treatment starting at 3.5 weeks of 
age in the more severe and already symptomatic mdx/Utr-/- double mutant mouse model also 
improved grip strength (Figure 4. 5K). This suggests that NR treatment can slow and 
potentially reverse components of muscular dysfunction in two separate mouse models of 
muscular dystrophy. 
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Figure 4. 5 NAD+ repletion causes compensatory increases in the expression of structural proteins and 
protects muscle from damage and fibrosis 
16-week-old mdx mice received a dietary supplement with NR (400 mg/kg/day) for 12 weeks. (A) NR-treated mdx 
mice exhibited increased α-dystrobrevin and δ-sarcoglycan protein expression in gastrocnemius extracts. NR 
attenuated mdx muscle damage as evidenced through (B) Evans Blue staining of both TA muscle and (C) 
sections of gastrocnemius and soleus muscles (Evans Blue - red and dapi - white), (D) quantified using ImageJ 
software (n=6, mdx; n=12, mdx NR). NR also (E) reduced basal plasma creatine kinase levels (n=5, mdx; n=6, 
mdx NR). (F) mdx mice treated with NR demonstrated an attenuation in the percent loss of torque in quadriceps, 
following muscle damage induced by lengthening contractions (n=7, mdx; n=6, mdx NR). (G) Representative 
images stained with dapi and laminin used to quantify (H) increases in the average minimal Feret’s diameter (in 
µm) and cross-sectional area (in µm2) of tibialis anterior muscle fibers, indicating increases in fiber size with NR 
treatment in mdx mice (8 weeks of NR treatment, n=5). Quantification of images was performed with ImageJ 
software. (I) Similarly, reduced CD45 staining was seen in diaphragms of mdx mice treated with NR. (J) 
Fibro/adipogenic precursors (FAPs) expressing mesenchymal PDGF receptor alpha (PDGFRα) were decreased 
in diaphragms of mdx mice treated with NR (n=3). Also, reductions in the fibrosis of mdx diaphragms were 
observed with less Picrosirius red staining in transverse muscle sections of NR treated mice. (K) As evidence for 
the therapeutic effectiveness of NR treatment, mdx/Utr-/- mice grip strength was improved from 8 weeks (n=4, 
mdx/Utr-/-; n=7, mdx/Utr-/- NR) to 10 weeks of age (n=3, mdx/Utr-/-; n=5, mdx/Utr-/- NR).  These mice received 5 
and 7 weeks of NR treatment (400 mg/kg/day), respectively. (L) Scheme summarizing the SIRT1-dependent 
effects of NR on mdx mouse muscle. 
4.5 Discussion and conclusions 
We demonstrate here that muscular dystrophy in mdx mice is associated with muscle NAD+ 
depletion, which can be monitored as an in vivo biomarker of disease severity using MRS. 
Reduced NAD+ levels are likely the result of PARP activation and reduced NAD+ salvage 
(Figure 4. 5L), as postulated from the robust PARP/NNMT gene enrichment signature in 
? ???
human dystrophy patients (Figure 4. 1G and figure 4. S2A). PARP activation was previously 
shown to have a negative correlation to energy expenditure; hence reducing PARP activity 
improves metabolism by increasing intracellular NAD+ levels in animals (157, 228). NAD+ 
repletion in mdx animals using NR exploits an alternative NAD+ synthesis pathway to counter 
increased PARP consumption of NAD+, leading to the recovery of NAD+-dependent sirtuin 
signaling. This effect attenuates the loss of mitochondrial function and the susceptibility for 
muscle degeneration and necrosis in mdx mice, which may in turn be responsible for the 
reduced necessity for global PARP activation. Despite elevations in NAD+ there are 
reductions of global PARylation owing to the fact that PARP activity is dependent on various 
other factors for activation, such as inflammation to which PARPs are responsive, as has 
been shown in liver inflammation and fibrosis (229). As inflammation is attenuated in mdx 
mice following NR treatment, we propose that this beneficial effect, that in turn lowers the 
level of PARP activation in muscle, may slow the development of fibrosis. These data 
underscore the importance of NR as an alternative substrate for NAD+ biosynthesis that can 
be exploited in mdx mice to increase muscle strength and decrease susceptibility to 
mechanical damage, while reducing plasma creatine kinase levels and fibrosis. We also 
demonstrate the potential for NR to improve muscle function and muscle strength in mdx/Utr-
/- mice. Our data therefore suggests that the use of other NAD+ precursors, such as NMN and 
NA analogs, and/or inhibitors of NAD+ consumption, such as PARP inhibitors, could be 
effective for treating muscular dystrophy. Indeed, all of these different compounds have been 
shown to improve respiratory capacity in diet or age-related mitochondrial dysfunction (157, 
159, 230). Finally, these data confirm the importance of SIRT1 as a target for treating the 
mdx phenotype (204) and to prevent FOXO-directed muscle degeneration (207, 231). More 
importantly, our work highlights the potential for NAD+ to act as a biomarker that responds to 
NAD+ boosting strategies as an effective adjunct therapy for muscular dystrophy. Our 
observations may furthermore have broad implications for other (neuro-)muscular diseases, 
injuries or forms of muscle denervation, that are characterized by mitochondrial dysfunction 
or general PARP activation. 
4.6 Supplementary materials 
4.6.1 Materials and Methods 
Animal experiments. Three weeks old male C57BL/10SnJ mice or C57BL/10ScSn-
Dmdmdx/J, purchased from The Jackson Laboratory, were fed with pellets containing vehicle 
or NR (400 mg/kg/day) for 8 weeks beginning at 3.5 weeks of age. The mdx/Utr-/- double 
mutant strain was generated by crossing C57BL/10ScSn-Dmdmdx/J mice with Utrntm1Ked/J 
mice from The Jackson Laboratory. Experiments with mdx/Utr-/- mice included both male and 
females fed with pellets containing vehicle or NR (400 mg/kg/day) up to 13 weeks, beginning 
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at 3.5 weeks of age. The pellets were prepared by mixing the powder chow diet (D12450B, 
Research Diets Inc.) with NR dissolved in water. Pellets were dried under a laminar flow 
hood at least over night. Control pellets without NR were made similarly. Most clinical tests 
were carried out according to standard operational procedures (SOPs) established and 
validated within the Eumorphia program (182). Body composition was determined by Echo-
MRI (Echo Medical Systems) and oxygen consumption (VO2), food intake and activity levels 
were monitored during the indirect calorimetry tests using the comprehensive laboratory 
animal monitoring system (CLAMS, Columbus Instruments) after 3 weeks of treatment. 
Endurance capacity test was performed as published (80, 232) after 7 weeks of treatment. 
All animals were sacrificed after an overnight fast and 4 to 6hr refed conditions. Blood was 
collected upon sacrifice, while tissues were collected, weighed and flash-frozen in liquid 
nitrogen.  
Ethical approval: These experiments were authorized by the Veterinary office of the Canton 
of Vaud, Switzerland (Authorization n°2665). 
Cell culture. The C2C12 mosue muscle derived cell line was obtained from ATCC (CRL-
1772TM). C2C12 myoblasts were cultured in Dulbecco’s modified Eagle’s medium (DMEM) 
including 4.5 g/L glucose, 20% fetal calf serum and 50 µg/ml gentamicin. Differentiation of 
C2C12 cells into myotubes was induced over four days in Dulbecco’s modified Eagle’s 
medium (DMEM) including 4.5 g/L glucose, 2% horse serum and 50 µg/ml gentamicin. Cells 
were tested for mycoplasma using Mycoprobe (#CUL001B, R&D systems, MN, USA), 
following the manufacturer’s instructions. 
Grip strength test. Muscle strength was assessed by a grip strength behavior task after 5 
weeks of NR treatment. The grasp strength of each mouse for all four limbs was measured 
on a pull-grid assembly connected to the grip strength meter (Columbus Instruments). The 
mouse was drawn along a straight line parallel to the grid until the grip is broken and the 
peak amount of force in grams was recorded. This was repeated 4 times with 5 minute 
intervals. 
Creatine Kinase. Collected plasma was used for creatine kinase measurements using the 
CKI Flex® reagent cartridge (Siemens Healthcare Diagnostics AG) on the Dimension®Xpand 
Plus instrument (Siemens Healthcare Diagnostics AG). 
Histology. Muscles prepared for histology were placed in Thermo Scientific™ Shandon™ 
Cryomatrix™ embedding resin and then frozen in isopentane cooled in liquid nitrogen for 2 
min before being placed on dry ice.  
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5-μm cryosections were stained for succinate dehydrogenase or cytochrome c oxidase 
activity as previously described (232), or with picrosirius red to assess fibrosis. 
Immunohistochemistry and immunofluorescence was performed on 5-μm cyrosections fixed 
with 4% paraformaldehyde, which were stained with various antibodies. Heat activated 
antigen retrieval was performed in pH 6.0 citrate buffer for 10min at 65°C. After washing with 
PBS-0.1% tween 20 (PBST), sections were blocked with 10% affinipure Fab goat anti mouse 
IgG (Jackson Immunoresearch) in PBST for 60min followed by PBST containing 2% BSA 
and 5% goat serum for 30min. Sections were then incubated over night at 4°C with primary 
antibodies, including anti-Laminin (Sigma), anti-CD45 (Life Technology), anti-F4/80 antigen 
(AbD Serotec) and anti-PDGF Receptor alpha (cell signaling). Subsequently, the slides were 
washed in PBST and incubated with appropriate secondary antibodies and labeling dyes. For 
immunofluorescence, secondary antibodies were coupled to Alexa-488 or Alexa-568 
fluorochromes (Life technology), and nuclei were stained with DAPI (Invitrogen). After 
washing in PBST, tissue sections were mounted with Dako mounting medium (Dako). For 
immunohistochemistry HRP-tagged secondary antibodies were used and visualized using 
diaminobenzidine staining, while Mayer's Hematoxylin was used to visualize the nuclei. 
Muscle damage was assessed with a 1% solution Evans Blue Dye (EBD), which is injected 
into the peritoneal cavity, using 1% volume to body weight, 24hrs before sacrifice. EBD is 
dissolved in PBS (0.15 M NaCl, 10 mM phosphate buffer, pH 7.4) and sterilized by passage 
through membrane filters with a 0.2 μm pore size. Upon sacrifice, the hind leg skin of the 
mice is removed, and the animals are photographed for dye uptake into skeletal muscles, 
indicated by blue coloration. Muscle sections from EBD-injected animals are incubated in ice-
cold acetone at −20°C for 10 min, washed 3×10 min with PBS, counterstained with 4',6-
diamidino-2-phenylindole (DAPI) and mounted with Vectashield mounting medium. 
Microscopy images of red emission fluorescence from EBD-positive muscle fibers were 
analyzed using ImageJ software.  
We determined the minimal Feret’s diameter and cross-sectional area in tibialis anterior 
muscles of CD and NR fed mdx mice using the ImageJ software quantification of laminin 
stained muscle images. We analyzed a minimum of 3,000 fibers for each condition and 
measurement. The minimal Feret’s diameter is defined as the minimum distance between 
two parallel tangents at opposing borders of the muscle fiber. This measure has been found 
to be resistant to deviations away from the optimal cross-sectioning profile during the 
sectioning process(233).  
Enzyme activity measurements. Total poly(ADP-ribose) polymerase activity was analyzed 
in tissue homogenates using the HT Colorimetric PARP Apoptosis Assay Kit (Trevigen). This 
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PARP activity assay kit is sensitive to PARylation of proteins that are 2 units of poly-
ADP-ribosyl units of length and larger. Citrate synthase activity was determined in tissue 
homogenates using a commercial CS Assay kit (Sigma). 
Tissue and C2C12 cell NAD+ quantification. NAD+ was extracted using acidic extraction 
method and analyzed with mass-spectrometry. Frozen muscle tissues or cultured cells taken 
from the -80 freezer were immediately extracted in 1M perchloric acid and neutralized in 3M 
K2CO3 on ice. After centrifugation, the supernatant was mixed with Buffer A (H2O + 20mM 
ammonium acetate, pH 9.4) and loaded on to a column (Kintex EVO C18, 100A, 
150x2.1mm). The HPLC was run for 2 min at a flow rate of  300ul/min with 100% Buffer A.  
Then a linear gradient to 100% Buffer B (Methanol + 5mM ammonium acetate, pH 8.5 ) was 
performed (from min. 2 to min. 11). 100% Buffer B was maintained for 4min (11 to 15min), 
then a linear gradient back to 100% Buffer A (from min15 to min 17) began. Buffer A was 
then maintained at 100% until the end (from min17 to min 25). NAD+ eluted as a sharp peak 
at and was quantitated based on the peak area compared to a standard curve and 
normalized to tissue weight or protein of frozen muscle tissues or to protein content of 
cultured cells. 
Identification of Nampt and Parp1-correlated genes and parameters. Quadriceps 
microarray data (Affymetrix Mouse Gene 1.0 ST) and phenotyping data from a BXD mouse 
genetic reference population (157, 213) were analyzed for correlations with Nampt or Parp1 
transcript expression using the GeneNetwork program (http://www.genenetwork.org). Raw 
microarray data are also publicly available on GEO under the accession number GSE60151. 
Raw phenotype data are available on GeneNetwork by setting the Group to BXD, type to 
Phenotype, and searching for the relevant phenotype trait named in Figure 1. Trait 15676 
describes soleus muscle mass, as a percentage of body weight, in chow diet fed BXD male 
mice. 
Gene expression analyses. Muscle total RNA was extracted using Trizol extraction. Total 
RNA was transcribed to cDNA using QuantiTect Reverse Transcription Kit (Qiagen). 
Expression of selected genes was analyzed using The LightCycler480 System (Roche) and 
SYBR Green chemistry. All qPCR results were presented relative to the mean of 36b4, b2m 
and gapdh. Primer sets for both quantitative real-time PCR analyses are shown below: 
Table S4. 1 Realtime-qPCR primers list 
Gene Description Forward Primer Reverse Primer 
36b4 
ribosomal 
protein, large, P0 
 
AGATTCGGGATATGCTGTTGG AAAGCCTGGAAGAAGGAGGTC 
b2m 
beta-2 
microglobulin 
 
TTCTGGTGCTTGTCTCACTG 
 
TATGTTCGGCTTCCCATTCT 
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gapd
h 
glyceraldehyde-
3-phosphate 
dehydrogenase 
  
TGTGTCCGTCGTGGATCTGA CCTGCTTCACCACCTTCTTGAT 
tnfα 
tumor necrosis 
factor 
 
GTA GCC CAC GTC GTA GCA AAC GCA GAC TTA CTG ACC AGC TCA GA 
Il13 interleukin 13  CACACTCCATACCATGCTGC TGTGTCTCTCCCTCTGACCC 
Il4 interleukin 4 ACAGGAGAAGGGACGCCAT GAAGCCCTACAGACGAGCTCA 
 
Western blotting. Samples were lysed in lysis buffer (50 mM Tris, 150 mM KCl, EDTA 1 
mM, NP40 1%, nicotinamide 5mM, sodium butyrate 1mM, protease inhibitors pH 7,4). 
Proteins were separated by SDS-PAGE and transferred onto nitrocellulose membranes. 
Blocking and antibody incubations were performed in 5% BSA. SIRT1 antibody was from 
Abcam; Anti-FOXO1 antibody was from Cell Signaling; PAR antibody was from Millipore; 
anti-acetyl-FRKH(FOXO) antibody was from Santa Cruz Inc. Antibody cocktail (the 
Mitoprofile Total OXPHOS Rodent WB Antibody Cocktail) for mitochondrial subunits was 
purchased from Mitosciences. Antibody detection reactions were developed by enhanced 
chemiluminescence (Advansta, CA, USA) using x-ray films or imaged using the c300 
imaging system (Azure Biosystems). 
Respirometry on C2C12 myotubes. C2C12 myotubes in suspension were used to measure 
basal respiration rates using high resolution respirometry (Oroboros Oxygraph-2k; Oroboros 
Instruments, Austria). Then, oligomycin (2.5 μM), a complex V inhibitor, was injected to 
measure proton leak, then the protonophore agent FCCP (0.2 mM) was titrated to achieve 
maximum electron transfer flux.  O2 flux obtained in each step of the protocol was normalized 
by the protein content of the sample used for the analysis. 
Blue-native Page. Blue-native Page on isolated mitochondria from muscle or C2C12 cells 
was performed using the Native-PAGETM Novex® Bis-Tris Gel system (Invitrogen). In short, 
50ug of isolated mitochondria was solubilized using Native-PAGE sample buffer with 0.5% n-
dodecyl-β-D-maltoside (Invitrogen) and complexes were separated using a Native-PAGE 
Novex 3–12% BisTris gel (Invitrogen). After running, the gel was transferred to a PVDF 
membrane using the iBlot TM Gel Transfer System (Invitrogen). The membrane was fixed with 
8% acetic acid. After overnight drying, the membrane was destained with methanol. To 
detect OXPHOS complex, the Mitoprofile Total OXPHOS Rodent WB Antibody Cocktail 
(Mitosciences) was used. After incubation in the primary antibody dilution, the membrane 
was washed and detected using the Western Breeze® Chromogenic Western Blot 
Immunodetection Kit (Invitrogen). 
In vivo spectroscopy and data analysis.  
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MRS methods: A Bruker 14T magnet was used to study the mouse hindlimb muscles (234). 
Briefly, mice were fasted overnight and then given food ad lib 2 hours prior to performing 
MRS and optical spectroscopy. Mice were anesthetized using 0.01 ml/g of 2.5% 
tribromoethanol. Left distal hindlimbs are shaved and cleared of dander and mice are 
situated in place using flexible hook and loop fastening straps to the inside of a custom-built 
MR/optics probe for the vertical bore 14T spectrometer (Bruker Billerica, MA) as previously 
described (234). Shaved distal hindlimbs were centered inside a horizontal MR solenoid coil 
with fiber optic wires situation to either side of the hindlimb. The MR solenoid coil was tuned 
and matched to 1H and 31P and MR was optimized by shimming the 1H signal of tissue H2O. 
31P spectra were then acquired using fully relaxed conditions with proton decoupling (80 
transients, 4096 complex points, 20 kHz sweep width, 30 s interpulse delay). Dynamic MR 
(45° flip angle, 4 transients, 4096 complex points, 20 kHz sweep width, 1.5 s interpulse 
delay) were acquired in the following periods: rest (2 min), ischemia (9 min), and recovery (9 
min). 100% O2 was administered starting after 1 min of rest during the dynamic phase and 
continued throughout the experiment.  All fully relaxed spectra were Fourier transformed with 
apodization of 40 HZ, baseline corrected. 
Peak simulations:  Solutions emulating in vivo conditions were prepared with NAD+ and 
NADP+ using binding constants taken from the USA National Institute of Standards and 
Technology (NIST) Critically Selected Stability Constants of Metal Complexes Database (see 
(235)). All solutions contained (in mmol/L): EGTA 15, MOPS 80, free Mg2+ 1, Na+ 83 and K+ 
52.  The following were varied in individual solutions:  ATP, ADP, Pi, Creatine Phosphate 
(PCr), ADP, NAD+, NADH, NADP+, or UDP-Glucose.  The ionic strength was maintained at 
0.175M, pH = 7.0 (36°C) in all solutions.  High-resolution MR spectra of solutions in an NMR 
tube were taken at 4.7T (sweep width=10,000 Hz, 16K complex points, 128 FIDs, 5 s delay 
between pulses).  The Spin Simulation feature of the Mnova software provided the NAD+ (-
10.74 ppm and J coupling, 20.03 Hz) and NADP+(-10.83 ppm and J coupling, 18.03 Hz) 
resonances at each field based on the spin parameters and chemical shifts at 4.7T as 
described (236).  
Metabolite Concentrations: Mice were euthanized within 20 minutes of the end of the MRS 
experiment. Gastrocnemius muscles were removed and frozen from anesthetized mice 
within 20 minutes of the end of the MRS experiments. Concentration of ATP was measured 
in the gastrocnemius muscle by HPLC (Waters, Milford, MA) using a protocol described in 
detail elsewhere (237). 
Analyses of in vivo ATP Fluxes: 31P MR spectra were exponentially multiplied (40Hz at 14T), 
fourier transformed, and manually phase corrected using Bruker TopSpin (14T) software. 
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Fully relaxed and dynamic phase spectra were then analyzed with custom written MATLAB 
software (Mathworks, Natick, MA).  
The method used for analyzing MR spectra is described in detail elsewhere(234).  Peak 
areas relative to gamma ATP peak area from fully relaxed spectra were used to calculate the 
resting inorganic phosphate Pi/ATP and PCr/ATP ratios. Three consecutive dynamic spectra 
were summed to improve signal-to-noise ratio before using the Fit-to-Standard algorithm 
(238) to determine PCr and Pi peak magnitudes throughout dynamic acquisition, relative to 
rest.  Absolute PCr and Pi concentrations were calculated using the ATP concentration 
measured by HPLC.  The chemical shift between the Pi and PCr peaks was used to calculate 
the cellular pH during the dynamic phase (239). Experiments where end of ischemia pH fell 
below 6.8 were excluded from analyses of ATPmax. 
 
NAD+ and NADP+ in vivo:  The NAD(P) region (-10.4 to -11.3 ppm) was extracted from the 
fully relaxed spectra by fitting a Lorenztian line shape to the a-ATP peak. The NAD+ and 
NADP+ peaks were estimated by a least squares fit of the simulated peaks to the -10.4 to -
11.0 ppm portion of the extracted region. 
In vivo measurement of isometric torque and induction of muscle injury. These 
experiments were performed as described (240). Briefly, animals were anesthetized using 
~2% isoflurane inhalation and sterile ophthalmic cream was applied to each eye. Under a 
heat lamp, a needle (25 G) is manually placed through the distal femur to stabilize the femur 
onto the rig. The ankle is then secured to a custom-machined adjustable lever arm with 
adhesive tape. The ankle rod should be adjusted so that it lies anteriorly on the distal leg just 
above the foot. The position of the ankle rod should not be altered between age-matched 
animals of the same species so that the lever is constant between tests. The lever arm is 
attached to a stepper motor (model T8904, NMB Technologies, Chatsworth, CA) and a 
torque sensor (model QWFK-8M, Sensotec, Columbus, OH). Subcutaneous electrodes (J05 
Needle Electrode Needles, 36BTP, Jari Electrode Supply) are used to stimulate the femoral 
nerve. To obtain maximal isometric torque, the pulse amplitude is adjusted to optimize twitch 
tension and the optimal position of the leg is determined by measuring twitches at different 
lengths of the quadriceps. Using commercial software (LabView version 2013, National 
Instruments) each experiment synchronizes contractile activation, the onset of knee rotation, 
and torque data collection. To assess injury during force lengthening contractions, 
stimulation of the quadriceps muscles is performed while a computer-controlled motor 
simultaneously moves the lever arm against the direction of knee extension. This leads to a 
lengthening (eccentric) contraction. The loss of force production during maximal and 
repeated lengthening contractions is a result of muscle injury. A maximal tetanic contraction 
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is then obtained to determine maximal contractile tension (P0). Maximal tetanic contractions 
can be performed repeatedly over time with the final tension expressed as percentage of P0. 
C. elegans studies.  C. elegans movement was recorded for 45 seconds at days 1-8 of 
adulthood using a Nikon DS-L2 / DS-Fi1 camera and controller setup, attached to both a 
computer and a standard bright field microscope. The movement of worms during aging was 
calculated by following worm centroids using a modified version of the freely-available 
software Parallel Worm Tracker for MATLAB (158, 241). These experiments were repeated 
at least three times. 
Treatments were performed by adding the NAD+ precursor NR at 1mM dissolved in water 
just before pouring the plates.  Worms were exposed to NR during the full life from eggs until 
death. To ensure a permanent exposure to the compound, plates were changed twice a 
week. Worm paralysis was assessed as previously described (242). 
Muscle degeneration experiments were performed on 90 mm Petri dishes containing 
Nematode Growth Medium (NGM) agar. Plates were induced overnight at room temperature 
with 4mM IPTG and seeded with HT115 bacteria expressing either empty vector RNAi L4440 
or sir-2.1 RNAi clone [R11A8.4, clone purchased from GeneService and sequenced] grown 
in Luria broth with 100μg/ml ampicilin and 12,5μg/ml tetracycline until reaching an optic 
density between 0.6 and 0.8. Synchronized egg populations of dys-1(cx18);hlh-1(cc561ts) 
double mutant animals (223) were cultured at 15°C during 8 days and harvested for a 25 min 
fixation in 1ml PBS supplemented with 20μl of 37% formaldehyde. Samples were then 
permeabilized by cold methanol during 2 minutes and stained by rhodamine-coupled 
phalloidin, a marker of filamentous actin, as described previously (243). Using a Zeiss 
Axioplan microscope (x40), the 2 most visible muscle quadrants of each animal were scored 
for missing cells or cells showing actin fibers fragmented, aggregated or destroyed (40 cells 
per animal and at least 60 worms per condition were examined per experiment). All 
experiments were performed blindly three times and compared using a Student’s t-test. 
Illustrative images of the actin network for each condition were recorded using a Zeiss LSM 
510 meta fluorescence confocal microscope (objective x40) and analyzed using ImageJ.  
Statistics. Differences between two groups were assessed using two-tailed t-tests. 
GraphPad Prism 5 (GraphPad Software, Inc.) for all statistical analyses. All p-values <0.05 
were considered significant. *p≤0.05; **p≤0.01; ***p≤0.001. All animal experiments were 
performed once.  
Sample size determination: For all experiments, sample size was estimated based on the 
known variability of the assay.  
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4.6.2 Supplementary Figures  
 
figure 4.S 1 The relationship between transcripts involved in NAD+-biosynthesis and consumption with 
muscular dystrophy in mice 
Expression of (A) Nampt and (B) Nmnat3 in the quadriceps of 42 strains of the BXD mouse genetic reference 
population. Each bar represents mRNA from a pool of 5 animals per strain. Extreme strains are labeled. Custom 
gene set analysis showing enrichment of mitochondrial-related transcripts with (C) Nampt in data from strains with 
the 10 highest and 10 lowest transcript levels from 42 strains of the BXDs (157). Using gene set enrichment 
analysis we found a positive correlation to Nampt transcript expression with an enrichment score=0.69 and 
p=0.01, with the Nampt gene excluded from the analysis. 
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figure 4.S 2 The relationship between transcripts involved in NAD+-biosynthesis and consumption with 
muscular dystrophy in patients 
The expression of transcripts related to NAD+ (A) consumption or (B) biosynthesis exhibit an enrichment 
signature of PARP genes and the NNMT gene that is consistent across skeletal muscle datasets (217, 218) from 
a variety of muscular dystrophies and in patients with (neuro)-muscular diseases. All results for a given condition 
are averaged from a group of datasets and expressed in relationship to the average of the control patient values 
(n value for each disease is indicated at the bottom of the heatmap; n=18 for the control group). 
 
figure 4.S 3 In vivo monitoring of NAD+ provides an efficacy biomarker for improvements in the 
phenotype of NR-treated mdx mice
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mdx mice treated for 12 weeks with NR demonstrated (A) restored NAD+ levels in liver (n=4 for WT and mdx CD, 
n=3 for mdx NR) yet (B) no changes in subcutaneous WAT (n=4 for WT and mdx CD, n=3 for mdx NR). NR 
treated mdx mice also showed no significant changes in (C) total body weight, lean mass (n=6) or (D) wet weights 
of quadriceps, gastrocnemius and soleus or tibialis anterior and extensor digitorum longus muscles (n=5). (E) 
Energy expenditure was evaluated through calculation of the respiratory exchange ratio (RER) over a 24 hr period 
for mdx mice with or without NR treatment compared to WT mice (n=6). 
 
figure 4.S 4 NAD+ repletion improves muscle function and protects muscle from damage and fibrosis 
mdx mice treated for 12 weeks with NR exhibited (A) increased limb grip strength in mdx mice (Newtons of force, 
n=6). Analysis of the (B) minimal Feret’s diameter (in µm) and the (C) cross-sectional area (in µm2) of mdx tibialis 
anterior muscle fibers show an increase in fiber size with NR treatment (8 weeks of NR treatment, n=5). 
Quantification of images was performed with ImageJ software.  NR-treated mdx mice also demonstrated (D) 
reduced macrophage content, quantified by counting F40/80-positive stained cells in mdx tibialis anterior muscles 
(n=4). Quantification of images was performed with ImageJ software. (E) mRNA levels of tnfα, a mediator of 
inflammation in mdx mice, was attenuated with NR treatment in gastrocnemius muscle (n=3). (F) CD45 positive 
cells were reduced in the longitudinal-sections of NR-treated mdx mouse diaphragms. PDGFR positive cells were 
reduced following NR in both (G) transverse-sections of TA muscle and in (H) quantified transverse-sections of 
diaphragms in mdx mice. Quantification of images was performed with ImageJ software (n=4 for mdx CD, n=5 for 
mdx NR). (I) Reduced PGDFR staining of longitudinal-sections of the diaphragm (J) quantified using ImageJ 
software (n=6 for mdx CD, n=5 for mdx NR). (K) Fibrosis was reduced in longitudinal sections of the diaphragm in 
mdx animals given an NR supplemented diet, as seen with less picosirius red staining. 
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Chapter 5. Discussion and conclusions 
5.1 Why NAD+ and mitochondria are important for 
quiescent stem cells? 
Quiescent adult stem cells, such as MuSCs, are thought to rely predominantly on 
mitochondrial-independent glycolysis for energy, a process that would reduce cellular 
concentrations of NAD+ (161). Following this theory, mitochondrial function in MuSC and 
other quiescent stem cells might be not as important as the most types of full-differentiated 
tissue, which largely relay on mitochondrial oxidative respiration for energy production. 
However, mitochondrial function has been recently linked to SCs maintenance and activation 
(55, 162-164), which indicates that mitochondria might be actually important in stem cell 
quiescence, and fate decision.  Our work in Chapter 2 shows that modulation of the NAD+ 
levels and mitochondrial function are essential for muscle, neural and melanocyte stem cell 
senescence in aging. Therefore our work shed light on a new intrinsic stem cell senescence 
regulatory pathway, and unveiled the importance of NAD+ levels and mitochondria in stem 
cell maintenance. This research work also brings to light several interesting questions around 
the role of mitochondrial homeostasis in stem cell function and aging.  
One fundamental question is why the NAD+ pool and the mitochondrial activity decline in the 
senescent stem cell in both natural aging mice and in the mdx muscular dystrophy mouse 
strain? There are several reasons that might explain the decline in NAD+ in MuSC 
senescence, which occurs in both aged and mdx mice(8). One possible reason is the 
reduction of NAD+ synthesis due to the dysfunction of the key enzymes involved in NAD+ 
biosynthesis, such as the decline of NAMPT (159). Another possibility is the increased 
expression and/or activity of NAD+ consuming enzymes, such as PARP(133) or CD38(244) 
enzymes, in the aged mice. PARPs transfer ADP-ribose from NAD+ to histones and other 
proteins at sites of DNA damage to facilitate DNA repair. Considering the requirements of 
DNA repair in the aged mice, the hyper-activation of PARPs in MuSCs of aged mice could be 
the mechanism of the NAD+ reduction in these cells. As for CD38, levels of this enzyme 
might be induced by lipopolysaccharides and inflammatory cytokines, such as TNF-α(244). 
The reduction in NAD+ levels could further deactivate sirtuins, especially the SIRT1 and 
SIRT3, which is linked to the reduction of mitochondrial biogenesis and function (8). 
Nevertheless, neither the decrease of NAD+ synthesis nor super-activation of PARPs or 
CD38 has been tested in stem cell aging(8). Moreover, we can not rule out other scenarios, 
such as that the metabolic change in aged stem cells might cause an imbalance in the 
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NAD+/NADH ratio by hyper-activation of glycolysis. More studies will be necessary to unveil 
the processes leading to NAD+ decline and mitochondrial dysfunction in aged stem cells.  
Another related question is how can NAD+ boosting and improvement of mitochondrial 
function prevent stem cell aging? One possible reason might reside in the fact that 
mitochondria may provide stem cells with the essential energy that cannot be sufficiently 
obtained from glycolysis. Additionally, mitochondria may be involved in several signaling 
pathways that are crucial for stem cell maintenance. Importantly, our research showed that 
the UPRmt might be one of the important signaling pathways responsible for preserving stem 
cell health in aged mice. In particular, UPRmt activation by NAD+ boosting inhibits expression 
of the senescent regulator CDKN1A in MuSCs (Chapter 2). More work will be needed to 
understand how UPRmt activation represses CDKN1A expression and the downstream 
activation of cell cycle genes (Figure 2.3 F-I).  
In the work presented here, we examined the beneficial effect of NAD+ boosting in muscle, 
neural and melanocyte stem cell aging. An interesting question is whether NR-treatment can 
also benefit other stem cell types. It is important to note that different stem cell types have 
totally different characteristics during the process of aging(245-248). For instance, even 
though most of the stem cell types exhibit altered proliferation and differentiation in aging, the 
change in cell proliferation frequency can be either increased (such as intestinal and 
hematopoietic stem cells) or decreased (such as MuSCs and Neural stem cells) (245, 247, 
248). We have shown that the muscle, neural and melanocyte stem cells all decline in 
proliferation with aging. However, other stem cells, such as hematopoietic and intestinal stem 
cells, have been reported to show an increase in proliferation in aged mice. Therefore, it will 
be important to test whether NAD+ boosters, such as NR, could also reduce senescence of 
these stem cells during aging. Another interesting stem cell type is the cancer stem cell. 
These cells can be quiescent for long time, and once activated, they possess high 
proliferation capacity(159). It will be very interesting to test the role of mitochondria in cancer 
stem cell function. Recently, NR has shown to be effective in the prevention of liver cancer, 
probably through reduction of DNA damage(249). Meanwhile, NAD+ depletion might also 
inhibit the growth of several cancers (reviewed in (181)). All together, whether NR has 
potential effects on cancer stem cell activation and proliferation is still unknown. 
Moreover, It would be interesting to test whether other strategies aimed at increasing NAD+ 
levels or improving mitochondrial activity also could similarly prevent stem cell senescence in 
aging and diseases. Nicotinamide mononucleotide (NMN), one NAD+ salvage synthesis 
substrate and therefore another NAD+ booster, has been shown to rescue the decline in 
neural stem cell number during aging(163). However, it is unknown whether the beneficial 
effect of NMN administration is occurring by inhibiting stem cell senescence. Besides, It 
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would be interesting to test whether NMN also prevents other stem cells from aging. 
Moreover, it will be necessary to evaluate whether PARP inhibitors, which have been 
repeatedly proven to boost NAD+ levels in adult tissue and diseases, could also benefit stem 
cells in aging and disease conditions. Likewise the impact of CD38 inhibitors would be 
interesting to test. Evaluating the effect of other mitochondrial biogenesis or functional 
activators, and UPRmt activators, in stem cell aging and function will be another interesting 
research topic.  
5.2 Anti-aging and muscular dystrophy: how important the 
stem cells are? 
The beneficial effect of NR on mdx mice might be pleiotropic. NR treatment improves 
mitochondrial function, increases muscle structural protein expression and reduces general 
PARylation, inflammation and fibrosis (Chapter 4). All these effects are mainly on muscle 
fibers. NR also prevents MuSC aging in normal and mdx mice, and therefore improves 
muscle regeneration ability in the mdx mice (Chapter 2). The decline of MuSC numbers in 
mdx mice has been shown at ages as early as 12 weeks(250), and apoptosis/senescence of 
MuSCs has been reported in young mdx mice throughout the ages of 4 to 23 weeks(251-
254). Therefore, the beneficial effects of NR might relay on both muscle fibers and MuSCs. 
Similarly, NAD+ boosters have been reported to show stem cell-independent beneficial 
effects on aged animals(133, 159). The question is, how much the stem cell pool contributed 
to the anti-aging and muscular dystrophy effect provided by NR? 
To address this question, we have performed MuSC-specific Sirt1 and Phb1 deficiency 
experiments. We found that the anti-senescence effect of NR-treatment was blocked in either 
SIRT1 or PHB1 deficient mice. Additionally, the SIRT1 and PHB1 deficient mice have 
compromised MuSC activation and muscle regeneration after muscle damage. Our results 
indicate that the effect of NR at least partly depend on improved MuSC function. However, to 
establish the contribution of stem cells in ameliorating aging and disease with NR, more work 
is required. First, MuSC-specific Sirt1 or Phb1 LOF mice might be helpful in addressing this 
question. Systemic phenotyping of skeletal muscle function and longevity of NR treated aged 
Sirt1 and Phb1 MuSC-specific LOF mice will help us to answer whether the physiological 
beneficial effect of NR is dependent on these particular proteins in aging MuSC function. 
Second, genetically modified mice that specifically improve mitochondrial biogenesis or 
activity in MuSCs, such as MuSC-specific SIRT1 overexpression mice, might be useful in 
investigating the contribution of stem cell mitochondrial activity on MuSC aging and muscle 
physiological function. Third, serial transplantation of fluorescent/luciferase labeled MuSCs 
isolated from control and NR treated aged mice can be performed in either aged wild type or 
mdx mice(5, 154). With this experiment, MuSC function with or without NR treatment can be 
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truly evaluated without the additional impact of NR on the stem cell niche. Moreover, the 
endogenous MuSCs of the pre-injured recipient mice can be radiation-ablated, therefore 
serving as a clean system to examine the regeneration activity of the transplanted MuSCs 
during aging and muscular dystrophy. 
5.3 Acetylation of histone vs. transcription regulators, what 
are their respective roles?   
KAT2A, as well as other HATs, can acetylate both histones and transcriptional 
factors/cofactors(2). For both protein groups, acetylation can have significant effect on their 
function and therefore on gene expression efficiency(2). Histone acetylation is an epigenetic 
modification that can strongly affect gene expression, because of its role in the direct 
modification of chromatin, both through local relaxation of chromatin structure and 
recruitment of chromatin remodeling complexes. Acetylated histone tails are generally 
associated with active chromatin, whereas deacetylated histone tails are associated with 
silent parts of the genome. Whereas, acetylation of transcription factors or cofactors can 
change their protein structure, binding ability and biological activity. Importantly, numerous 
transcription factors or cofactors possess acetyltransferases or deacetylases activity 
themselves, such as SRCs, TAFII250 and CLOCK (Table 1.4), which further highlights the 
importance of protein acetylation in gene expression control.  
Considering the occurrence of acetylation on both histones and non-histone proteins, one 
fundamental question is how can they be regulated and what is the “combined” impact of 
their acetylation in MuSC maintenance and activation?  
One possibility is that different KATs and KDACs have a different affinity for histones and 
non-histone transcription regulators. Therefore, even though most of them acetylate both 
histone and other proteins, each of the KATs or KDACs has it’s own preferred targets, which 
can be either histones or transcriptional factors/cofactors. Thus, histones and non-histone 
transcription factors/cofactors are mainly (de-) acetylated by different specific KDACs and 
KATs. However, it is also known that the specificity of KATs and KDACs can also rely on 
their binding proteins. As such, KATs and KDACs can be recruited to specific areas of 
chromatin in a manner that is dependent on their binding to transcriptional regulators. At a 
specific chromatin location, KATs and KDACs can acetylate and deacetylate both histones 
and transcription factors/cofactors. While histone acetylation controls the general relaxation 
of chromatin along with the recruitment of transcriptional factors/cofactors, the acetylation of 
transcriptal factors/cofactors can further fine-tune the transcriptional activity of given gene at 
this chromatin location. Therefore the general gene transcription level determined by more 
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global histone acetylation levels combined with the acetylation status of specific 
transcriptional regulators will ultimately govern the unique expression levels of select genes.  
In the case of KAT2A in MuSCs, our experimental results unveiled acetylation as a new PTM 
of PAX7, and highlighted the importance of this acetylation in MuSC function regulation 
(chapter 3). It is easy to understand the significant impact of PAX7 acetylation in MuSC 
function considering the key role of PAX7 in MuSC maintenance. However, we cannot rule 
out the possibility that KAT2A also regulates MuSCs function by histone acetylation. Further 
work will be needed to investigate the role of KAT2A mediated PAX7 acetylation in MuSC 
function. To do this, KAT2A-acetylated PAX7 lysine(s) will be identified using nano liquid 
chromatography tandem mass spectrometry (LC-MS/MS). PAX7 mutant proteins will be 
generated to mimic constitutively acetylated and deacetylated lysines by converting an 
existing lysine to glutamine or arginine, respectively. Secondly, the DNA binding ability, 
acetylation activity, the activity of downstream signaling cascade and resulting alterations in 
MuSC function will be evaluated for constitutively acetylated and deacetylated PAX7 mutant 
proteins, both in vitro in C2C12 cell lines and in vivo using adenovirus-introduced PAX7 GOF 
and LOF experiments in mice. Finally, to explore the possible involvement of histone 
acetylation in MuSC function, histone acetylation status will be examined in C2C12 cells with 
KAT2A GOF and LOF and in vivo using in KAT2A MuSC-specific LOF mice. Importantly, one 
of the key histones, H4K16, has been shown to activate myogenic gene transcription in 
MuSC when acetylated, driving the transition from MuSC quiescence to proliferation. The 
acetylation of H4K16 during MuSC activation may partially be due to the decline of NAD+ 
levels and in turn the deactivation of SIRT1 driven deacetylation(55). However, knowing that 
KAT2A is activated in early MuSC activation, it would be interesting to check whether KAT2A 
mediates H4K16 acetylation. 
5.4 How far are we from clinical treatment? 
Our work highlights the tremendous potential of NAD+ boosting and subsequent 
improvements in mitochondrial function in preventing the senescence of multiple types of 
stem cells in aged mice. More importantly, NAD+ boosting by NR treatment extends mouse 
lifespan even in mice treated at the late stage of life (chapter 2). The decline of NAD+ levels 
has also been found in human aging(255). It is therefore reasonable to expect that NAD+ 
boosters might also benefit healthy human aging. In the mdx mice, NR not only improves 
MuSC function, but also reduces general PARylation, inflammation and fibrosis in muscle 
fibers in muscular disease (chapter 4). Overall, NR benefits muscular diseases through 
effects on both MuSCs and myofibers. NR hence could be a nutritional intervention that 
benefits human muscular dystrophy (and potentially other neuro-muscular diseases) and 
aging. The investigation of PTM in MuSC regulation also brought the relevance of KAT2A 
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into the light. KAT2A is important for MuSC function and maintenance. More importantly, 
Kat2a expression declines in MuSCs during the process of aging (chapter 3). We therefore 
hypothesize that increasing the expression of KAT2A may therefore prove beneficial for 
MuSC aging. With all these promising results, one question is how far are we from translating 
these results to the clinic? 
To use NR in the clinical treatment of muscular dystrophy diseases or aging-related diseases, 
we need to first test its toxicity in human beings. Preliminary studies have been started in 
humans from both the industrial and academic sides. For instance, preliminary results from 
ChromaDex, a natural products company, did not reveal safety issues with NR(256). And 
recently the company announced that their initial results from the first human clinical study 
for NR met their primary endpoint. The results demonstrated that a single dose of NR 
resulted in statistically significant increases in the co-enzyme NAD+ in healthy human 
volunteers (http://investors.chromadex.com/). This study showed for the first time that NR 
converted into elevated tissue NAD+ levels, as has been shown in animal studies.  
After confirming that NR was non-toxic, the preventative or curative benefits of NR will need 
further confirmation in humans. From our data and other publications, NR may show benefits 
in diseases that include muscular dystrophy and aging-related diseases, including obesity 
and diabetes, non-alcoholic fatty liver disease (NAFLD) and liver cancer. NR has been 
shown beneficial effects on all of these diseases in mouse models(101, 249, 257, 258). 
Moreover, animal and clinical work will be required to test whether NR and other NAD+ 
boosters also benefit other muscular diseases and aged related diseases, such as 
Alzheimer’s disease (AD) and other dementias, including Parkinson’s disease (PD) and PD-
related disorders, Huntington’s disease (HD) etc.  
Research on KATs and KDACs covers broad clinical application, such as cancer, rheumatoid 
arthritis, Alzheimer’s disease, stroke, and heart disease(259). In humans, several HDAC 
inhibitors, such as Vorinostat, Romidepsin, Chidamide and Belinostat have been approved 
by the U.S Food and Drug Administration (FDA) for the treatment of T cell lymphoma. 
Panobinostat, another pan-HDAC inhibitor, was licensed for the treatment of multiple 
myelomas. In addition, there are several HDAC inhibitors under different phases of clinical 
trials(260, 261). Considering the decline of KAT2A levels in the MuSCs during aging, HDAC 
inhibitors or KAT2A activators might also benefits aged MuSCs. It is therefore important to 
test this hypothesis in both aged and dystrophic animals, and, thereafter, human patients. 
One of the limitations for using KDAC inhibitors and KAT activators for clinical application is 
the availability of specific inhibitors and activators. Therefore, finding more specific HDACs 
and HATs inhibitors and activators might largely improve the use of protein acetylation 
modulators when it comes to chromatin specific modulation. However, this approach must be 
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taken cautiously as the potential for affecting multiple chromatin locations is very likely, which 
could lead to various unexpected side effects in the clinic. The wide array of signaling 
pathways affected by KDAC and KAT inhibitors or activators will hence be one a major 
pharmaceutical challenge to overcome. 
Altogether, in spite of the high potential for clinical usage of both NAD+ boosters and KDACs 
and KATs modulators as novel therapeutics, more investigations, both in basic research as 
well as in clinical tests, will be necessary before approval for a wide and secure application of 
these compounds. 
5.5 Conclusion 
Skeletal muscle serves crucial roles in locomotion and energy metabolism. However, its 
function can be compromised in disease and in aging. Within my thesis projects, we explored 
a link between cellular energy metabolism and muscle and MuSCs function. By controlling 
the concentration of key cellular metabolites, such as NAD+ and Acetyl-CoA, we can control 
energy metabolism to directly regulate muscle metabolic and structural homeostasis, and 
MuSCs activation and senescence, through modulation of mitochondrial activity, PARylation, 
KAT and KDAC activity.  
We found that NAD+ depletion may act as a biomarker for the progression of muscular 
dystrophy and MuSC aging. In patients with Duchenne’s muscular dystrophy and in the mdx 
mouse model, we found a particular signature of enrichment for various PARPs and the 
NNMT transcript, all major consumers of NAD+ involved in pleiotropic events, including 
inflammation. Replenishing NAD+ stores with dietary NR supplementation benefits muscle 
function in mdx and mdx/Utr-/- mice, an effect replicated in a C. elegans model of DMD.  
Interestingly, NAD+ decline is also found during MuSC senescence in both aged and mdx 
mice, a quiescent and specific stem cell that was thought to rely predominantly on 
mitochondrial-independent glycolysis for energy. NR treatment prevents MuSC senescence 
and also improves neural and melanotyce stem cell function in aged mice, and extends 
mouse healthspan and lifespan.  
We found that the acetyl-CoA-dependent KAT2A acetyltransferase is an important MuSC 
function regulator. By acetylating the MuSC transcription factor PAX7, KAT2A supports 
MuSC activation and differentiation. KAT2A deficient MuSCs lose their myogenic 
differentiation ability and MuSC–specific KAT2A LOF mice have compromised muscle 
regeneration after muscle damage. 
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Our research therefore not only answers basic biological questions, such as the molecular 
mechanisms that regulate MuSC activation, differentiation, and senescence; as well as the 
fundamentals concerning the pathogenesis of muscular dystrophy in DMD patients, but also 
provides evidence for potential treatments for human muscular diseases and healthy aging 
by replenishing the cellular NAD+ pool during aging and disease.  
? ???
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